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Abstract 
 Asthma exacerbations result in significant morbidity and rhinoviruses (RVs) 
are largely responsible.  Asthmatics have increased susceptibility to RV infections 
and defective RV-induced interferon (IFN) production in atopic asthmatics (AA) has 
been observed in human bronchial epithelial cells (HBECs) and bronchoalveolar 
lavage (BAL) cells.  70-90% of asthmatics are atopic.   Whether the previously 
observed IFN deficiency is asthma- or atopy-specific is unknown.  Asthmatics have 
increased risk of invasive disease with Streptococcus pneumoniae (Spn) and 
proinflammatory/antibacterial cytokines are protective against bacterial infections.  
IFNs are anti-viral cytokines, but models of Spn infection have demonstrated type I 
IFNs are protective.  Investigation of toll-like receptors (TLRs) might delineate the 
signalling pathways involved in IFN/proinflammatory cytokine deficiencies further.  
This study hypothesised that RV, Spn and TLR stimulation of HBECs, BAL 
cells and peripheral blood mononuclear cells (PBMCs) would result in deficient IFN 
production in AA and non-atopic asthmatics (NAA), compared to atopic non-
asthmatics (ANA) and non-atopic non-asthmatics (NANA).  IFN and proinflammatory 
cytokine mRNA and protein expression was analysed by qPCR and the MesoScale 
Discovery platform. 
IFNs were induced in all cell types following stimulation with RVs and 
TLR3/7/8 agonists.  No differences were observed between asthmatics or controls; 
thus the role of atopy in IFN deficiency is still uncertain.  IFNs were not induced from 
Spn-stimulated cells.  Anti-bacterial cytokines were induced in PBMCs stimulated 
with Spn, but no differences were observed between asthmatics or controls.  HBECs 
responded to TLR1/2/6/4/5/9 stimulation with non-significant increases in anti-
bacterial cytokines and type III IFNs.  PBMCs responded to TLR1/2/6/4/5/9 
stimulation with no induction of type I or III IFNs, but increases in anti-bacterial 
cytokine proteins.  Deficiency in asthmatics was not observed. 
The lack of IFN/proinflammatory cytokine deficiency was suggested to be due 
to the asthmatics having relatively mild disease.  Further studies in more severe 
forms of asthma are required to investigate these responses further. 
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Chapter 1: Introduction 
 
1.1 Asthma 
1.1.1 Epidemiology 
Asthma is a chronic inflammatory airway disease affecting approximately 300 
million people worldwide 1.  The prevalence has increased in the last few decades 2, 
particularly in westernised and English-speaking countries, with some studies finding 
up to a 40% increase in the past 20 years 3, 4.  Asthma is characterised by airway 
hyperresponsiveness, leading to widespread reversible airways obstruction with 
symptoms of wheeze, chest tightness and cough, particularly at night.  The GINA 
guidelines classify asthma severity as mild intermittent, mild persistent, moderate 
persistent or severe persistent 5. There is a huge burden of healthcare associated 
with asthma, particularly with asthma exacerbations, and asthma is a major cause of 
absence from work in many countries.  The WHO has estimated that 15 million 
disability-adjusted life-years are lost annually due to asthma, representing 1% of the 
total global disease burden 6.  There are an estimated 250,000 worldwide deaths 
attributed to asthma 6. 
There are many factors involved in the development of asthma.  These can be 
divided into host and environmental factors.  Table 1.1 illustrates these factors 5.  
The major association with asthma is atopy, with 70-90% of adult asthmatics being 
atopic 7.  There is overlap with environmental factors and their influence in the 
development of asthma and their role in triggering asthma symptoms.  Much of the 
information about asthma risk factors comes from studies in children.  Risk factors 
for the development of asthma in adults are less understood but the persistence of 
adult atopic asthma is strongly associated with childhood eczema and rhinitis 8. 
For many years asthmatics have been subclassed into atopic (extrinsic) and non-
atopic (intrinsic) on the basis of whether a known allergen provokes airway 
obstruction and the presence of positive skin tests 9.  For the purposes of research 
the atopic status of asthmatics has long been determined on the basis of skin prick 
testing 10.  Gender differences have been observed in the incidence of non-atopic 
asthma.  In men the incidence rate is low until the age of 40 years, whereas the 
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incidence rate in women is relatively high between the ages of 20 and 30 years, and 
remains higher than in men throughout reproductive years 11.  The explanation for 
this is unclear.  The prevalence of asthma is increasing, but this increase is largely 
due to the increase in the prevalence of atopy, and subsequently the prevalence of 
non-atopic asthma is unchanged over the last 20 years 12.  The prevalence of non-
atopic asthma is also higher in lower socio-economic groups 13, 14. 
 
Table 1.1.  Factors influencing the development and expression of asthma 
Factors Influencing the Development and Expression of Asthma 
HOST FACTORS 
  Genetic – genes predisposing to atopy, genes predisposing to AHR 
  Obesity 
  Sex – males in childhood asthma, females in adult asthma 
ENVIRONMENTAL FACTORS 
  Allergens – mites, furred animals, cockroach, fungi, moulds, yeasts, 
pollen 
  Infections – predominantly viral 
  Occupational exposures – over 300 substances have been associated 
with occupational asthma 
  Tobacco smoke 
  Air pollution 
  Diet – breast feeding, processed foods 
 
1.1.2 Asthma exacerbations 
 Asthma exacerbations can be defined as a transient worsening of asthma 
symptoms following exposure to various risk factors 5.  For research purposes there 
is no commonly accepted definition for asthma exacerbations and a definition could 
be obtained by phenotyping exacerbations based on clinical signs, lung function 
parameters and biomarkers 15.  Exacerbations differ from poor asthma control and 
asthmatics are vulnerable to exacerbations, even when asthma is controlled 16.  
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They are common, with 56% of asthmatics reporting one or more exacerbation in the 
preceding 12 months between 2001 and 2003 in the US 17. 
 Treatments available for exacerbations are only partially effective.  These can 
be divided into those that prevent exacerbations and those that treat exacerbations.  
Inhaled corticosteroids (ICS) and combinations of ICS and long acting beta-2 
agonists (LABA) are the mainstay of preventative treatment.  A combination of 
LABA/ICS in asthmatics results in improved lung function, symptoms and decreased 
use of reliever therapy compared to high dose ICS 18.  There are no statistically 
significant differences between the different LABA/ICS combinations in the need for 
oral corticosteroids or number of adverse events 19.  Other agents are also used in 
combination, particularly the leukotriene antagonists.  Montelukast as an add-on 
treatment to ICS is more effective than ICS alone 20.  However, salmeterol/ICS is 
more effective than montelukast/ICS.  Leukotriene antagonists have been shown to 
reduce exacerbation frequency; zafirlukast in mild-moderate adult asthmatics 21 and 
montelukast in children during the predictable September peak in asthma symptoms 
22. 
 Exacerbations are treated using ICS, LABA and oral corticosteroids (OCS).  
Steroids act by binding and activating the glucocorticoid receptor, which is then 
translocated from the cytosol to the nucleus where it acts through a number of 
mechanisms, including upregulation of anti-inflammatory gene expression, 
suppression of proinflammatory cytokines, chemokines, arachadonic acid 
metabolites and adhesion molecules, and interaction with transcription factors such 
as nuclear factor kappa B (NF-κB) 23-25. 
 
1.2 Viruses and asthma 
 
1.2.1 Respiratory virus infection and asthma exacerbations 
Multiple studies have reported the association between asthma exacerbations 
and respiratory virus infection.  Many use different study designs, methods of 
detection and definitions.  Nine studies, in patients with a known diagnosis of 
asthma, a defined exacerbation and using the reverse transcriptase-polymerase 
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chain reaction (RT-PCR) for virus detection detected one or more respiratory viruses 
in 56% exacerbations, with a range of 26-80% 26-34.  Rhinoviruses were the most 
commonly identified virus.  Other viruses identified were coronaviruses, influenza 
viruses, parainfluenza viruses, respiratory syncytial viruses (RSV) and adenoviruses. 
 
1.2.2 Rhinoviruses and asthma 
Rhinoviruses (RVs) are the major virus type associated with exacerbations of 
asthma.  Studies have shown that, in adults and children, RVs are responsible for 
60-65% of viral exacerbations.  The peak period for RV infection is September in the 
northern hemisphere and peaks of asthma exacerbation requiring hospital treatment 
occur globally after school return. A time trend analysis of upper respiratory 
infections and hospital admissions for asthma identified a strong correlation between 
the seasonal patterns of infection and hospital admissions 35.  This relationship was 
stronger for paediatric than for adult admissions.  RVs were the major pathogens 
implicated in these infections.  It was speculated that it was the children’s school 
attendance that facilitates the spread of virus, leading to an increased number of 
asthma admissions.  Another study showed human picornaviruses were detected in 
52% of paediatric asthma admissions and 29% of controls and these cases were 
less likely to have been prescribed controller medication, suggesting that children 
with asthma who are prescribed anti-inflammatory medications are less likely to 
require emergency department treatment during this period of high risk of 
exacerbation 28. 
Asthmatic individuals have increased susceptibility to RV infection.  This was first 
addressed in the 1970s in prospective longitudinal studies comparing infection rates 
in cohabiting child and adult asthmatic and non-asthmatics 36, 37.  Increased 
incidences of confirmed colds were identified in asthmatics.  A more recent study of 
cohabiting couples, one of whom had asthma, showed that asthmatics were no more 
likely to develop RV infection, but had longer lasting and significantly more severe 
lower respiratory tract symptoms associated with RV infections compared to healthy 
controls 38.  RV ribonucleic acid (RNA) has been detected in nasal aspirates from 
>40% of asthmatic children 6 weeks after an acute exacerbation 39.  In patients who 
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had persistent RV RNA after 6 weeks, measurements of peak expiratory flow in the 
emergency room were significantly lower than in patients in whom RV RNA was 
present in the emergency room but absent after six weeks.  This suggests that the 
severity of acute asthma may be linked to prolonged and possibly more severe RV 
infections.  These studies identifying the importance of RV in the pathogenesis of 
asthma exacerbations highlight the importance of developing new therapeutic 
options for RV induced asthma exacerbations.   
 
1.2.3 Rhinoviruses 
RVs belong to the Picornaviridae family of viruses.  They are small, non-
enveloped, icosahedral, RNA viruses, with at least 100 serotypes known.  The virus 
is composed of a single stranded positive sense RNA molecule encased by a capsid 
formed from 60 copies of four viral proteins (VP1-4) 40, 41.  A protein shell, created by 
VP1-3, is on the exterior of the virus, with VP4 being in contact with the viral RNA.  
The structure of RVs include a well conserved region, a ‘canyon’ 41, which is the site 
for interaction between the virus and its receptors 42.   
RVs can be classified into the major and minor groups based on the receptors 
they use to enter the host cell.   The major group bind the surface glycoprotein 
human intercellular adhesion molecule-1 (ICAM-1) 43 and form the majority of RVs, 
with over 90 serotypes.  The minor group bind to low density lipoprotein receptors 
(LDLR) 44.  The alternative classification is according to VP4/VP2 nucleotide gene 
sequence analysis with type A, type B and the recently identified type C 45, 46.  Type 
C has been identified to be an important cause of hospitalisations 47.   
Following binding to the cell surface receptors intracellular internalisation of 
RV occurs.  Viral replication occurs by the virus hijacking the host cell translational 
machinery.  RVs have a protein, VPg, covalently linked to the 5'-ends of their 
genomes.  Uridylylation of VPg serves as the protein primer for RNA synthesis, 
linked to the presence of the internal cis-acting replication element (cre) 48, 49.  
Positive sense RNA undergoes translation by host ribosomes.  The resulting product 
is cleaved by viral proteases and transcribed by viral RNA polymerase into negative 
sense RNA which is further transcribed into positive sense RNA.  Viral proteins and 
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positive sense RNA form virions which are released from the cell 50.  RVs replicate in 
6h, with 100,000 virions being released from infected cells in vitro 51. 
 
1.2.4 Rhinovirus infection of airway cells 
 The bronchial epithelium is important in RV induced asthma exacerbations.  
Several genes that are associated with asthma susceptibility are expressed in the 
epithelium 52.  RV is usually a mild infection in non-asthmatics, but is associated with 
cytotoxicity and delayed epithelial repair in asthmatics 53.  Human bronchial epithelial 
cells (HBECs) express ICAM-1 54-56 and LDLR 57.  RVs infect HBECs in vitro and in 
vivo with the upper and the lower airways being infected and replication peaking at 
24-48h post infection 58.  In situ hybridisation for RV16 on bronchial biopsy samples 
from an experimental model of infection identified RV16 localised predominantly to 
the columnar epithelial layer.  Infection results in production of interleukin (IL)-6, 
CXCL8/IL-8, IL-16 and CCL5/RANTES, and RVs are cytotoxic to epithelial cells in 
culture 58, 59.  RV infection induces type I 60 and type III 61 interferon (IFN) production 
with the IFN responses of HBECs from asthmatics being deficient. 
 The other key airway cell related to RV infection is the alveolar macrophage.  
These cells are resident in the lung and are the predominant immune effector cells in 
the airway and alveolar spaces.  They are important for microbial clearance 62, 
decrease antigen presentation function of dendritic cells 63, decrease humoral 
responses to inhaled antigens 64 and promote a T helper (Th)-1 response 65.  Lung 
macrophages express high levels of both ICAM-1 66 and LDLR 67.  Clear interactions 
occur between RV and alveolar macrophages.  Some reports confirm RV binding to 
macrophages with subsequent cytokine induction, but no productive RV replication 
or release of new virions 68.  More recently, RV replication has been demonstrated in 
a human monocyte cell line but was limited in primary human monocytes, the 
difference being suggested due to the robust type I IFN response in primary cells 
and not in the cell line-derived macrophages 69.  Though replication may or may not 
occur, exposure of alveolar macrophages to RV results in cell activation and 
induction of IFNs 61.  Following activation macrophages secrete antiviral and 
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proinflammatory cytokines including CXCL8/IL-8, IL-10, IL-12, tumour necrosis factor 
(TNF)-α and CCL2/monocyte chemotactic protein 1 (MCP-1) 70-73. 
 Differences in alveolar macrophage cytokine production between non-atopic 
non-asthmatics (NANA) and atopic asthmatics (AA) have been observed, with 
reduced IL-12 74, IL-18 75 and IL-15 76 production in AA.  Macrophages from AA have 
been shown to have deficient RV-induced type III IFN production 61.  The important 
immune role alveolar macrophages have in host defence against viral and bacterial 
infection and the differences in their function in AA and NANA makes them an 
important cell type to study further, in particular whether the atopic status of the cell 
type is important. 
  
1.2.5 Rhinovirus infection and peripheral blood mononuclear cells (PBMCs) 
 Intranasal inoculation of RV results in changes in peripheral blood leucocytes, 
with a significant decrease in total lymphocyte count and a strong correlation 
between decreases in lymphocytes and severity of symptoms 77.  PBMC activation 
occurs without active RV replication and results in induction of IFN-γ, IL-12, IL-10 
and IL-13 78, 79.  Following infection with RV, production of type I and III IFNs have 
been observed in PBMCs, with IFN-α as the predominant type followed by IFN-β and 
IFN-λ 80.  There is data to suggest impaired IFN-α production in PBMCs stimulated 
with RV from adolescent asthmatics but not adults, and impaired IL-6, TNF-α and IL-
10 production in adolescent and adult asthmatics 81.  A deficient type I IFN response 
has also been observed in PBMCs from AA following infection with RSV and 
Newcastle disease virus (NDV) 82.  Similarly, differences in RV-induced cytokine 
production by PBMCs between asthmatics and non-asthmatics have been observed, 
with NANA producing significantly more IFN-γ and AA producing significantly more 
IL-10 78. 
 The observed differences in IFN and cytokine production from PBMCs in 
asthmatics following respiratory virus infection warrant further investigation, and in 
particular whether atopy is important. 
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1.3 Bacteria and asthma 
 
1.3.1 Atypical bacteria and asthma 
Numerous studies have investigated the association of atypical bacteria such as 
Chlamydophila pneumoniae (Cpn) in both stable and exacerbations of asthma.  
Many studies rely on serology and are unable to distinguish between acute and 
chronic infection.  A study of AA and NANA spouse pairs, with regular nasal aspirate 
sampling and detection of Cpn by RT-PCR showed that Cpn was positive in 6.4% of 
samples from atopic asthmatics compared to 2.3% of samples from controls, 
confirming that Cpn infection is detected more frequently among asthmatics than 
non-asthmatic participants 83.  Another study examined the association between 
immunoglobulin (Ig)G and IgA titres to Cpn and asthma severity 84.  Higher titres of 
antibodies were associated with markers of asthma severity.  High dose inhaled 
steroid use was associated with a 74.1% increase in IgG titre and a 70.6% increase 
in IgA compared to low dose inhaled steroid use.  The titre of antibody increased by 
0.8% for every 1% decrease in % predicted forced expiratory volume in 1 second 
(FEV1).  An elevation in IgA was associated with a higher daytime symptom score.  A 
study investigating the prevalence of Cpn infection in asthmatic patients, identified 
that the frequency of PCR positivity for Cpn in throat wash samples was higher in 
stable asthmatics (28.6%) than in healthy controls (11.8%) 85.  These studies confirm 
increased detection of Cpn in patients with asthma.  The importance of this 
association requires further study. 
There is also evidence suggesting a role for atypical bacteria in the aetiology of 
asthma exacerbations.  A study of asthmatic children was performed with nasal 
aspirates taken when respiratory symptoms were reported and the presence of Cpn 
was tested by PCR and Cpn-specific IgA was detected by ELISA 86.  This showed 
that although Cpn detections were similar between symptomatic and asymptomatic 
episodes, those children who reported multiple episodes remained PCR positive, 
suggesting chronic Cpn infection.  IgA antibodies were more than seven times 
greater in subjects who reported four or more exacerbations compared to those who 
reported just one.  This demonstrates that immune responses to Cpn are positively 
associated with frequency of asthma exacerbations.  Of interest, samples were 
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analysed from a previous study which had detected virus infections in 80-85% of 
exacerbations 29, indicating that virus infections may interact with Cpn to increase 
risk or frequency of exacerbations.  The mechanisms of this interaction are poorly 
understood. 
Similarly, in an adult asthmatic population presenting to the emergency 
department who underwent sputum induction and spirometry at presentation and 
had acute and convalescent serology for Cpn-specific IgA and IgG, 20 (38%) 
subjects demonstrated an increase in Cpn antibody levels 87.  15 of these had an 
increase in IgA levels on a background of raised IgG, suggesting reactivation of 
chronic infection, and 5 had a rise in IgG having been serologically negative at the 
first visit, indicating an acute infection.  These patients with serological responses to 
Cpn had four times higher sputum neutrophil levels and sputum eosinophilic cationic 
protein concentrations than those patients who had exacerbation symptoms without 
serological responses, suggesting Cpn reactivation is associated with increased 
airway inflammation. 
 
1.3.2 Typical bacteria and asthma 
There is less evidence for a role for typical bacteria, such as Streptococcus 
pneumoniae (Spn), in asthma pathogenesis.  Early studies suggest that infection 
with Spn is no more common in asthmatics than controls and with no difference 
between atopic and non-atopic asthmatics 10.  Spn is commonly carried 
asymptomatically in the respiratory tract and is a major cause of community acquired 
pneumonia in children and adults.  There is evidence from the Copenhagen birth 
cohort that neonates colonised with Spn, Haemophilus influenzae, Moraxella 
catarrhalis or any combination have increased risk of recurrent wheeze and early life 
asthma 88.  A recent study has identified house dust mite-sensitised children with 
lower IgG1 antibody titres to Spn surface antigens (PspA and PspC) which are 
associated with asthma.  Of interest, antibacterial IgE was associated with a reduced 
risk for asthma 89.  The question of whether antibiotics in early life confer protection 
from the subsequent development of asthma has not been assessed by clinical 
trials, but population based cohort studies suggest that antibiotic administration early 
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in life does not reduce the risk of asthma 90.  Early studies suggest an association 
between asthma and bacterial sinusitis in children, with treatment of the bacterial 
infection resulting in improved asthma scores 91.  IL-17 has a role in the 
pathogenesis of asthma.  A polymorphism of IL-17 is associated with several asthma 
traits and detection of Spn has been shown to be higher in children with this 
polymorphism, suggesting a link between bacterial colonisation and the onset of 
asthma 92.  Oropharyngeal pneumococcal carriage is more common in asthmatics 
than non-asthmatics 93, 94.  This may in part be explained by the fact that the use of 
inhaled corticosteroids in asthmatic children increases the risk of pneumococcal 
colonisation 95.  Of several risk factors, including asthma, smoking, allergic rhinitis, 
atopy and body mass index, the only significant risk factor for Spn oropharyngeal 
carriage was asthma (OR, 2.04) 93.   
While these studies demonstrate an association with asthma, the role of Spn in 
asthma exacerbations is less clear.  Some older studies demonstrate bacteria being 
causative organisms in asthma exacerbations 96 and vaccination against Spn 
reduces the number of hospital admissions for asthma exacerbations in children 97 
and the elderly 98.  Children admitted to the emergency department for asthma 
exacerbations have reduced IgG responses to house dust mite allergens 99.  In 
children following an acute exacerbation there is a marked increase in anti-bacterial 
IgE, with a reduced IgE response to house dust mite 100.  These studies support the 
concept of Th2 responses to bacterial antigens playing a role in asthma 
pathogenesis.  
There are studies that suggest a protective role of Spn in the development of 
asthmatic symptoms, through induction of regulatory T cells 101, 102.  Spn has been 
observed to suppress allergic airways disease by inducing regulatory T cells, leading 
to an inhibition of T cell proliferation and Th2 cytokine release 101. 
Asthma is a risk factor for invasive pneumococcal disease.  Case-control studies 
to examine the association between asthma and invasive pneumococcal disease 
showed that asthma was an independent risk factor for invasive pneumococcal 
disease, with the risk among asthmatics at least double that of controls 103, 104.  
These studies raise important questions about the relationship between asthma and 
Spn.  The mechanisms for this increased susceptibility are unknown but asthmatics 
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have lower serotype-specific pneumococcal antibodies than non-asthmatics 105 and 
interferon production has been found to be deficient in asthmatic bronchoalveolar 
macrophages following stimulation with lipopolysaccharide (LPS) 61.  Of interest, 
atopic conditions other than asthma, particularly atopic dermatitis, have an increased 
risk of severe pneumococcal disease 106. 
There is some evidence that virus-induced asthma exacerbations may be 
worsened by concomitant bacterial infection.  Studies have examined the effects of 
RV infection on Spn adherence to human nasal 107 and tracheal epithelial cells 108.  
With cells infected with RV-14, the number of Spn adhering increased and the use of 
NF-κB inhibitors decreased adherence.  This suggests that RV infection stimulates 
bacterial adhesion to airway epithelial cells and this is, at least in part, mediated 
through activation of transcription factors.  This increase in Spn adherence following 
RNA viral infection may be explained by the fact that the toll-like receptor (TLR)3 
agonist polyinosinic:polycytidylic acid (poly(IC)) has been demonstrated to enhance 
platelet activating factor receptor (PAFR) expression on airway epithelial cells 109.  
PAFR is used by Spn and PAFR-deficient mice are relatively resistant to Spn 
infection and have less pulmonary inflammation 110.  Other respiratory viruses (RSV 
and human parainfluenza virus) have been shown to promote Spn adherence to the 
bronchial epithelium 111.  RV circulation within the community is associated with the 
development of invasive pneumococcal disease in children under 5 years of age 112.  
A possible mechanism for this increased risk of bacterial infection is that RV infection 
results in impaired cytokine responses to bacterial LPS and lipoteichoic acid (LTA) 
by alveolar macrophages 113.  This has important implications in the pathogenesis of 
asthma exacerbations. 
 
1.3.3 Streptococcus pneumoniae (Spn) 
 To date there are more than 90 serotypes of Spn known.  Each serotype has 
an individual polysaccharide capsule which functions as a key virulence factor by 
inhibiting phagocytosis, complement factor binding and entrapment by neutrophil 
extracellular traps 114-116.  The exotoxin, pneumolysin, is another key pneumococcal 
virulence factor.  It is cytotoxic to mammalian cells by binding to cell membrane 
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cholesterol and forming large pores in the membrane 117.  This pore formation results 
in leakage of intracellular solutes and an influx of water, leading to osmotic lysis of 
the cell 118.  It also induces separation of tight junctions of epithelial cells, thereby 
facilitating bloodstream invasion and inhibits polymorph chemotaxis 118.  Expression 
of haemolytic pneumolysin by Spn inhibits dendritic cell maturation, thereby limiting 
induction of innate immune responses 119.  Pneumolysin also inhibits ciliary beating 
on respiratory epithelial cells 120 and activates the classical complement pathway 117, 
121.  Other cell wall components, such as LTA lead to complement activation 118.  
Other pathogenic features of Spn include LPXTG-anchored surface proteins 
(hyaluronidase and neuraminidase which cleave sialic acid residues thus damaging 
host tissues, and serine protease) and various bacterial lipoproteins 117.  Spn 
virulence factors are schematically illustrated in figure 1.1. 
 
 
Figure 1.1.  Streptococcus pneumoniae virulence factors.  (adapted from Kadioglu et al. 
120
) 
Virulence factors include the capsule, cell wall, pneumolysin, LPXTG-anchored neuraminidase 
proteins, hyaluronate lyase (Hyl), autolysin (LytA), enolase (Eno), pneumococcal adhesion and 
virulence A (PavA), pneumococcal surface proteins A and C (PspA and PspC), and the metal-binding 
proteins pneumococcal surface antigen A (PsaA), pneumococcal iron acquisition A (PiaA) and 
pneumococcal iron uptake A (PiuA) 
120
.  Several of these are recognised by pattern recognition 
receptors. 
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1.3.4 Spn infection of airway cells 
 Adhesion of bacteria to the bronchial epithelial cell is fundamental for 
colonisation and infection of the airway 122.  Spn has been shown to bind specifically 
to bronchial epithelial cells 123 and this binding is dependent on sialylated 
carbohydrate ligands 124.  It is thought that changes in virulence factors allow for 
colonisation 125.  In vitro Spn has been demonstrated to induce release of CXCL8/IL-
8 from bronchial epithelial cells and to disrupt airway barrier function 126.  The role of 
Spn and the bronchial epithelium in asthma is not well understood.  A feature of 
chronic respiratory diseases such as asthma is mucus overproduction.  Spn has 
been identified as an inducer of MUC5AC mucin expression from human epithelial 
cell lines 127. 
 There has been evidence for the involvement of alveolar macrophages in Spn 
infection since the 1970s, particularly identifying the phagocytic activity of 
macrophages 128-130.  Spn binds to alveolar macrophages and with opsonisation this 
results in internalisation and killing of the bacterium 131.  Alveolar macrophages are 
important for early proinflammatory cytokine release following Spn infection, 
suggesting a role for them in the innate immune response 132.  The NF-κB protein 
RelA is important for host defence in Spn pneumonia and it has been demonstrated 
that RelA in alveolar macrophages is critical for the earliest innate immune response 
133.  Spn virulence factors such as LTA have been demonstrated to induce cytokine 
secretion, particularly TNF-α, from alveolar macrophages 134.  A mouse model of Spn 
infection demonstrates the importance of pneumolysin in the secretion of IL-1β from 
airway macrophages 135. 
 
1.3.5 Spn infection and PBMCs 
 Pneumolysin from Spn results in stimulation of TNF-α and IL-1β from human 
peripheral blood monocytes 136.  Significant production of cytokines CXCL8/IL-8, IL-
6, IL-1β, CCL3/macrophage inflammatory protein (MIP)-1α and TNF-α occurs 
following stimulation of PBMCs with a number of bacterial pathogens, including Spn, 
with the peak of cytokine production at 24h post stimulation 137, 138.  Whether Spn 
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induces type I and III IFN production in PBMCs is unknown.  Very little is known 
about Spn and PBMCs between asthmatic and non-asthmatics. 
 
1.4 Immunology of RV-induced asthma exacerbations 
 
The mechanisms of RV-induced asthma exacerbations have so far been 
elucidated largely from experimental infection models in asthmatics and non-
asthmatics, in vitro studies of cell lines and studies of natural colds.  RV infection of 
the upper respiratory tract and the resultant pathology is thought to be due to 
cytokine dysfunction as infection does not lead to extensive epithelial cytotoxicity 139. 
RV infection results in neutrophilic infiltration and in the upregulation of many 
proinflammatory cytokines, namely IL-6, CXCL8/IL-8, IL-16, CCL11/eotaxin, 
CXCL10/IP-10, CCL5/RANTES, CXCL5/ENA-78 and G-CSF 140-142.  Neutrophilic 
inflammation may have a role in persistent airway obstruction in asthma as higher 
sputum neutrophil counts are associated with lower post bronchodilator FEV1 
143
.  
Other cell types involved in RV-induced airway inflammation include eosinophils and 
lymphocytes.  In stable asthmatics sputum cell counts are normal, but during an 
exacerbation sputa become eosinophilic, neutrophilic or with a mixed cellular 
response 144.  RV infection is associated with increased submucosal lymphocytes 
and increases in bronchoalveolar lavage (BAL) lymphocytes have been observed in 
a human exacerbation model 71. 
 
1.4.1 Interleukin-6 (IL-6) 
 IL-6 is a cytokine that acts both in an anti- and a pro-inflammatory manner in 
humans.  It acts mainly through a cell surface receptor consisting of IL-6Rα and the 
signal transducer gp130 145.  Soluble IL-6 receptor has been recognised 146.  IL-6 is 
important in the acute phase and immune responses, by stimulating production of 
acute phase proteins, immunoglobulins, B-cell differentiation and T-cell activation 145, 
147.   
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A number of studies have demonstrated that IL-6 is produced following RV 
infection and that this production is mediated by an NF-κB-dependent transcriptional 
pathway 148.  Experimental RV infection in atopic asthmatics results in an increase in 
IL-6 in the sputum, with levels remaining elevated as long as 9 days after infection 
149, 150.  IL-6 is produced by bronchial epithelial cells 151, monocytes and alveolar 
macrophages 152.  In comparison to non-asthmatics, asthmatic bronchial epithelial 
cells in vitro have been observed to produce higher levels of IL-6 spontaneously 151, 
but IL-6 responses to RV infection in HBECs have been shown to be similar between 
asthmatics and non-asthmatics 153.  IL-6 is also induced following RV infection in 
PBMCs and a recent study suggests the concentration is significantly reduced in 
asthmatics compared to non-asthmatic controls 81.  The important role IL-6 plays in 
inflammation is therefore of interest in asthma exacerbations. 
 
1.4.2 Interleukin-8 (CXCL8/IL-8) 
 CXCL8/IL-8 is a major mediator of immune responses whose key function is 
in neutrophil chemotaxis.  RV is a potent stimulator of CXCL8/IL-8 in vivo and in vitro 
and this production is, at least in part, mediated by an NF-κB-dependent 
transcriptional pathway 154.  CXCL8/IL-8 is produced following RV infection in HBECs 
155, macrophages 73 and in PBMCs 156.  Experimental RV infection in atopic 
asthmatics results in an increase in CXCL8/IL-8 in the sputum, with levels remaining 
elevated as long as 9 days after infection 149.  However the inflammatory responses 
in the upper and lower airways following experimental RV infection of asthmatics are 
no different from non-asthmatics 150.   Nasal lavage from asthmatics and non-atopic 
non-asthmatic subjects experimentally inoculated with RV had peak CXCL8/IL-8 
levels correlating with cold scores and nasal neutrophil counts, highlighting the 
neutrophil chemotaxis function of CXCL8/IL-8 157.  The role CXCL8/IL-8 has in the 
pathogenesis of RV infection and asthma exacerbations makes it an important 
cytokine to examine further. 
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1.4.3 Interleukin-1β (IL-1β) 
 IL-1β has a major role in the communication between monocytes and 
epithelial cells.  IL-1β production from mononuclear cells has been identified as 
required for the inflammatory response from airway cells 158.  Studies have identified 
increased levels of IL-1β in nasal lavage from volunteers experimentally infected with 
RV16 159 and differences have been observed between asthmatics and non-
asthmatics 160.  RV infection of upper airway epithelial cells results in increased 
production of IL-1β with a study demonstrating the use of neutralising antibodies to 
IL-1β resulting in significantly decreased viral titres and ICAM-1 mRNA expression.  
This suggests that the upregulation of ICAM-1 by RV is mediated through the effects 
of IL-1β 161.  IL-1β and myeloid differentiation factor (MyD) 88 play a crucial role in 
regulating RV replication and the inflammatory response to viral infection of airway 
cells and exogenous IL-1β amplifies CXCL8/IL-8 release from RV-infected cells 162.  
IL-1β is of interest in RV-induced asthma exacerbations. 
 
1.4.4 Tumour Necrosis Factor-α (TNF-α) 
 TNF-α is produced largely from activated macrophages and plays an 
important part in the acute phase and immune response.  It is produced by airway 
epithelial cells 161, macrophages 69 and PBMCs 163.  RV infection of upper airway 
epithelial cells results in increased production of TNF-α 161 and this increased 
expression is at least in part mediated through NF-κB 164.  Stimulation of tracheal 
epithelial cells with exogenous TNF-α results in significant upregulation of ICAM-1 
and subsequent increases in neutrophilic adhesion 165.  TNF-α secretion results in 
increases in other proinflammatory cytokines and chemokines such as CXCL8/IL-8 
from bronchial epithelial cells 166.  RV and TNF-α stimulation of primary HBECs result 
in cooperative increases in chemokine expression such as CXCL8/IL-8.  This 
provides a possible cellular mechanism for RV-induced asthma exacerbations 167.  
RV infection of human macrophages results in a time- and dose-dependent induction 
of TNF-α 69. 
TNF-α has been implicated in asthma for several years 168.  It is thought to 
play a key role in the initiation of airway inflammation in asthma and the resultant 
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bronchial hyperreactivity 169 and much work has been carried out in the investigation 
of anti-TNF-α as a treatment modality in severe asthma 170.  Alveolar macrophages 
and PBMCs from asthmatics have been observed to produce significantly more TNF-
α than in control subjects 171.  The key role TNF-α has in the inflammatory response 
makes it an important cytokine to investigate further 
1.4.5 Other proinflammatory cytokines 
 Cytokines which may be of importance in RV-induced asthma exacerbations 
include IL-16, CCL5/RANTES, CXCL10/IP-10, CXCL5/ENA and eotaxins.  IL-16 is 
induced by RV and is a powerful lymphocyte chemoattractant and activator of 
eosinophils and macrophages 58.  CCL5/RANTES attracts eosinophils and 
lymphocytes and results in upregulation of other proinflammatory cytokines leading 
to airway hyperresponsiveness, inflammation and mucus secretion 142.  CXCL10/1P-
10 is involved in T cell recruitment and is stimulated by RV and secreted from airway 
epithelial cells in vitro and in vivo 172.  An increased level of CXCL10/IP-10 in the 
serum of asthmatics has been observed 153.  CXCL5/ENA induces neutrophil 
migration 173.  Eotaxins are eosinophil chemoattractants and are secreted from 
airway epithelial cells following RV infection 141. 
 For the purposes of this study IL-6, CXCL8/IL-8, IL-1β and TNF-α were 
chosen as the proinflammatory cytokines to be investigated. 
 
1.5 Proinflammatory cytokine expression following airway infection with Spn 
 
1.5.1 IL-6 and CXCL8/IL-8 
Pneumococcal peptidoglycan-polysaccharides and lipopolysaccharides 
induce CXCL8/IL-8 production in bronchial epithelial cells via an NF-κB and 
activation protein (AP)-1 dependent mechanism 174.  Pneumolysin interacts with 
TLR4.  TLR4 deficient mice have increased susceptibility to pneumococcal infection 
175.  Pneumolysin induces production of CXCL8/IL-8 in airway cells using signalling 
pathways involving calcium flux and activation of NF-κB via TLR4 176.  Indeed, 
pneumolysin is thought to be the major factor responsible for the induction of 
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inflammation and induces proinflammatory cytokine expression in a time-dependent 
manner 177.  The pneumococcal virulence factor choline binding protein A (CbpA) 
participates in the induction of IL-6 and CXCL8/IL-8 from bronchial epithelial cells, 
thereby having an immunopathological role 178. 
 
1.5.2 IL-1β 
The role of IL-1β in the airway immune response to Spn is not well 
recognised.  IL-1β is thought to be important in the communication between airway 
epithelial cells and macrophages, regulating CXCL8/IL-8 release and enhancing 
neutrophil recruitment 179.  Streptococcus species other than Spn have been 
identified to stimulate release of IL-1β from PBMCs 180.  IL-1 is secreted from human 
monocytes stimulated with pneumococcal cell wall components 181. 
 
1.5.3 TNF-α 
 TNF-α has long been implicated in the pathogenesis of pneumococcal 
pneumonia, with its production being thought to be protective, preventing 
bacteraemia 182.  Significant production of TNF-α from murine lung cells has been 
observed following Spn infection 183.  As well as having a protective role, TNF-α can 
be detrimental by inducing lung tissue injury.  The role of TNF-α from Spn-stimulated 
human airway cells is not well recognised.  With TNF-α playing an important role in 
asthma pathogenesis, further study is warranted. 
 
1.6 Role of interferons in virus and bacterial infection 
 
1.6.1 Interferons 
 IFNs are antiviral cytokines, first discovered in 1957 by their ability to 
‘interfere’ with viral replication 184.  They are of central importance in the innate 
immune response to viral infections, including rhinoviruses.  The antiviral activity of 
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IFNs is the result of upregulation of interferon stimulated genes (ISGs) leading to the 
production of IFN stimulated proteins.  These proteins have antiviral, antimicrobial, 
antiproliferative, antitumour and immunomodulatory effects 185. 
 There are three classes of IFN – type I, type II and type III.  Type I IFNs are 
divided into various subtypes, the most important being IFN-α and IFN-β.  IFN-α 
genes have more than 13 subtypes whereas IFN-β only has one subtype 185.  
Virtually all cell types express type I and III IFNs.  By contrast, Type II IFN or IFN-γ, 
which is structurally unrelated to type I IFNs, is induced by cytokines such as IL-12 
and is expressed only in immune cells such as T cells, NK cells and 
monocytes/macrophages.  Type III IFNs have been identified more recently and are 
known as IFN-λ1, IFN-λ2 and IFN-λ3 (or IL-29, IL-28A and IL-28B respectively) 186.  
Table 1.2 illustrates the different IFNs. 
 
Table 1.2.  The interferon family members.  The different types, subtypes, receptor, gene locus and 
cell expression of the IFNs 
187
. 
Type Subtype Receptor Gene 
locus 
Expression pattern 
I IFN-α IFNAR1/IFNAR2 9p21 Ubiquitous 
 IFN-β IFNAR1/IFNAR2 9p21 Ubiquitous 
 IFN-ε IFNAR1/IFNAR2 9p21 Uterus, ovary 
 IFN-ω IFNAR1/IFNAR2 9p21 Leucocytes 
 IFN-κ IFNAR1/IFNAR2 9p21 Selective expression in epidermal 
keratinocytes 
 IFN-δ IFNAR1/IFNAR2 None Trophoblasts 
 IFN-τ IFNAR1/IFNAR2 None Trophoblasts 
 
 
IFN-ζ IFNAR1/IFNAR2 None Spleen, thymus, lymph node 
II 
 
IFN-γ IFNGR1/IFNGR2 12q24.1 Activated T cells, macrophages, NK 
cells 
III IFN-λ1 (IL-29) IL-28Rα/IL-10R2 19q1 Ubiquitous 
 IFN-λ2 (IL-28A) IL-28Rα/IL-10R2 19q1 Ubiquitous 
 IFN-λ3 (IL-28B) IL-28Rα/IL-10R2 19q1 Ubiquitous 
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1.6.1.1 Type I interferons 
 Type I IFNs are a family of intronless genes, present in all vertebrates, which 
originated 250 million years ago 188.  The group includes IFN-α, IFN-β, IFN-ω, IFN-ε, 
IFN-κ, found in humans, and IFN-δ, IFN-τ, IFN-ζ, found in cattle and pigs 189.  In 
humans the gene is located on the short arm of chromosome 9 190.  The IFNs of 
most importance in humans are IFN-α and IFN-β 189.  Type I IFNs interact with an 
evolutionary conserved single cell surface receptor, the IFN-α receptor (IFNAR), 
made up of an extracellular binding domain and an intracellular kinase domain.  The 
receptor is composed of two subunits, IFNAR1 and IFNAR2, which are associated 
with two cytoplasmic tyrosine kinases, tyrosine kinase 2 (TYK2) and Janus kinase 1 
(JAK1) respectively 191-193.  Both subunits are required for receptor function 194.  Type 
I IFN binding induces phosphorylation of these kinases, which activates signal 
transducers and activators of transcription (STAT) 1 and 2.  In resting cells STATs 
reside in the cytoplasm as inactive homodimers 195.  Upon activation STATs form 
heterodimers and complex with IFN regulatory factor (IRF) 9 to form IFN-stimulated 
gene factor (ISGF) -3 for translocation to the cell nucleus where they upregulate the 
expression of ISGs by binding to the IFN stimulated response element (ISRE) 
enhancer family 196, 197 (Figure 1.2). 
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Figure 1.2.  Activation of JAK-STAT pathway by type I IFN.  (original figure) Type I IFN binds to 
the IFN receptor composed of IFNAR1 and IFNAR2.  This associates with TYK2 and JAK1 resulting 
in phosphorylation of STAT1 and STAT2 which form a heterodimer before complexing with the 
translocation factor IRF9 to form ISGF-3.  This complex translocates to the nucleus and binds to ISRE 
to initiate gene transcription. 
 
1.6.1.2 Type III interferons 
 The IFN-λs are known as the type III IFNs.  They are structurally distinct from 
type I IFNs and bind to a different receptor.  Their mechanisms of induction, signal 
transduction and biological actions are similar to type I IFNs 186, 198.  The three 
functional IFN-λ genes are located on chromosome 19 and encode highly 
homologous proteins with IFN-λ2 having 96% homology with IFN-λ3 and IFN-λ1 
having 81% homology with IFN-λ2 198. There is only a 20% homology between all 
IFN-λs and type I IFNs 186.  Whereas type I IFN genes have no introns, the coding 
regions of the IFN-λ genes are interrupted by 4 introns 199.  IFN-λs interact with a 
different cell surface receptor comprising IFN-λR1 and IL-10R2. Despite signalling 
through distinct receptors, type I and III IFNs trigger similar signalling pathways, 
ending in the formation of ISGF-3 which binds to the ISRE 199.  There is emerging 
evidence that IFN-λs may have a role beyond innate antiviral protection with type III 
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IFNs having a unique function in antiviral protection of the gastrointestinal epithelium 
that is independent of, and not overlapping with, the type I IFN system 200, leading to 
the suggestion that type III IFNs may be involved in GI tract homeostasis. 
 
1.6.1.3 Defective interferon production in asthmatics 
 Defective RV-induced IFN induction has been reported in HBECs and BAL 
cells from AA 60, 61, 201.  HBECs stimulated with RV produce significant concentrations 
of type I IFNs, particularly IFN-β, and IFN-λ 80 and, compared to those from NANA, 
HBECs from AA have been shown to have significantly reduced IFN-β mRNA levels 
at 8h and protein at 48h following infection with RV16 60.  In addition to this AA have 
increased virus release and virus RNA from infected cells and impaired apoptosis.  
HBECs from AA treated with exogenous IFN-β have responses to RV similar to that 
of NANA 60.  Likewise, HBECs from asthmatic donors have been shown to have a 
normal antiviral response to exogenous IFN-β, with exogenous IFN-β significantly 
suppressing RV replication and significantly reducing RV-induced CXCL10/IP-10, 
CCL5/RANTES and IL-6 expression 202. 
 Induction of IFN-λ has also been reported as defective in HBECs and BAL 
cells from AA infected ex vivo with RV16 61.  This study was a human asthma 
exacerbation model and the IFN-λ response was related to BAL virus load, 
inflammation in BAL and sputum and positively correlated with reductions in lung 
function during in vivo infection.  Table 1.3 is a summary of studies that do and do 
not demonstrate type I and III IFN deficiency in asthma. 
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Table 1.3.  Summary of studies assessing the role of type I and III IFNs in asthma   
Studies demonstrating Type I and III 
IFN deficiency in asthma 
 
Studies not demonstrating Type I and III 
IFN deficiency in asthma 
Study Key findings Study Key findings 
Wark et al. 
60
 Deficient IFN-β, impaired 
apoptosis and increased 
virus replication in atopic 
asthmatic HBECs 
Lopez-Souza et al. 
203
 No significant differences 
between asthmatic and 
healthy subjects in RV-
induced IFN-β expression 
in nasal epithelial cells and 
HBECs. 
Contoli et al. 
61
 Deficient RV-induced 
production of IFN-λ in 
asthmatic HBECs and 
alveolar macrophages; highly 
correlated with severity of 
RV-induced asthma 
exacerbation 
Bochkov et al. 
204
 Using microarrays and 
qPCR, no difference in RV-
induced type I or III IFN 
expression between NANA 
and AA was observed 
Gill et al. 
205
 Plasmacytoid dendritic cells 
secreted significantly less 
IFN-α upon exposure to 
influenza A in asthmatics 
  
Bufe et al. 
206
 Children with AA produced 
significantly lower levels of 
virus-induced IFN-α from 
blood cultures than healthy 
children and children with 
NAA 
  
Edwards et al. 
207
 HBECs from severe therapy 
resistant atopic asthmatic 
children have profoundly 
impaired RV-induced IFN-β 
and IFN-λ mRNA and protein 
production 
  
Sykes et al. 
208
 RV induction of type I IFNs in 
BAL cells is delayed and 
deficient in asthmatics and is 
associated with greater AHR 
and skin prick test positivity 
  
Baraldo et al. 
209
 In children, deficient RV-
induced IFN responses 
present in asthmatics 
irrespective of their atopic 
status and in atopic patients 
without asthma 
  
 
 
  
43 
 
1.6.2 Is there a role for interferons in defence against bacteria? 
As well as asthma, Cpn has been associated with atherosclerosis.  Cpn has 
been shown to induce IFN-β in bronchial and vascular smooth muscle cells, 
suggesting a possible role for Cpn-induced IFN-β production by smooth muscle cells 
in modulating inflammation 210.  Mouse bone marrow-derived macrophages (BMMs) 
infected with Cpn have been shown to induce IFN-α/β, leading to expression of IFN-
γ, which controls bacterial growth 211.  This is controlled by IRAK-4 and STAT-1 as is 
demonstrated in mouse knockout studies 211, 212. 
Other intracellular bacteria such as Listeria monocytogenes can activate the 
type I IFN pathway through TANK-binding kinase 1 (TBK-1) 213.  The importance of 
TBK-1 in antiviral immunity is well established, but much less is understood in 
bacterial infection.  Studies of TBK-1 knockout mice showed increased Salmonella, 
E. coli and S. pyogenes replication in the cytosol and that TBK-1 appears important 
for the integrity of pathogen-containing vacuoles within the cell 214.  Infection of 
mouse BMMs with Listeria results in the early induction of IFN-β and this expression 
is dependent on IRF-3 and TLR-independent as evidenced by the fact that TLR-
deficient mice had similar levels of expression of IFN-β 215.   
Do extracellular bacteria induce interferons?  Studies of the extracellular 
bacteria group B streptococcus have identified induction of type I IFNs via TBK-1 
and IRF-3, via intracellular recognition of the bacterial DNA 216.  Macrophages from 
mice homozygous for a Map3k8 gene mutation have been found to have a high 
susceptibility to group B streptococcus infection, with impaired TNF-α and type I IFN 
production 217.  Interestingly the same mutation did not result in susceptibility to viral 
infections.  S. pyogenes (group A streptococcus) has been shown to induce type I 
IFNs through the IRF-3 signalling pathway 218, through a MyD88-dependent receptor 
other than those typically used by bacteria 219.  S. pyogenes has also been shown to 
upregulate TLR3 and TLR7 gene expression and that this upregulation is dependent 
on IFN-α/β 220. 
 There is evidence that IFNs are involved in Spn infection.  A study using 
DNA microarray in a mouse model of asymptomatic carriage identified that Spn 
colonisation induces early expression of type I IFNs with increases in transcripts 
44 
 
associated with T cell development and activation 221.  Nasopharyngeal colonisation 
with Spn in mice results in a moderate increase in type I IFN mRNA 222.  Spn has 
been shown to activate the type I IFN cascade in airway epithelial and dendritic cells, 
a response dependent on the pore-forming toxin pneumolysin 223.  IFN-α/β receptor 
null mice have significantly increased nasal colonisation of Spn than wild type mice, 
suggesting type I IFNs are important in the mucosal response to airway bacterial 
pathogens.  More recent data suggest the epithelial cell is not the main producer of 
type I IFNs, but are activated in a paracrine manner to express ISGs by IFN-α/β 
produced by macrophages 224.  Spn stimulates type I IFN in alveolar macrophages 
through a cytosolic DNA-sensing pathway involving the adaptor molecule STING and 
IRF-3.  In contrast to this, but also suggesting a role for IFNs in bacterial infections 
another study suggests that type I IFNs mediate the development of post influenza 
bacterial pneumonia in mice 225.  IFN-α/β receptor null mice had improved survival 
and clearance of Spn from the lungs and blood compared to wild type animals, 
demonstrating that an IFN inhibitory pathway on other CXC chemokine production 
(CXCL1/KC and CCL2/MCP-1) is important following a secondary challenge with 
Spn.  Also of interest is the finding that mast cells, following TLR activation by Gram-
positive and –negative bacteria, elicit proinflammatory, but not type I IFN responses 
226. 
These studies emphasise the importance of examining C. pneumoniae as an 
intracellular bacterium which has been established as important in asthma 
pathogenesis, and S. pneumoniae as a relevant respiratory tract extracellular 
bacterium. 
 
1.7 Role of atopy in asthma 
 
Most studies investigating risk factors for exacerbations of asthma define 
atopy as a positive allergen-specific IgE or skin test to common inhaled or food 
allergens.  A significant proportion of individuals with positive tests have no evidence 
of allergic disease.  Some investigators propose that a positive test should not be the 
sole marker of atopy 227.  IgE-mediated sensitisation is not a simple yes/no 
phenomenon, demonstrated by the finding that the probability of childhood wheeze 
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and reduced lung function increases with increasing concentrations of serum specific 
IgE antibodies 228. 
Many studies have addressed the importance of allergen exposure in the first 
2 years of life and the development of asthma 229, 230.  Allergen exposure has also 
been implicated in exacerbations of asthma with high exposure to aeroallergens 
being associated with increased asthma related hospitalisations 231, 232.   
Evidence for the involvement of atopy in interferon deficiency is less clear.  A 
case report demonstrated undetectable IFN-α in the serum of a 3 year old child with 
atopic dermatitis 233 and IFN-α treatment has been shown to improve severe atopic 
dermatitis with significant reductions in serum concentrations of IgE and in 
production of IgE by patients’ PBMCs in vitro 234.  A study of children suggested an 
atopic phenotype (both asthmatic and non-asthmatic) was related to a reduction in 
virus induced IFN-α release from whole blood cultures 206.  Modest associations 
have been observed between asthma, bronchial hyperresponsiveness and atopy 
and variants of multiple genes in the type I IFN cluster on chromosome 9p22 235.  
CD4+ Th2 cells mediate atopic responses to allergens normally innocuous in non-
atopic individuals by the selective secretion of various cytokines including IL-4, IL-5 
and IL-13 236.  IL-4 is the key signal driving Th2 commitment by recruitment and 
phosphorylation of STAT-6 237 and regulation of induction of GATA3 transcription 238.  
GATA3 expression is essential for the maintenance of the Th2 phenotype 
239.  Type I 
IFNs have been identified to inhibit GATA3 during Th2 development, suggesting a 
potential therapeutic role for IFNα/β in asthma and atopy 240, 241.  A study of the 
effects of IL-4 on mouse bone marrow-derived dendritic cells found that exogenous 
IL-4 renders dendritic cells less responsive to paracrine type I IFNs and less potent 
in sustaining the autocrine positive loop that normally amplifies the effects of type I 
IFNs 242.  With atopy having a Th2-skewed cytokine response, these effects of IL-4 
could explain a deficient interferon response in asthma.  A study to compare TLR9 
mediated innate immune responses in dendritic cells between allergic and non-
allergic individuals identified a six-fold less IFN-α production in cells from allergic 
subjects (both asthmatic and non-asthmatic) when stimulated with the TLR9 ligand 
CpG 243.  
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The role of atopy in bacterial infection of the airway is less well understood.  
The presence of underlying Th2-immune responses to bacteria, especially bacterial-
specific IgE, in asthmatics has been known for many years 244, 245.  These responses 
have been shown to be increased following severe asthma exacerbations in children 
100.  The significance of this is unclear.  Of interest a more recent study suggested 
IgE titres against Spn surface antigens were independently associated with 
decreased asthma risk 246.  The role of atopy in bacterial infection in asthma requires 
further clarification. 
 
1.8 Interferon signalling pathways 
 
1.8.1 Pattern recognition receptors 
 Cells of the innate immune system express pattern recognition receptors 
(PRRs) which recognise pattern associated molecular patterns (PAMPs) found in 
viruses and bacteria.  The aim of such a system is rapidly to detect and eliminate 
foreign pathogens 247.  The most important PRRs for virus-induced interferon 
production are the toll like receptors (TLRs), RNA helicases and RIG-I like receptors 
248, 249.  TLRs are found in the extracellular and endosomal compartments, whereas 
the RNA helicases patrol the cytoplasm for the presence of viral double-stranded 
DNA.  More recently discovered and having a role in the recognition of bacterial cell 
products are the nucleotide-binding oligomerization domain (NOD)-like receptors 250. 
 
1.8.2 Toll like receptors 
 TLRs are major PRRs involved in induction of IFNs.  The involvement of TLRs 
in innate immunity was first described in drosophila.  There are 13 TLRs in 
mammals.  10 are known in humans, with TLR11-13 expressed in the mouse, but in 
humans are only represented as a pseudogene.  TLRs are hetero- and homodimers 
of type I transmembrane glycoproteins. Each TLR mediates pattern recognition 
through extracellular leucine repeats, have a transmembrane domain which 
determines the location within the cell and have an intracellular Toll/IL-1 receptor 
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(TIR) domain which is required for intracellular signalling 251-253.  Recognition of 
PAMPs by TLRs occurs in different cellular locations: the plasma membrane, 
lysosomes, endosomes and endolysosomes.  The location is important for ligand 
access and downstream signalling 252.  TLR signalling occurs through the MyD88 
dependent and independent pathways.  The ligands recognised, cellular location and 
IFN induction pathways used for each TLR is shown in table 1.4.   
TLR stimulation in the airway has many effects on the immune pathway.  It 
controls Th1, Th2 and Th17 cell differentiation; results in cytokine production; results in 
eosinophil activation; and increases expression of major histocompatibility complex 
proteins and T-cell coreceptors in dendritic cells, resulting in T-cell activation 254. 
 
Table 1.4. Toll like receptors: ligands, IFN induction pathways used and cellular location 
Toll Like 
Receptor 
Ligand IFN 
induction 
pathway 
Cellular 
location 
TLR1 Forms heterodimer with TLR2 to 
recognise triacylated lipopeptides from 
gram negative bacteria 
MyD88 
dependent 
Cell surface 
TLR2 Forms heterodimer with TLR1 and 
TLR6 to recognise peptidoglycan, LTA 
and haemagglutinin 
MyD88 
dependent 
Cell surface 
TLR6 Forms heterodimer with TLR2 to 
recognise diacylated lipopeptides from 
gram positive bacteria 
MyD88 
dependent 
Cell surface 
TLR3 dsRNA, poly(IC) MyD88 
independent 
Endosomal 
TLR4 LPS, RSV fusion proteins, 
pneumolysin, paclitaxel 
MyD88 
dependent & 
independent 
Cell surface 
TLR5 Flagellin MyD88 
dependent 
Cell surface 
TLR7 ssRNA, R848 MyD88 
dependent 
Endosomal 
TLR8 ssRNA, RNA40 MyD88 
dependent 
Endosomal 
TLR9 CpG-ODN in bacterial DNA, CMV, 
HSV1 and HSV2 
MyD88 
dependent 
Endosomal 
TLR10 Unknown, may form heterodimers with 
TLR1 and TLR2 to recognise bacterial 
lipopeptides 255 
Unknown Cell surface 
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1.8.2.1 TLR1, TLR2 & TLR6 
TLR2 recognises lipoproteins and lipoteichoic acid from bacteria and zymosan 
from fungi.  Upon recognition of its ligands TLR2 forms a heterodimer with either 
TLR1 or TLR6. These heterodimers recognise distinct ligands (triacyl lipoproteins for 
TLR1/TLR2 and diacyl lipoproteins for TLR2/TLR6) and it is understood to be the 
formation of these heterodimers which results in bringing intracellular TIR domains 
close together to initiate the signalling pathway 256.  Until recently TLR2 activation by 
bacterial ligands was thought to be associated with upregulation of proinflammatory 
cytokines but not with type I IFNs.  Recent data suggest TLR2 activation induces 
type I IFNs from endolysosomal compartments 257.  IRF2 has been shown to be 
activated by LTA resulting in upregulation of IRF1 and secretion of IFN-α 258.  
Another study demonstrates viruses but not bacteria can stimulate TLR2 to induce 
type I IFNs 259. 
 
1.8.2.2 TLR3 
 TLR3 recognises dsRNA viruses and the synthetic analogue of dsRNA, 
poly(IC).  TLR3-deficient mice have an impaired type I IFN and proinflammatory 
cytokine response to poly(IC) and poly(IC) was identified as an activator of NF-κB 
260.  Human TLR3-deficiency results in increased susceptibility to herpes simplex 
encephalitis 261 and may be implicated in polio infection 262.  It is expressed on 
macrophages, dendritic cells, fibroblasts and epithelial cells 263.  dsRNA binds to 
TLR3 which forms a homodimer and induces IFN production through an MyD88-
independent pathway (see section 1.8.3). 
 
1.8.2.3 TLR4 
 TLR4 recognises LPS, the component of the outer membrane of gram 
negative bacteria, the virulence factor pneumolysin from S. pneumoniae, the RSV 
fusion protein and the cytotoxic drug paclitaxel 264.  Several accessory molecules are 
used by TLR4 to bind LPS, including CD14 and LPS-binding protein (LBP).  TLR4 
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complexes with the cell surface receptor myeloid differentiation factor 2 (MD2) and 
binds to a LPS-LBP complex to form a homodimer which is then internalised into the 
cytosol 265.  TLR4 signalling then follows either the TIRAP/MyD88 pathway resulting 
in the production of proinflammatory cytokines, or the TRIF/TRAM, MyD88 
independent pathway to result in the production of type I IFNs 264. 
 
1.8.2.4 TLR5 
 TLR5 recognises the flagellar element of motile bacteria and is expressed by 
epithelial cells, monocytes and immature dendritic cells, particularly in the lungs and 
gut.  Stimulation of TLR5 results in NF-κB upregulation and the production of 
proinflammatory cytokines as well as maturation of human dendritic cells 266.  This is 
mediated through the MyD88 pathway 267.  Although limited data suggest a role for 
TLR5 in type I IFN production, the TLR5 ligand flagellin has been observed to 
stimulate IFN-β expression in mouse bone marrow derived macrophages 268. 
 
1.8.2.5 TLR7 & TLR8 
TLR7 and TLR8 are found on the endolysosomes and both recognise ssRNA 
viruses and imidazoquinoline derivatives such as imiquimod and resiquimod (R848).  
Upon recognition an antiviral response is triggered resulting in the NF-κB activation 
and type I IFN production via the MyD88 dependent signalling pathway 264.  TLR7 is 
expressed on dendritic cells and B cells and TLR8 is expressed highly on monocytes 
as well as dendritic cells, B cells and neutrophils.   
 
1.8.2.6 TLR9 
 TLR9 recognises unmethylated 2’-deoxyribo CpG motifs found in bacterial 
and not human DNA.  It is sequestered in the endoplasmic reticulum and upon 
stimulation of the cell moves to the endolysosome 269.  TLR9 has been identified to 
play an early role in clearance of Spn from the lower respiratory tract of mice 270.  
Spn infection triggers a TLR9 and MyD88-dependent activation of phagocytic activity 
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from airway macrophages.  TLR9 activation also leads to type I IFN responses in 
human primary cells 271, 272 via the MyD88 dependent pathway.  There is some 
evidence that DNA viruses such as herpes viruses can stimulate production of type I 
IFNs through TLR9-dependent pathways 273.  Different CpG ODNs (A, B & C) have 
different type I IFN inducing potencies and have been shown to have different effects 
on different cell types 274. 
 
1.8.3 TLR signalling pathways 
Recognition of PAMPs by TLRs leads to different signalling cascades and the 
upregulation of distinct genes.  The different signalling cascades for individual TLRs 
can partly be explained by the TIR domain-containing adaptor molecules recruited to 
TLRs 264.  TLR signalling is divided into two distinct pathways depending on the use 
of two adaptor molecules, namely MyD88 and TRIF (figure 1.3).  The following 
description explains pathways used in the production of type I IFNs.  Signalling 
pathways used in the production of type III IFN are not well understood. 
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Figure 1.3.  Toll-like receptor signalling.  (adapted from O’ Neill et al. 
275
) TLRs recognise microbial 
products.  Resultant dimerisation of the receptor (or heterodimerisation for TLR2/6 and TLR1/6) is 
followed by downstream signalling.  All TLRs engage the MyD88 adaptor molecule (except TLR3, 
which signals through TRIF). TLR4 signalling follows MyD88/TIRAP-dependent and/or TRIF/TRAM-
dependent pathways.  Signalling results in activation of NF-κB, activator protein (AP)-1 and interferon 
regulatory factors (IRFs) which induce expression of genes encoding proinflammatory cytokines, type 
1 IFN and IFN-inducible genes (MyD88 = Myeloid differentiation factor-88; TIRAP = TIR-associated 
protein; TRIF = TIR-domain-containing adapter-inducing interferon-β; TRAM = TRIF-related adaptor 
molecule; TRAF = TNF receptor associated factor). 
 
1.8.3.1 The MyD88-dependent signalling pathway 
MyD88 is required for the downstream signalling of most TLRs, with the 
exception of TLR3 (figure 1.3).  Children with autosomal recessive MyD88 deficiency 
suffer from life threatening and recurrent pyogenic bacterial infections including 
invasive pneumococcal disease 276.  TIRAP is required as a bridge between TLR2 
and TLR4, and MyD88 277.  MyD88 acts to facilitate the interaction of TNFR-
associated factor 6 (TRAF6) with IL-1R-associated kinase (IRAK)-4.  IRAK-4 
activates other IRAK family members, IRAK-1 and IRAK-2.  A series of ubiquitination 
and phosphorylation events results in the activation of IκB kinase (IKK)-β and MAP 
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kinase (MAPK)-6.  The resultant IKK complex, composed of IKK-α, IKK-β, and NF-
κB essential modulator (NEMO), phosphorylates IκB.  Phosphorylated IκB 
undergoes polyubiquitination and degradation, thereby allowing the transcription 
factor NF-κB to translocate into the nucleus and activate gene expression of 
proinflammatory cytokines.  NF-κB is a family of proteins, RelA (p65), RelB, C-Rel, 
p105 (NF-κB1) and p100 which form homo or heterodimers to control upregulation of 
gene expression 278.   
Activation of the MAP kinases such as c-Jun, N-terminal kinase (JNK), p38 
and extracellular signal regulated kinase (ERK) is responsible for the formation of the 
transcription factor complex, AP-1, composed of heterodimers of Jun, Fos and ATF 
proteins, that target cytokine genes 279.   
The other proteins implicated in the MyD88 pathway are the IRF family.  The 
9 IRFs in humans contain a conserved DNA binding domain which recognises the 
ISRE.  Four IRFs (IRF1, IRF3, IRF5 and IRF7) have been identified as regulators of 
type I IFN production 280.  IRF5 is involved in the MyD88-TRAF6 pathway and has a 
role in proinflammatory cytokine production as observed in that haematopoietic cells 
from IRF5-deficient mice have impaired cytokine production following stimulation of 
TLR4, TLR5, TLR7 and TLR9 281.  IRF3 and IRF7 are important regulators of type I 
IFN induction.  IRF3 is essential for LPS-mediated IFN-β induction 282 and IRF3 
deficient mice have impaired type I IFN responses to rotavirus 283.  IRF3 is 
constitutively expressed whereas IRF7 is induced by virus infection 280.  IRF7 is 
involved in the MyD88-TRAF6-TRAF3 pathway, whereas IRF3 activation is 
controlled by the MyD88-independent pathway 284. 
 
1.8.3.2 The TRIF-dependent signalling pathway 
Following stimulation with dsRNA, TLR3 recruits the adaptor protein TIR-
domain-containing adapter-inducing interferon-β (TRIF).  TLR4 signals through both 
MyD88 and TRIF. TLR4, but not TLR3, requires another adaptor, TRIF-related 
adaptor molecule (TRAM), to activate TRIF 285.  TRIF associates with TRAF3 and 
TRAF6.  TRAF3 activates TANK-binding kinase 1 (TBK1) and IKK-ε which leads to 
the phosphorylation of IRF3 286.  IRF3 dimers translocate to the nucleus, resulting in 
induction of type I IFNs and expression of IFN-inducible genes.  TRAF6 and receptor 
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interacting protein 1 (RIP-1) activate NF-κB through the activation of IKKα/β resulting 
in proinflammatory cytokine release. 
 
1.8.4 Pattern recognition receptors in S. pneumoniae cell signalling 
LTA and lipoproteins within the cell wall of Spn are recognised by TLR2 287, 288.  
Pneumococci have been shown to enhance TLR1 and TLR2 mRNA in BEAS-2B 
cells and stimulation of TLR1/2 leads to NF-κB recruitment to the CXCL8/IL-8 
promoter 287.  TLR2 modulates bacterial clearance in granulocytes, TLR2 deficient 
cells having impaired phagocytosis and oxidative killing of Spn 289.  LTA from Spn 
has been demonstrated to stimulate PBMCs via TLR2 with the help of CD14 and 
TLR1 290.  Blocking TLR2, 4 or 9 in PBMCs results in marked reductions in the 
inflammatory response to Spn 291. TLR9 detects pneumococcal DNA with TLR9 
deficient mice having reduced survival from Spn pneumonia, with enhanced bacterial 
load in the lung 270.  TLR4 is best known for its detection of LPS of gram negative 
bacteria, but studies have identified TLR4 interaction with pneumolysin and 
subsequent inflammatory response mediated by MyD88 175, 292.  TLR4 deficient mice 
have increased susceptibility and higher bacterial loads after Spn lung infection than 
wild type mice 175, 293.  Pneumolysin can also activate TLR4-independent innate 
immune responses.  While mouse studies of TLR2, TLR4 and TLR9 deficiencies 
reveal some susceptibility to pneumococcal infections, deficiency of the adaptor 
protein MyD88 leads to profound susceptibility to pneumococcus 294.  This is 
consistent with a human study reporting autosomal recessive deficiencies of MyD88 
being associated with life threatening Spn infections in infancy and early childhood 
276. 
NOD like receptors also have a role in the innate immune response to 
pneumococci.  NOD1 is a host cytoplasmic peptidoglycan-recognition molecule 295.  
NOD2 has been implicated in NF-κB induction by Spn 296 with upregulation of NOD1 
and NOD2 mRNA following pneumococcal infection in vivo in C57BL/6 mice and in 
vitro in BEAS-2B cells.  NOD2 in macrophages has been identified to sense digested 
peptidoglycan, requiring the pore-forming toxin pneumolysin 297.  This sensing results 
in release of the chemokine CCL2/MCP-1 with resulting recruitment of additional 
macrophages required for clearance of Spn.   
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The expression of NF-κB-dependent proinflammatory genes such as IL-1β 
requires a second signal from inflammasomes 298.  Inflammasomes are multiprotein 
complexes which mediate caspase-1 dependent cytokine maturation.  The 
inflammasome best characterised is NOD-like receptor, pyrin domain containing 3 
(NLRP3) which is activated by bacteria expressing pore forming toxins 299.  NLRP3 
has also recently been shown to be activated by Spn and pneumolysin 300. 
It is unclear which PRR is involved in the IFN response following pneumococcal 
infection, but the response is dependent on cytosolic recognition of bacterial DNA 
and the transcription factor IRF3 224.  NOD2 contributes to type I IFN responses to 
pneumococcus in vivo 222.  More investigation is needed to further determine the 
signalling pathways used in Spn infection. 
 
1.9 Rationale, Hypothesis and Aims  
1.9.1 Rationale 
 The rationale of this study is to investigate further the deficiency of IFN 
production in asthma.  The majority of asthma morbidity, mortality and healthcare 
costs is due to exacerbations, commonly due to viral and particularly RV infection.  
Atopic asthmatics have been observed to have increased susceptibility to RV 
infection.  To date defective IFN production in asthma has been observed in virus 
induced models in vitro and in vivo with HBECs from AA having impaired type I and 
III IFN response to RV infection and BAL cells having impaired type III IFN 
responses 60, 61.  To date this deficiency in IFN production has been observed in AA, 
and the role of atopy in this process has not yet been elucidated.  There is increasing 
evidence for a role for bacteria, both typical and atypical, in the pathogenesis of 
asthma and there is some evidence that bacteria may induce IFNs.  The possibility 
that exacerbations are related to IFN deficiency in asthmatics requires further 
investigation.  This project aims to investigate type I and III IFN and proinflammatory 
cytokine responses to RV and respiratory bacteria in HBECs, BAL cells and PBMCs 
in asthmatics, non-asthmatics, and atopics and non-atopics, specifically to 
investigate whether the atopic status has a role in IFN deficiency.  Further 
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understanding of this IFN deficiency has the potential to identify therapeutic targets 
in the management of asthma exacerbations. 
1.9.2 Specific Hypotheses 
In this study I hypothesise that: 
 (1) following rhinovirus infection of BAL cells and HBECs, deficiencies 
in type I and III interferon production will be observed in atopic and 
non-atopic asthmatics but not in atopic non-asthmatic and normal 
subjects 
 (2) deficiencies will be observed following infection with bacteria such 
as Streptococcus pneumoniae and stimulation with bacterial TLR 
ligands 
 (3) observations made in BECs and airway macrophages will be 
reflected in supernatants of stimulated PBMCs 
1.9.3 Aims 
The aim of this study is to further identify the defect(s) which results in the 
deficient production of interferons in asthma in BAL macrophages, PBMCs and 
HBECs 
 (1) in response to rhinovirus infection and “viral” TLR ligand stimulation, 
focussing on IFN and proinflammatory cytokine responses 
 (2) in response to bacterial infections and “bacterial” TLR ligand 
stimulation, examining IFN and proinflammatory cytokine responses, 
with an introduction of the concentration-timing experiments with Spn 
and “bacterial” TLR ligands in BEAS-2B cells, primary HBECs and 
PBMCs 
 (3) to compare asthmatics and non-asthmatics 
 (4) to compare atopics and non-atopics 
Different cell types will be investigated to examine whether any deficiency is cell- or 
asthma-/atopy-specific, and specifically whether any observations made in airway 
cells are observed in PBMCs. 
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Chapter 2: Materials and Methods 
 
2.1 Materials 
2.1.1 Clinical Equipment 
Table 2.1 Clinical equipment used in the project in order of application 
Name Composition Application Source 
Vacutainer blood tubes 9NC SST Vacutainer tubes Blood testing BD, USA 
Disposable sheathed cytology 
brush BC-202D-5010 
5mm cytology brush Bronchoscopy Olympus 
EndoJaw single use biopsy forceps 
FB-211D 
Disposable endobronchial 
biopsy forceps 
Bronchoscopy Olympus 
Keymed BF260 bronchoscope Fibreoptic bronchoscope Bronchoscopy Olympus 
Salbutamol nebules 2.5mg Salbutamol 
sulphate in normal saline 
Bronchoscopy Allen & 
Hanburys, UK 
Ipratropium bromide nebules 0.25mg Ipratropium 
bromide in normal saline 
Bronchoscopy Allen & 
Hanburys, UK 
Nebuliser (Porta Neb) Portable air compressor Drug administration  Profile 
Therapeutics 
Histamine Histamine Acid 
phosphate, 32mg/mL 
PC20 NPH Pharmacy 
ALK Lancet Disposable micro-lancet Skin Prick Tests Boge Alle 
Cat allergen (507) Allergen solution Skin Prick Tests Modelo Harwell 
Dog allergen (509) Allergen solution Skin Prick Tests Modelo Harwell 
6 grass mix allergen (688) Allergen solution Skin Prick Tests Modelo Harwell 
House dust mite allergen (315) Allergen solution Skin Prick Tests Modelo Harwell 
Alternaria alternata allergen (400) Allergen solution Skin Prick Tests Modelo Harwell 
Aspergillus fumigatus allergen 
(401) 
Allergen solution Skin Prick Tests Modelo Harwell 
Cladosporium herbarum allergen 
(414) 
Allergen solution Skin Prick Tests Modelo Harwell 
Birch allergen (615) Allergen solution Skin Prick Tests Modelo Harwell 
Tree mix allergen (718) Allergen solution Skin Prick Tests Modelo Harwell 
Mugwort allergen (605) Allergen solution Skin Prick Tests Modelo Harwell 
Spirometer Portable spirometer Spirometry Micro medical, 
UK 
Spiroguard bacterial/viral filters Filter for spirometer Spirometry Spiroguard 
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2.1.2 Laboratory instruments 
Table 2.2 Laboratory instruments used in the project in alphabetical order 
Name Application Company 
Acrodisc 0.2µm filters Media and reagent filtering Pall Life Sciences 
Amicon Ultra-0.5, Ultracel-30 
membrane, 30kDa filter unit  
RV filtering Millipore, Billerica, MA, 
USA 
Cell strainer, 100µm BAL processing BD, USA Falcon 
Centrifuge (Eppendorf 5415) RNA isolation, RV filtering Eppendorf, Hamburg, 
Germany 
Centrifuge (Eppendorf 5810R) Centrifugation of cultured 
cells 
Eppendorf, Hamburg, 
Germany 
Cytospin 3 system BAL cytospin preparation Shandon, USA 
HERA Category II tissue culture 
hood 
All sterile cell work Kendro Lab. Products, 
Hanau, Germany 
Hotplate and stirrer (Jenway 1000) Buffer and solution 
preparation 
Grant Instruments Ltd, 
Cambridge, UK 
Incubator (NU 500E air jacketed 
automatic CO2) 
Cell culture NuAire Inc., Plymouth, 
MN, USA 
Inverted microscope (Leica DME) Cell quantification Leica Microsystems, 
Wetzlar, Germany 
Meso Scale Discovery SECTOR
® 
Imager 2400 
MSD Meso Scale Discovery, 
Gaithersburg, MD, USA 
Plate reader (spectramax plus 384) ELISA Molecular Devices Ltd, 
Wokingham, UK 
Realtime PCR system (ABI7500) Taqman RT-PCR Applied Biosystems, 
Foster City, CA, USA 
Shaker (R100) rotatest RV infection of cells, HBEC 
experiments 
Luckham Ltd, Sussex, UK 
Taqman RT-PCR hood (Bioair 
instruments, Aura Mini) 
Primer and probe handling Wolf Laboratories Ltd, 
Pocklington, UK 
UV crosslinker (Stratalinker240) UV inactivation of RV Stratagene, Amsterdam, 
Netherlands 
Vortex HBEC culture, reagent 
preparation 
VWR International 
Water bath cDNA synthesis Grant Instruments Ltd, 
Cambridge, UK 
 
2.1.3 Buffers and reagents 
Table 2.3 Buffers and reagents used in the project in alphabetical order 
Name Composition Application Source 
3,3’,5,5-
tetramethylbenzidine 
(TMB) 
1x TMB. No other details given by 
manufacturer 
ELISA substrate Invitrogen, UK 
Bovine Serum 
Albumin Powder 
(BSA) 
1% BSA in 0.15M NaCl pH 7.0 ELISA, HBEC culture Sigma Aldrich, 
USA 
Diluent-1 RPMI-like medium. No other details 
given by manufacturer 
MSD MSD, USA 
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Diluent-100 Contains blocking and stabilizing 
agents. No other details given by 
manufacturer 
MSD MSD, USA 
Dulbecco’s PBS 1x 
(D-PBS) 
Phosphate buffered saline 0.0014M 
KH2PO4, 0.008M Na2HPO4-7H2O, 
0.0026M KCl, 0.137M NaCl 
Cell culture Invitrogen, UK 
ELISA blocking 
solution 
1% BSA in ELISA wash buffer ELISA Sigma Aldrich, 
USA 
ELISA diluent buffer 0.2% BSA in ELISA wash buffer ELISA Sigma Aldrich, 
USA 
ELISA stop solution 2M H2SO4 ELISA Sigma Aldrich, 
USA 
ELISA/MSD wash 
buffer 
PBS, 0.05% Tween-20 ELISA, MSD Sigma Aldrich, 
USA 
Ethanol 96.6% Ethanol RNA isolation VWR International 
Histopaque
®
-1077 Sterile solution of polysucrose, 57 g/L 
and sodium diatrizoate, 90 g/L. 
Density: 1.076–1.078 g/mL. 
Endotoxin: 0.3 EU/mL. pH: 8.8–9.0 
PBMC processing Sigma Aldrich, 
USA 
MSD Read buffer T 
(4x) 
4x Read buffer. No other details given 
by manufacturer 
MSD MSD, USA 
MSD SULFO-TAG 
labelled Streptavidin 
In PBS containing 2% BSA, 0.05% 
Azide and 0.02% Kathon CG 
MSD (for IL-29 
prototype) 
MSD, USA 
Nuclease-free water Nuclease-free water Primer and probe 
dilution, Taqman RT-
PCR 
Promega, USA 
PBS (per tablet) 0.001M phosphate buffer, 0.0027M 
KCl, 0.137M NaCl in 200ml distilled 
H2O 
ELISA Sigma Aldrich, 
USA 
Quantitect probe 
PCR master mix 
HotStar Taq DNA polymerase, 
quantitect probe PCR buffer (Tris-
HCl,KCl,(NH4)2SO4, 8mM MgCl2 pH 
8.7), dNTP mix  
Taqman RT-PCR Qiagen, UK 
Random primers Random hexadeoxynucleotides 
(0.5µug/mL), in nuclease free H2O 
cDNA synthesis Promega, USA 
Recombinant human 
CXCL8/IL-8 
Reconstituted at 100 μg/mL in sterile 
PBS containing 0.1% BSA 
ELISA R&D systems, 
USA 
Recombinant human 
IL-6 
Reconstituted at 100 μg/mL in sterile 
PBS containing 0.1% BSA 
ELISA R&D systems, 
USA 
Streptavidin-HRP 
(Horseradish 
Peroxidase) 
In PBS pH 7.2 containing 0.01% 
Thimerosal and 40% glycerol 
ELISA BiosourceI Int. 
TE buffer (1x) 
Molecular grade 
10mM Tris-HCl containing 1mM 
EDTANa2  
Primer and probe 
resuspension 
Promega, USA 
Trypan blue 0.4% trypan blue in 0.85% saline 
solution 
Cell viability Invitrogen, UK 
Tween-20 
(polyoxyethylene-
sorbitan 
monolaurate) 
20 ethylene oxide units, 1 sorbitol unit, 
1 lauric acid unit 
ELISA, MSD Sigma Aldrich, 
USA 
β-mercaptoethanol 
(β-ME) 
14.3M C2H6O5 RNA isolation Sigma Aldrich, 
USA 
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2.1.4 Media and supplements 
Table 2.4 Media and media supplements used in the project in alphabetical order 
Name Composition Application Source 
BEBM single 
quot additives 
13g/L bovine pituitary extract, 5g/l insulin, 
50g/L gentamicin, 0.1mg/L retinoic acid, 10g/L 
transferrin, 6.5mg/L triiodothyronine, 0.5g/L 
hydrocortisone, 0.5g/L epinephrine, 0.5mg/L 
human epidermal growth factor 
HBEC culture Lonza, USA 
BEGM 
complete 
BEBM with BEGM single quot additives, 5mL 
pen/strep 
HBEC culture Lonza, USA 
BEGM 
infection+P/S 
BEGM complete without 2mL bovine pituitary 
extract 
HBEC culture Lonza, USA 
BEGM 
infection-P/S 
BEGM complete without 2mL bovine pituitary 
extract or 5mL pen/strep 
HBEC culture Lonza, USA 
Bovine serum 
albumin 
1% BSA in filtered water HBEC culture Sigma Aldrich, 
USA 
Bronchial 
epithelium basal 
medium 
(BEBM) 
Refer to manufacturer’s formulation HBEC culture Lonza, USA 
Dulbecco’s 
modified eagles 
medium 
(DMEM) 
Refer to manufacturer’s formulation HeLa & virus 
culture, virus 
titration 
Invitrogen, UK 
Fibronectin 
(pure) 
Lypophilizate from human plasma HBEC culture Roche, 
Switzerland 
Foetal Bovine 
Serum (FBS) 
Heat inactivated foetal bovine serum HeLa, BEAS-2B, 
PBMC & BAL cell 
culture 
Invitrogen, UK 
HBEC collagen 
coating mx 
9mL BEGM complete, 1mL 1% BSA, 100µL 
recombinant human like collagen, 100µL 
fibronectin (pure) 
HBEC culture Lonza, USA 
HeLa cell 
complete 
medium 
DMEM plus 10% FBS, 12.5mL HEPES buffer, 
5mL Sodium bicarbonate 
HeLa cell culture Invitrogen, UK 
HeLa cell 
titration medium 
DMEM plus 4% FBS, 12.5mL HEPES buffer, 
5mL Sodium bicarbonate, 5ml pen/strep 
Virus titration Invitrogen, UK 
HEPES buffer C8H18N2O4S 1M solution 4-(2-
hydroxyethyl)piperazine-1-ethanesulphonic 
acid solution 
HeLa, BEAS-2B, 
PBMC & BAL cell 
culture, virus 
culture & titration 
Sigma Aldrich, 
USA 
Hepes buffered 
saline solution 
30mM HEPES HBEC culture 
(cell splitting) 
Lonza, USA 
Penicillin/ 
Streptomycin 
10,000 units/mL penicillin, 10,000µg/mL 
streptomycin 
HBEC culture, 
virus titration, 
PBMC & BAL 
culture 
Gibco, UK 
Recombinant 
human like 
collagen 
>95% human collagen from E. coli HBEC culture Biovision 
RPMI complete 
 
RPMI-1640 plus 10% FBS, 12.5mL HEPES 
buffer, 5ml sodium bicarbonate 
BEAS-2B cell 
culture 
Invitrogen, UK 
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RPMI infection 
 
RPMI-1640 plus 2% FBS, 12.5mL HEPES 
buffer, 5ml sodium bicarbonate 
BEAS-2B cell 
infection 
Invitrogen, UK 
RPMI+P/S 
 
RPMI-1640 plus 10% FBS, 12.5mL HEPES 
buffer, 5mL pen/strep 
PBMC & BAL 
culture 
Invitrogen, UK 
RPMI-1640 Refer to manufacturer’s formulation BEAS-2B, PBMC 
& BAL culture 
Invitrogen, UK 
RPMI-P/S RPMI-1640 plus 10% FBS, 12.5mL HEPES 
buffer 
PBMC & BAL 
culture 
Invitrogen, UK 
Sodium 
bicarbonate 
7.5% sodium bicarbonate HeLa, BEAS-2B 
cell culture 
Invitrogen, UK 
Trypsin EDTA 
(1x) 
0.025% trypsin, 0.01% EDTA HBEC culture 
(cell splitting) 
Lonza, USA 
Trypsin EDTA 
(10x) 
 HeLa, BEAS-2B 
cell culture 
Invitrogen,UK 
Trypsin 
neutralising 
solution (TNS) 
No supplier information HBEC culture 
(cell splitting) 
Lonza, USA 
Ultroser™G Serum substitute – lyophilized Ultroser G HBEC culture Pall Life 
Sciences 
Virus culture 
medium 
DMEM plus 12.5mL HEPES buffer, 5mL 
Sodium bicarbonate 
Rhinovirus culture Invitrogen, UK 
 
2.1.5 Toll like Receptor (TLR) Ligands 
Table 2.5 TLR ligands in order of preference used in this study, with the receptor they bind to 
and the concentrations used in HBECs, BAL cells and PBMCs 
Name Receptor 
 
Source 
 
Concentration 
HBECs BAL PBMCs 
Lipoteichoic Acid (LTA-SA) TLR2 InvivoGen 25µg/mL 25µg/mL 25µg/mL 
Lipopolysaccharide (LPS) TLR4 Sigma Aldrich, 
USA 
10μg/mL 10μg/mL 10μg/mL 
CpG-C-ODN TLR9 Eurogentec 3μM 3μM 3μM 
Flagellin (FLA) TLR5 InvivoGen 100ng/mL 100ng/mL 100ng/mL 
Pam3CSK4 (PAM) TLR1/2 InvivoGen 10μg/mL 10μg/mL 10μg/mL 
Synthetic lipoprotein (FSL-
1) 
TLR2/6 InvivoGen 1μg/mL 1μg/mL 1μg/mL 
Peptidoglycan (PGN-SA) TLR2 InvivoGen 10μg/mL 10μg/mL 10μg/mL 
R848 (Resiquimod) TLR7/8 Eurogentec 1mM 1mM 1mM 
Polyinosinic-Polycytidylic 
Acid (poly(IC)) 
TLR3 Sigma Aldrich, 
USA 
10μg/mL 100μg/mL 100μg/mL 
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2.1.6 Primers and Probes for Realtime RT-PCR 
Realtime RT-PCR primers were purchased from Invitrogen, UK (Paisley, UK) in a 
desalted, dry pellet form.  All probes were purchased from Qiagen (Crawley, UK) in a 
HPLC purified, dry pellet form, and stored at -20°C until resuspension. 
Table 2.6 TaqMan Realtime RT-PCR primers and probes and their optimal concentrations used. 
Name Sequence (FAM-5’-3’-TAMRA) 
18S forward (300nM) CGCCGCTAGAGGTGAAATTCT 
18S reverse (300nM) CATTCTTGGCAAATGCTTTCG 
18S probe (100nM) ACCGGCGCAAGACGGACCAGA 
IFN-β forward (300nM) CACGGATACAGAACCTATGG 
IFN-β reverse (900nM) ACGAACAGTGTCGCCTACTA 
IFN-β probe (100nM) TCAGACAAGATTCATCTAGCACTGGCTGGA 
IFN-α(A2) forward (50nM) CTGGCACAAATGGGAAGAAT 
IFN-α(A2) reverse (50nM) CTTGAGCCTTCTGGAACTGG 
IFN-α(A2) probe (128nM) TTTCTCCTGCCTGAAGGACAGACATGA 
IL-28 (IFN-λ2/3) forward (300nM) CTGCCACATAGCCCAGTTCA 
IL-28 (IFN-λ2/3) reverse (900nM) AGAAGCGACTCTTCTAAGGCATCTT 
IL-28 (IFN-λ2/3) probe (100nM) TCTCCACAGGAGCTGCAGGCCTTTA 
IL-29 (IFN-λ1) forward (300nM) GGACGCCTTGGAAGAGTCACT 
IL-29 (IFN-λ1) reverse (900nM) GGACGCCTTGGAAGAGTCACT 
IL-29 (IFN-λ1)  probe (100nM) AGTTGCAGCTCTCCTGTCTTCCCCG 
IL-6 forward (300nM) CCAGGAGCCCAGCTATGAAC 
IL-6 reverse (900nM) CCCAGGGAGAAGGCA ACTG 
IL-6 probe (100nM) CCTTCTCCACAAGCG CCTTCGGT 
IL-8 forward (900nM) CTGGCCGTGGCTCTCTTG 
IL-8 reverse (900nM) CCTTGGCAAAACTGCACCTT 
IL-8 probe (100nM) CAGCCTTCCTGATTTCTGCAGCTCTGTGT 
Rhinovirus forward (50nM) GTGAAGAGCCSCRTGTGCT 
Rhinovirus reverse (300nM) GCTSCAGGGTTAAGGTTAGCC 
Rhinovirus probe (100nM) TGAGTCCTCCGGCCCCTGAATG 
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2.1.7 Antibodies 
Table 2.7 Antibodies used in the project and their working concentrations (the antibodies are 
selective with known cross reactivity to other cytokines) 
Antibody Isotype Working 
concentration 
Application Supplier 
Capture, anti-
human IL-6 
Mouse IgG/6708 4µg/mL ELISA R&D systems, 
USA 
Detection, anti-
human IL-6 
Biotinylated goat 
IgG 
25ng/mL ELISA R&D systems, 
USA 
Capture, anti-
human IL-8 
Mouse IgG1/6217 4µg/mL ELISA R&D systems, 
USA 
Detection, anti-
human IL-8 
Biotinylated goat 
IgG 
25ng/mL ELISA R&D systems, 
USA 
 
2.1.8 Commercial kits 
Table 2.8 Commercially available kits used in the project, listed in alphabetical order 
Name Components Application Source 
Human IFN-α2a Tissue 
Culture Kit 
Read Buffer T (4X), Diluent 1, 
Diluent 100, MULTI-SPOT
®
 96-well 
plates spotted with anti-IFNα2a 
capture antibody, SULFO-TAG™ 
labelled anti-IFNα2a detection 
antibody (50X), Human IFN-α2a 
Calibrator (1µg/mL) 
MSD MSD, USA 
Human IFN-β Tissue 
Culture Kit 
Read Buffer T (4X), Diluent 1, 
Diluent 100, MULTI-ARRAY® 96-well 
Avidin Plates, SULFO-TAG™ Anti-
hIFN-β Antibody (50X), Anti-hIFN-β 
Biotinylated Capture Antibody 
(50X), Human IFN-β Calibrator 
MSD MSD, USA 
Human IL-29/IL-28B 
DuoSet 
Capture antibody (mouse anti-
human IL-29/IL-28B); detection 
antibody (biotinylated goat anti-
human IL-29/IL-28B); standard 
(recombinant human IL-29/IL-28B); 
streptavidin-HRP 
MSD (IL-29) R&D systems, 
USA 
Human Proinflammatory 
4-plex II Tissue Culture 
Kit 
Read Buffer T (4X), Diluent 1, 
Diluent 100, MULTI-SPOT
®
 96-well 
4-plex plates spotted with anti-IL-1β, 
anti-IL-6, anti-IL-8, anti-TNF-α 
capture antibody mix, SULFO-
TAG™ labelled anti-IL-1β, anti-IL-6, 
anti-IL-8, anti-TNF-α detection 
antibody mix (50X), Human IL-1β, 
IL-6, IL-8, TNF-α Calibrator mix 
(1µg/mL) 
MSD MSD, USA 
MULTI-SPOT
®
 96-well 4-
spot prototype human IL-
29 
MULTI-SPOT
®
 96-well 4-plex plates 
spotted with anti-IL-29 capture 
antibody 
MSD MSD, USA 
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Omniscript RT (reverse 
transcriptase) kit 
dATP, dCTP, dGTP, dTTP (5mM 
each) in water, 10x buffer RT, 
omniscript reverse transcriptase, 
RNase free water 
cDNA 
synthesis 
Qiagen, UK 
REASTAIN quick-diff kit Reastain Quick-Diff Fix: methanol 
100%, methylene blue <0.1%; 
Reastain Quick-Diff Red: Eosin Y 
0.12%, sodium azide 
<0.1%Reastain Quick-Diff Blue: 
Azur II 0.09%, glycerol 5%, sodium 
azide <0.1%;  
Cytospin 
staining 
Reagena, 
Finland 
RNase free DNase set 1500 units RNase free DNase 1, 
RNase free buffer RDD 
RNA isolation Qiagen, UK 
RNeasy Mini kit Buffer RLT, Buffer RW1, Buffer 
RPE, RNase free water, RNeasy 
mini spin columns, collection tubes 
RNA isolation Qiagen, UK 
 
2.1.9 Software 
Table 2.9 Software used in the project listed in alphabetical order 
Name Application Company 
Softmax Pro v3.1.2 ELISA and Taqman RT-PCR 
data analysis 
Molecular Devices Corporation, 
CA, USA 
Discovery Workbench
® 
3.0 
Software 
MSD data analysis MSD, USA 
ABI Prism 7500 SDS software 
v1.4.0 
Taqman RT-PCR data analysis Applied Biosystems, USA 
GraphPad Prism v4.0 Statistical analysis of data GraphPad Software Inc., CA, 
USA 
Primer Express v3.0 Primer and probe design Applied Biosystems, USA 
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2.2 Clinical Methods 
 
2.2.1 Participant Recruitment 
Ethical approval for the study was obtained from the St Mary’s Research 
Ethics Committee (reference 08/H0712/39).  The aim was to recruit 48 subjects; 12 
atopic asthmatics (AA), 12 non-atopic asthmatics (NAA), 12 atopic non-asthmatics 
(ANA) and 12 non-atopic non-asthmatics (NANA).  A formal power calculation was 
not performed, however significant data had been observed in similar numbers of 
volunteers from other human studies 60, 61, 208.  Participants were recruited from 
records of previous studies performed in the department, from advertisements in 
local newspapers, and hospital and college websites, and attempts were made to 
recruit from established asthma clinics from 3 sites around London.  Participants 
were telephone screened and then invited to St Mary’s Hospital, London for 
screening investigations.  
Clinical characterisation was determined by clinical history and examination, 
skin prick testing, serum total IgE, spirometry, histamine challenge, 
electrocardiogram and chest radiograph.  If an electrocardiogram or chest 
radiograph had been performed in the previous year, this was not repeated and 
results were obtained from the participant’s medical practitioner.  Blood tests for full 
blood count, clotting (INR and APTT), urea and electrolytes and total IgE were 
performed.  Table 2.10 illustrates the inclusion and exclusion criteria. 
 
2.2.2 Screening Investigations 
2.2.2.1 Spirometry 
Spirometry was performed according to BTS/ARTP guidelines 301 using 
Microlab medical spirometer.  The same spirometer was used for all participants and 
it was regularly calibrated according to the manufacturer’s instructions.  The FEV1, 
FVC, PEF and FEV1/FVC ratio were recorded and the best of three attempts by the 
participant was used. 
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2.2.2.2 Histamine challenge 
The histamine challenge was performed according to ERS guidelines 302 
using a tidal breathing method.  Asthmatic participants were asked to withhold LABA 
for 48 hours and SABA for 12 hours prior to the investigation.  A diagnosis of asthma 
was supported by a PC20 ≤8 mg/mL.  Non-asthmatics were required to have PC20 
≥16 mg/mL. 
2.2.2.3 Skin prick testing 
Atopy was defined by skin prick testing to a panel of common aeroallergens 
(Modelo Harwell) including: 6 grass mix, house dust mite (Dermatophagoides 
pteronissinus), Cladosporium herbarum, Alternaria alternata, Aspergillus fumigatus, 
Silver birch, 3 trees (Betula verrucosa, Alnus glutinosa, Corylus avellana), mugwort, 
cat dander and dog hair.  Participants were asked to withhold antihistamine 
medication for 48 hours prior to the test.  Drops of allergens, a positive control 
(histamine) and a negative control (normal saline) were placed on the participant’s 
forearm and were introduced intraepidermally using an ALK sterile disposable lancet.  
A single wheal 3 mm greater than the negative control was considered diagnostic of 
atopy. 
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Table 2.10 Inclusion and Exclusion criteria 
AA Inclusion Criteria 
 
NANA Inclusion Criteria Exclusion Criteria 
 
 Age 18-55. 
 Clinical diagnosis of asthma. 
 Symptom questionnaires 
positive for asthma.  
 Skin Prick test Positive (1 
positive reaction – wheal 3 mm 
greater than the control will be 
considered diagnostic of 
atopy) 
 PC20 ≤8mg/ml or >20% 
variability over two weeks on 
peak flow testing. 
 No other chronic respiratory 
condition or systemic disease. 
 Up to step 3 BTS Guidelines / 
GINA intermittent or mild 
persistent 
 No respiratory tract infection or 
exacerbation for 6 weeks 
 Current non-smokers of >1 
year (if ex-smokers <5 pack 
year history) 
 Age 18–55. 
 Negative asthma symptom 
questionnaire. 
 IgE <50 IU/ml. 
 Skin Prick testing negative. 
 Minimal Peak flow 
variability in two weeks 
peak flow diary (<15%). 
 PC20 >8mg/ml. 
 No history of atopy, 
asthma, eczema or allergic 
rhinitis or food allergy. 
 No chronic respiratory 
conditions. 
 No significant systemic 
disease. 
 No respiratory tract 
infection for 6 weeks. 
 Current non-smokers of >1 
year (if ex-smokers <5 pack 
year history) 
 
 Current 
smoker/smoker 
in the past year. 
 Current 
significant other 
chronic 
respiratory or 
systemic 
disease. 
 Severe or 
uncontrolled 
asthmatics 
(GINA – 
moderate 
persistent or 
severe 
persistent). 
 Significant other 
abnormalities on 
lung function 
testing i.e. 
restrictive defect 
etc. 
 NAA Inclusion Criteria 
 
ANA Inclusion Criteria 
 Age 18-55. 
 Clinical diagnosis of asthma. 
 Symptom questionnaires 
positive for asthma.  
 No history of atopy, eczema, 
allergic rhinitis or food allergy. 
 Skin Prick test negative 
 IgE <50 IU/ml. 
 PC20 ≤8mg/ml or >20% 
variability over two weeks on 
peak flow testing. 
 No other chronic respiratory 
condition or systemic disease. 
 Up to step 3 BTS Guidelines / 
GINA intermittent or mild 
persistent 
 No respiratory tract infection or 
exacerbation for 6 weeks 
 Current non-smokers of >1 
year (if ex-smokers <5 pack 
year history) 
 Age 18–55. 
 Negative asthma symptom 
questionnaire. 
 Skin Prick testing positive. 
 Minimal Peak flow 
variability in two weeks 
peak flow diary (<15%). 
 PC20 >8mg/ml. 
 No chronic respiratory 
conditions. 
 No significant systemic 
disease. 
 No respiratory tract 
infection for 6 weeks 
 Current non-smokers of >1 
year (if ex -smokers <5 
pack year history) 
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2.2.2.4 Asthma Control Questionnaire 
 In order to establish how well symptoms were controlled, asthmatics were 
asked to complete an asthma control questionnaire (ACQ) 303.  ACQ scores were 
made on the basis of participants’ answers to six questions (table 2.11), dividing the 
total score by six.  Scores ˂1 were considered good control, ˃3 suboptimal and 6 
poor control 304. 
Table 2.11 Asthma Control Questionnaire 
Question Answer Answer score 
On average, during the past week, 
how often were you woken by 
your asthma during the night? 
Never 0 
Hardly ever 1 
A few times 2 
Several times 3 
Many times 4 
A great many times 5 
Unable to sleep because of asthma 6 
On average, during the past week, 
how bad were your asthma 
symptoms when you woke in the 
morning? 
No symptoms 0 
Very mild symptoms 1 
Mild symptoms 2 
Moderate symptoms 3 
Quite severe symptoms 4 
Severe symptoms 5 
Very severe symptoms 6 
In general, during the past week, 
how limited were you in your 
activities because of you asthma? 
Not limited at all 0 
Very slightly limited 1 
Slightly limited 2 
Moderately limited 3 
Very limited 4 
Extremely limited 5 
Totally limited 6 
In general, during the last week, 
how much shortness of breath did 
you experience because of your 
asthma? 
None 0 
A very little 1 
A little 2 
A moderate amount 3 
Quite a lot 4 
A great deal 5 
A very great deal 6 
In general, during the past week, 
how much of the time did you 
wheeze? 
Not at all 0 
Hardly any of the time 1 
A little of the time 2 
A moderate amount of time 3 
A lot of the time 4 
Most of the time 5 
All of the time 6 
On average, during the past week, 
how many puffs of short-acting 
bronchodilator (e.g. Ventolin, 
Bricanyl) have you used each 
day? 
None 0 
1-2 puffs most days 1 
3-4 puffs most days 2 
5-8 puffs most days 3 
9-12 puffs most days 4 
13-16 puffs most days 5 
More than 16 puffs most days 6 
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2.3 Clinical Sample Collection 
 
2.3.1 Peripheral Blood Collection 
60ml of fresh blood was collected in heparinised tubes (BD, USA).   
2.3.2 Bronchoscopy 
Bronchoscopies were performed according to BTS guidelines 305 in the 
endoscopy unit at St Mary’s Hospital, London, using the Keymed BF260 
bronchoscope (Olympus, UK).  Participants were monitored by a separate doctor or 
nurse.  Spirometry (FEV1) was recorded before and after bronchoscopy.  All 
participants received nebulised 5mg Salbutamol (Allen & Hanburys) and 500µg 
Ipratropium bromide (Allen & Hanburys) prior to the procedure.  At bronchoscopy, 
HBECs were collected using bronchial brushes and bronchoalveolar lavage was 
performed to obtain BAL cells and BAL supernatant. 
 
2.3.2.1 Bronchial Brushings 
Seven bronchial brushings were taken with 5mm sheathed endobronchial 
brushes (Olympus BC-202D-5010) under direct vision by inserting the bronchoscope 
into a right lower lobe bronchial sub segment and brushing 5–10 strokes against 
bronchial wall.  6 sheathed brushes were removed from the bronchoscope and 
shaken into warmed BEGM in a single 50mL sterile tube.  Brushes and sheaths were 
detached into the media and this was immediately transported to the laboratory for 
counting and culture.  The processing team aimed to keep the HBECs at 37°C and 
into the incubator within 30 minutes of collection. The remaining sheathed brush was 
placed in a cryo-vial and snap frozen for storage in liquid nitrogen. 
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2.3.2.2 Bronchoalveolar lavage (BAL) 
Sterile normal saline (at room temperature) was instilled into the right upper 
lobe bronchus in 6 x 20mL aliquots with a 10 second dwell time.  BAL was collected 
in a single plastic bottle and transferred immediately to 50mL polypropylene tubes on 
ice for transport to the laboratory and further processing. 
 
2.4 Clinical Sample Processing 
 
2.4.1 PBMC Processing 
The blood collected in heparinised tubes was diluted 1:1 with Dulbecco’s 
phosphate buffered saline (D-PBS) and then layered over histopaque (Sigma 
Aldrich, USA).  Tubes were centrifuged at 2500rpm, with the brake and accelerator 
turned off, for 30min.  The layers of PBMCs were transferred to a single 
polypropylene tube and washed 2x with RPMI-1640 supplemented with 10% foetal 
bovine serum and 12.5mL HEPES buffer (RPMI-P/S) and centrifuged at 1500rpm for 
10min. The wash supernatant was discarded and the cell pellet was resuspended in 
10mL RPMI-P/S.  The cell suspension was diluted 1:10 in 0.1% trypan blue 
(Invitrogen, UK) for counting and assessment of viability.  A Neubauer 
haemocytometer with coverslip was filled with cell/trypan blue suspension (approx. 
5-10µL) and viewed under a light microscope.  Viable cells were counted and cells 
per mL calculated.   
Cells at a concentration of 2x106/mL were incubated at 37˚C (5% CO2) for 
30min, then centrifuged at 1500rpm for 10 min.  The supernatant was discarded and 
cell pellet resuspended in 1mL RPMI+/-P/S.  Cells were stimulated with virus, 
bacteria or TLR ligands described in more detail below (see sections 2.5.2.4, 2.5.3.2 
and 2.5.4).  Cells were harvested at 8, 24 and 48h.  This involved centrifugation for 
10min at 1500rpm, removal and saving of the supernatant and lysis of the cell pellet 
in RLT/2βME (RLT buffer [Qiagen] and 1:100 2-β mercaptoethanol) for RNA 
analysis. 
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2.4.2 BAL processing 
1mL of unfiltered BAL was removed and stored at -80˚C, but not used in this 
study.  The remaining BAL fluid was filtered through a 100µm cell strainer (BD 
Falcon, USA) and then centrifuged at 1500rpm for 10min to form a cell pellet.  The 
supernatant was removed and stored at -80˚C in 1.5mL aliquots.  The cell pellet was 
resuspended and washed in 40mL RPMI-P/S and centrifuged again.  The 
supernatant was discarded and cell pellet resuspended in 2mL RPMI-P/S.  The cell 
suspension was diluted 1:10 in 0.1% trypan blue (Invitrogen, UK) for counting and 
assessment of viability.  A Neubauer haemocytometer with coverslip was filled with 
cell/trypan blue suspension (approx. 5-10µL) and viewed under a light microscope.  
Viable cells were counted and cells per mL calculated.  Cells at 2x106/mL were 
incubated at 37˚C (5% CO2) for 20min, and processing continued as for PBMCs (see 
section 2.4.1).   
 
2.4.2.1 BAL Cytospin 
Two cytospins of 20,000 cells were made using BAL cell suspension added to 
a cytospin funnel attached to a Shandon cytoslide (Thermo Scientific) and 
centrifuged at 500rpm for 5 min using the Cytospin 3 system (Shandon, USA).  
Slides were air dried for at least 2h and stained using a REASTAIN Quick-Diff Kit 
(Reagena, Finland).  After drying, cells were differentially counted, blinded to subject 
identification and differential cell count was expressed as a percentage. 
 
2.4.3 Bronchial epithelial cell (HBEC) processing 
BEGM containing the HBECs, brushes and sheaths were gently vortexed to 
detach cells.  Brushes were passed through a pipette tip to remove adhered HBECs 
and the pipette tip and sheaths were flushed with BEGM.  The BEGM/HBEC mix 
was then centrifuged at 1150rpm for 6min and the cell pellet was resuspended in 
1mL BEGM through a 19G sterile needle to reduce clumping of the cells and made 
up to 10mL with BEGM.  Cell counts were performed by diluting the cell suspension 
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in 0.1% trypan blue and counted using a Neubauer haemocytometer.  Total cell 
count and ciliated cell count was performed.  The cell suspension was placed in a 
25cm2 flask (Nunc), pre-coated for 4h with collagen mix (see table 2.4) and placed in 
a humidified incubator at 37˚C (5% CO2).  After 48h, to allow maximal adherence of 
HBECs, cells were washed twice with warmed BEGM and the medium was replaced 
with 10mL fresh warmed BEGM + 100µL Ultroser®-G (Pall Lifesciences, France).  
The medium was changed every 2-3 days, adding Ultroser®-G to the BEGM until the 
HBECs were well established.   
Once the HBECs were 80-90% confluent, cells were passaged.  Cells were 
washed with 4mL HEPES buffered saline solution (Lonza, USA) which was then 
removed.  2mL trypsin-EDTA (Lonza, USA) was added and cells were incubated at 
37C until they detached with flask tapping.  4mL trypsin neutralising solution (Lonza, 
USA) was added, and cells were centrifuged at 1150rpm for 6min.  The supernatant 
was discarded and the cells were resuspended in 4mL complete BEGM.  2mL cell 
suspension was added to 2 collagen pre-coated 75cm2 flasks containing pre-warmed 
BEGM and returned to the incubator.  The residual cells from the initial flask were 
washed with BEGM and more BEGM was added for further incubation and culture. 
Cells were further passaged to P2 and when 80% confluent, were split as described 
above, counted with a haemocytometer (Neubauer) and seeded onto collagen 
coated 24 well plates (Nunc) and Lab-Tek chamber slides with covers (Nunc) at a 
concentration of 0.8x105 cells/mL for further experimentation. 
 
2.5 Cell Culture Methods 
 
2.5.1 Tissue Culture 
 All tissue culture was performed in a category II hood assigned for use with 
animal and human samples.  All media used is listed in table 2.4. 
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2.5.1.1 BEAS-2B cell culture 
 BEAS-2B cells were purchased from ATCC, provided in frozen cryovials.  
Cells were stored in liquid nitrogen until resuscitated in pre-warmed RPMI complete 
medium and grown to confluence in a 75cm2 tissue culture flask in a humidified 
incubator at 37˚C (5% CO2).  This was subsequently passaged into 175 cm
2 tissue 
culture flasks.  Cells were washed twice with D-PBS.  5mL trypsin-EDTA diluted 1:10 
in D-PBS was added to coat the flask and then discarded.  Cells were left for 30s at 
room temperature and were detached from the flask by tapping.  Cells were 
resuspended in 10mL RPMI complete to deactivate the trypsin-EDTA.  The cell 
suspension was divided between the required number of tissue culture flasks 
containing pre-warmed RPMI complete.  For experiments, cells were plated into 24 
well plates at a density of 1.7x105cells/mL. 
 
2.5.1.2 Primary HBEC culture 
 Primary HBECs were obtained from Lonza (USA). The cells had been 
obtained from a non-asthmatic, non-smoking, non-alcoholic subject and were 
provided in a frozen cryovial (source number 7F3143).  Cells were stored in liquid 
nitrogen until resuscitated in pre-warmed BEGM complete medium and grown to 
confluence in a 25cm2 tissue culture flask in a humidified incubator at 37˚C (5% 
CO2).  Cells were passaged as in section 2.4.3.  HBECs were plated into 24 well 
plates at a density of 1.0x105cells/mL. 
 
2.5.1.3 HeLa cell culture 
 HeLa (Ohio) cells were obtained from ATCC, stored in liquid nitrogen and 
resuscitated into 175cm2 tissue culture flasks in pre-warmed HeLa cell complete 
medium.  Cells were passaged into 175cm2 tissue culture flasks by washing twice 
with D-PBS, adding 2mL trypsin-EDTA (diluted 1:10 in D-PBS), and incubating in a 
humidified incubator at 37˚C (5% CO2) until the cells detached.  Cells were 
resuspended in 10mL HeLa cell complete medium to deactivate the trypsin-EDTA.  
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The cell suspension was divided between the required number of tissue culture 
flasks containing pre-warmed HeLa cell complete medium and incubated at 37˚C 
(5% CO2). 
 
2.5.2 RV Culture  
2mL RV16 and RV1B was expanded to produce 1150mL virus stock by 
passage through HeLa cell culture.  This stock was stored in single use aliquots at -
80˚C.   
Expansion was performed by culturing RV in 175cm2 flasks of confluent HeLa 
cells.  Cells were washed twice in 10mL HeLa cell infection medium.  2mL RV stock 
was added to 8mL HeLa infection medium.  This was added to the HeLa cells and 
was shaken gently at room temperature for 1h, when a further 10mL of medium was 
added.  The flask was incubated at 37˚C (5% CO2).  About 24 hours later, when 90% 
cytopathic effect was observed, the cells were disrupted and contents of the flask 
were frozen at -80˚C.  Cells were lysed by 3x freeze/thawing.  RV inoculum was 
produced by centrifuging 4000rpm for 15min at 4˚C to pellet cell debris and filtering 
the supernatant through a 0.2μm filter (Acrodisc).  This inoculum was used to infect 
further flasks of HeLa cells and the process repeated, generating the final volume of 
1150mL filtered HeLa cell supernatant containing RV16 or RV1B. 
RV was titrated in HeLa cells to estimate virus concentration, and the identity 
of the final virus stock was be confirmed by neutralisation of cytopathological effect 
by RV16 or RV1B specific antisera.  All virus stocks were tested for Mycoplasma 
contamination using commercial reagents (Roche, Switzerland).  The potency of the 
virus was tested in BEAS-2B cells, with IL-6 and IL-8 being measured in the 
supernatants by ELISA. 
 
2.5.2.1 Virus Titration in HeLa cells 
 Ohio HeLa cells were cultured, split, resuspended in HeLa cell titration 
medium, counted and diluted to give a concentration of 0.8x105cells/mL.  150µL of 
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cells were placed in each well of a flat bottomed 96 well cell culture cluster plate 
(Costar).  To establish virus concentration, virus was serially diluted 1:10 (neat to 
1:10-7) in HeLa cell titration medium with each dilution being placed in a row of 8 
wells, leaving 2 wells with cells alone to act as a control.  For HBEC experiments to 
establish viral replication cell supernatants were serially diluted and protocol 
continued as above.  Plates were incubated at 37°C (5% CO2) for 4 days.  
Cytopathic effect (CPE) was determined by light microscopy and wells positive for 
CPE were counted on day 4.  Tissue culture infective dose 50% (TCID50)/mL value 
was determined by scoring the sum of positive wells and using the Spearman Karber 
formula (M= xk +d[0.5-(1/n)(r)], wherein xk= dose of highest dilution, r = sum of 
negative responses, d = spacing between dilutions and n = wells per dilution). 
 
2.5.2.2 Filtration of virus stock to produce RV filter control 
As a negative control for RV a filtered control was produced for in vitro 
experiments.  500µL RV (neat for RV16, 1:10 RV1B) was placed in an Amicon Ultra-
0.5, Ultracel-30 membrane, 30kDa filter unit (Millipore) and centrifuged at 12000rpm 
for 8min. 
 
2.5.2.3 Virus infection of HBECs and BEAS2B cells 
 HBECs (both obtained from study participants and primary HBECs from 
Lonza, USA) and BEAS-2B cells were cultured in 24 well plates until 80% confluent.  
Cells were serum starved overnight in BEGM infection–P/S medium (HBECs) or 
RPMI infection medium (BEAS-2Bs).  The medium was removed and 100µL virus 
(neat RV16, 1:10 RV1B) or filtered virus was added to the cells.  The plate was 
placed on a shaker for 1h at room temperature.  The virus was removed and 
replaced with 0.5mL warmed BEGM infection+P/S medium (HBECs) or RPMI 
infection medium (BEAS-2Bs).  For HBECs, wells being used for virus titrations were 
washed 3 times in BEGM infection+P/S medium prior to the addition of BEGM 
infection+P/S medium.  Cells were incubated at 37°C (5% CO2).    Cells and 
supernatants were harvested at 8h, 24h and 48h. 
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2.5.2.4 Virus infection of PBMCs and BAL cells 
 PBMCs and BAL cells were processed as in sections 2.4.1 and 2.4.2.  1mL of 
cells, in sterile polypropylene tubes, at a concentration of 2x106cells/mL was 
stimulated with 1mL RV (RV16, neat and RV1B, 1:10 dilution) or filtered RV, which 
was then incubated at 37°C (5% CO2) for 1h.  Tubes were then centrifuged at 
1500rpm for 10min, the supernatant discarded and the cell pellet was resuspended 
in 2mL RPMI+P/S and incubated 37°C (5% CO2) until harvesting at 8h, 24h and 48h, 
depending on cell number. 
 
2.5.3 Streptococcus pneumoniae (Spn) culture 
Spn stock (strain D39, an encapsulated human pathogen) was used from a 
gift of Professor Tracy Hussell, Imperial College, London.  Briefly, Spn frozen stock 
was added to Todd Hewitt Broth + 0.05% yeast extract and grown until the 
OD600nm was 0.4.  At this point serial dilutions were made and plated onto blood 
agar to determine the concentration in colony forming units/mL (cfu/mL).  The stock 
was aliquotted and stored in 10% glycerol at -80˚C.  Filtered Spn using a 0.2µm filter 
(Acrodisc) was used as a control.  Spn was tested in BEAS-2B cells, primary HBECs 
and PBMCs prior to its use in the participants’ samples. 
 
2.5.3.1 Spn infection of HBECs and BEAS2B cells 
 Cells were grown to 80% confluence in 24 well plates.  Cells were serum 
starved overnight in BEGM infection–P/S medium (HBECs) or RPMI infection 
medium (BEAS-2Bs).  The medium was removed and 0.5mL Spn (diluted to 1x104 
cfu/mL) or filtered Spn was added to the cells.  The plate was placed on a shaker for 
1h at room temperature.  Spn was then removed and the cells were washed 3 times 
with the appropriate infection medium.  Cells were incubated at 37°C (5% CO2).  
Cells and supernatants were harvested at 8h, 24h and 48h. 
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2.5.3.2 Spn infection of PBMCs and BAL cells 
 PBMCs and BAL cells were processed as in sections 2.4.1 and 2.4.2.  1mL of 
cells, in sterile polypropylene tubes, at a concentration of 2x106cells/mL was 
stimulated with 1mL Spn (1x104cfu/mL, diluted in RPMI-P/S) or filtered Spn, which 
was then incubated at 37°C (5% CO2) for 1h.  Tubes were then centrifuged at 
1500rpm for 10min, the supernatant discarded and the cell pellet was resuspended 
in 2mL RPMI-P/S and incubated 37°C (5% CO2) until harvesting at 8h, 24h and 48h, 
depending on cell number. 
 
2.5.4 TLR ligands 
2.5.4.1 Lipoteichoic Acid (LTA) 
 LTA is found in the cell wall of most gram-positive bacteria and is linked to the 
cytoplasmic membrane and stimulates TLR2.  LTA from Staphylococcus aureus was 
resuspended to a concentration of 1mg/mL in endotoxin-free water (InvivoGen) as 
per the manufacturer’s instructions, aliquotted and stored at -20°C. 
 
2.5.4.2 Lipopolysaccharide (LPS) 
 LPS is a toxic component of the outer leaflet of the outer membrane of gram-
negative bacteria which stimulates TLR4.  It was resuspended to a concentration of 
1mg/mL in nuclease free water (Promega, USA), aliquotted and stored at -80°C.  
LPS was used at a concentration of 10µg/mL in all cell types.  This dilution was 
chosen from protocols already established in the department (A. Sykes, unpublished 
data). 
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2.5.4.3 CpG-C ODN 
 Synthetic oligodeoxynucleotides (ODN) containing the CpG dinucleotides 
have been used to mimic bacterial CpG-DNA.  These are ligands for TLR9.  The 
sequence for CpG-C-ODN is (5’-3’):  TCGTCGTTTTCGGCGCGCGCCG (the 
sequence underlined is a signature CpG sequence).  CpG-C was diluted to a 3µM 
solution in the appropriate medium for the different cell types and was stored at -
80°C until further use.  This dilution was chosen from protocols already established 
in the department (A. Sykes, unpublished data). 
 
2.5.4.4 Flagellin (FLA) 
 Flagellin is the major component of the bacterial flagellar filament, which 
confers motility on a wide range of bacterial species.  It is recognised by TLR5.  
Flagellin from Salmonella typhimurium was resuspended to a concentration of 
100µg/mL in endotoxin-free water (InvivoGen) as per the manufacturer’s instructions, 
aliquotted and stored at -20°C. 
 
2.5.4.5 Pam3CSK4 (PAM) 
 Pam3CysSerLys4 (Pam3CSK4) is a synthetic tripalmitoylated lipopeptide that 
mimics the acylated amino terminus of bacterial lipoproteins.  Bacterial lipoproteins 
are found in both gram-positive and gram-negative bacteria. Pam3CSK4 is 
recognised by TLR2 which cooperates with TLR1.  Pam3CSK4 was resuspended to a 
concentration of 1mg/mL in endotoxin-free water (InvivoGen) as per the 
manufacturer’s instructions, aliquotted and stored at -20°C. 
 
2.5.4.6 Synthetic Lipoprotein (FSL) 
 Pam2CGDPKHPKSF (FSL-1) is a synthetic lipoprotein which contains a 
lipolyated N-terminal diacylated cysteine residue which is recognised by TLR2 and 
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TLR6.  FSL-1 was resuspended to a concentration of 100µg/mL in endotoxin-free 
water (InvivoGen) as per the manufacturer’s instructions, aliquotted and stored at -
20°C. 
 
2.5.4.7 Peptidoglycan (PGN) 
 Peptidoglycan is a surface component of gram-positive bacteria and is 
recognised by TLR2.  There is evidence that peptidoglycan is recognised by other 
pattern recognition receptors such as NOD1 and NOD2.  Peptidoglycan from 
Staphylococcus aureus was resuspended to a concentration of 200µg/mL in 
endotoxin-free water (InvivoGen) as per the manufacturer’s instructions, aliquotted 
and stored at -20°C. 
 
2.5.4.8 Resiquimod (R848) 
 R848 is an imidazoquinoline antiviral drug which stimulates TLR7/TLR8.  It 
was diluted to a 1mM solution in the appropriate medium for the different cell types 
and was stored at -20°C until further use.   This dilution was chosen from protocols 
already established in the department (A. Sykes, unpublished data). 
 
2.5.4.9 Polyinosinic:polycytidylic Acid (poly(IC)) 
 Poly(IC) is a synthetic, mismatched double stranded RNA with one strand of 
polyinosinic acid and one of polycytidylic acid.  It is a TLR3 agonist.  It was 
resuspended to a concentration of 1mg/mL in nuclease free water (Promega, USA) 
as per the manufacturer’s protocol.  It was aliquotted and stored at -80°C until further 
use.  Poly(IC) was used at a concentration of 10µg/mL in HBECs and 100µg/mL in 
PBMCs.  This dilution was chosen from protocols already established in the 
department (A. Sykes, unpublished data). 
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2.6 Molecular Biology Techniques 
 
2.6.1 RNA extraction and cDNA synthesis 
RNA was extracted from lysed cells using the RNEasy mini kits (Qiagen, UK) 
according to the manufacturer’s protocol.  Lysates were thawed, mixed with 350µL 
70% ethanol and placed in the RNeasy spin column.  This was spun at 10,000rpm 
for 1min.  The flow through was discarded, 350µL buffer RW1 was added to the 
column and this was again spun at 10,000rpm for 1min.  80µL DNase 1 (diluted 1:8 
with buffer RDD, Qiagen, UK) was applied directly to the column filter and incubated 
for 15min at room temperature.  350µL buffer RW1 was added to wash off the 
DNase 1 and the column was spun at 10,000rpm for 1min.  The collection tubes 
were replaced and the spin filter was washed twice with 500µL buffer RPE, spinning 
at 10,000rpm once for 1min and once for 2min, followed by a dry spin for 1min to 
remove excess liquid.  RNA was eluted from the column filter with 39µL nuclease 
free water (Qiagen, UK). 
cDNA synthesis was performed using the Omniscript reverse transcriptase kit 
(Qiagen, UK) and random hexamer primers (Promega, USA) as per manufacturer’s 
protocol.  Table 2.12 lists the components of the kit and volumes required for each 
reaction.  Samples were mixed and incubated at 37°C for 1.5h and stored at -80°C 
until further use. 
 
Table 2.12 Components of the reaction for cDNA synthesis 
Component 
 
Volume per reaction (µL) 
10 Buffer RT 6.0 
dNTP mix (5mM each dNTP) 6.0 
Random hexamer primers 3.0 
RNase free water 3.0 
Omniscript RT 3.0 
Template RNA 39.0 
Total volume 60.0 
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2.6.2 Primers and probes for Realtime RT-PCR 
Primers and probes were all handled in a designated nuclease-free flow hood.  
All primers and probes were resuspended in sterile TE buffer to a stock 
concentration of 100µM and stored at -20oC.  Working stocks of primers and probes 
were prepared by diluting to 5µM in nuclease-free water (Promega, USA, Madison, 
WI, USA) and stored at -20oC.  Sequences of primers and probes and their optimal 
concentrations (nM) are listed in table 2.6.  All primer and probe sequences were 
already established in the lab.  Briefly, genomic and mRNA sequences of the gene of 
interest were found using NCBI PubMed and primers and probes overlapping an 
exon-exon boundary were selected using Primer Express v3.0.  Optimal 
forward/reverse primer concentrations were already established. 
 
2.6.3 Realtime RT-PCR 
TaqMan™ RT-PCR (Applied Biosystems Fast 7500 machine) and specific 
primer and probe sequences were used to detect mRNA expression of IL-6, 
CXCL8/IL-8, RV, IFN-λ1, IFN-λ2/3, IFN-β and IFN-α(A2).  A fast 96-well optical PCR 
plate (Applied Biosystems) was used.  In each well 6.25µL 2x QuantiTect probe PCR 
Master Mix, forward and reverse primers (at the optimised nM ratio, Table 2.6), 
175nM probe and 1µL cDNA was used.  For 18S rRNA measurements, the cDNA 
was diluted 1/100 in nuclease-free water (Promega, USA).  Non template controls 
(RNase free water in place of cDNA) were included.  The PCR plate was sealed with 
a Microamp optical adhesive cover (Applied Biosystems) and was analysed with the 
Applied Biosystems Fast 7500 machine.  The thermal cycle conditions consisted of 
50oC for 2min, 95oC for 10min, then 45 cycles of 95oC for 15s and 60oC for 15s.  
Data was analysed using version 1.4.0 ABI Prism 7500 SDS software.  Threshold 
cycle numbers from samples were compared to standard curves already established 
in the lab.  Data was normalised to 18S rRNA and was presented as normalised 
copy number per µL of cDNA.   
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2.7 Protein analysis techniques 
 
2.7.1 Enzyme-Linked ImmunoSorbent Assay (ELISA) to test RV induced 
production of IL-6 and IL-8 in BEAS2B cells, Primary HBECs (Lonza) and 
PBMCs 
 IL-6 and CXCL8/IL-8 production was measured by ELISA to test stocks of 
RV16 and RV1B in BEAS-2B cells, and to test a concentration response of serial 
dilutions of RV16 and RV1B in primary HBECs (Lonza) and PBMCs in order to 
establish the optimal concentration of RV for use in the remaining study. 
 Paired antibodies to IL-6 and CXCL8/IL-8 (R&D systems, USA) were used.  
96 well microtitre plates (Nunc) were coated overnight with 100µL of anti-human IL-6 
or CXCL8/IL-8 coating antibody (4.0µg/mL, diluted in D-PBS).  Plates were washed 3 
times with ELISA wash buffer, blocked with blocking buffer (1% BSA/0.1% Tween 
20/PBS) for 2h, followed by 3 washes with ELISA wash buffer.  IL-6 or CXCL8/IL-8 
recombinant protein standard was serially diluted from 1000pg/mL to 3.9pg/mL and 
100µL of standard or sample was added to the plate and incubated at room 
temperature for 1h.  Plates were washed 3 times with wash buffer and 100μL of 
25ng/mL IL-6 or CXCL8/IL-8 biotinylated detection antibody was applied and 
incubated at room temperature for 1h.  After 3 further washes 100µL Streptavidin-
HRP (diluted 1:5000 in diluent buffer) was added, incubated for a further 15min in 
the dark with shaking and washed 3 times.  100µL TMB substrate was added to the 
wells and incubated in the dark until colour began to develop in background wells.  
The reaction was stopped with 50µL 2M H2SO4 and the absorbance was measured 
at 450nm on a microplate reader.  The absorbance readings were compared to 
those of the linear portion of the standard curve to give concentrations in pg/mL, 
using the Softmax Pro v3.1.2 software (Molecular Devices Corporation, USA). 
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2.7.2 Development of a Meso Scale Discovery (MSD) prototype to measure IL-
29 
 MULTI-SPOT® 96 4 spot plates were pre-coated with human IL-29 capture 
antibody (DY1598, R&D systems, USA) by MSD.  In order to test the IL-29 MSD 
plates samples of supernatants from polarised monocyte-derived macrophages 
stimulated with differing MOI of RV were acquired from a colleague in the 
department.  Comparisons were made to data from these samples analysed with 
ELISA using the same human IL-29 antibody kit (DY1598, R&D systems, USA; 
35.8% cross reactivity with IL-28A, no cross-reactivity with IFN-α or IFN-β).  Reverse 
pipetting was used throughout the procedure to ensure no bubbles would interfere 
with the plate reading.  Half the plate was blocked with 1% BSA (in D-PBS), 
150µL/well, for 1h at room temperature.  The plate was washed 3 times with 
150µL/well 0.05% Tween-20/PBS.  IL-29 standard was serially diluted 1:4 from 
20,000pg/mL to 0pg/mL in Diluent 1 (MSD).  25µL of sample, both undiluted and a 
1:10 dilution (in Diluent 1) were added to the blocked wells.  Only diluted samples 
were added to the unblocked wells.  25µL of standards, in duplicate, were added to 
both blocked and unblocked wells.  The plate was sealed with an adhesive plate seal 
and incubated for 2h with vigorous shaking (600rpm) at room temperature.  The 
plate was washed 3 times with 0.05% Tween-20/PBS.  25µL IL-29 detection 
antibody (0.5µg/mL, R&D systems, USA)/SULFO-TAG™ labelled streptavidin 
(1µg/mL, MSD) was added to each well.  The plate was sealed and incubated for a 
further 1.5h with vigorous shaking at room temperature.  The plate was washed 3 
times with 0.05% Tween-20/PBS.  150µL of 2x Read Buffer T (MSD) was added to 
each well and the plate was analysed immediately on the SECTOR® Imager 2400.  
Data was analysed using the Discovery Workbench® 3.0 Software (MSD; the basis of 
which is the signal detected on the imager is compared to the standard curve of 
known cytokine concentration to give a sample concentration). 
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2.7.3 Meso Scale Discovery (MSD) to measure proinflammatory cytokines IL-
1β, IL-6, IL-8 and TNF-α, and interferons IFN-α, IFN-β and IL-29 (IFN-λ1) in 
HBECs, BAL macrophages and PBMCs 
MSD for proinflammatory cytokines, IFN-α2a and IFN-β was performed 
according to the manufacturer’s protocols.  An MSD prototype assay for IL-29 was 
manufactured by MSD and tested as above (see section 2.7.2). 
 
2.7.3.1 Proinflammatory cytokines (IL-1β, IL-6, CXCL8/IL-8, TNF-α) 
IL-1β, IL-6, CXCL8/IL-8 and TNF-α were quantified with an MSD human 
proinflammatory-4 II Tissue Culture Kit (K11025B-4, MSD).  The manufacturer’s 
protocol was followed.  Serial 1:4 dilutions of human ProInflammatory-4 II calibrator 
stock were made in Diluent 1 (MSD) starting at 10,000pg/mL to 0pg/mL.  Samples 
were diluted 1:10 in Diluent 1 (MSD).  25µL/well of calibrator (in duplicate) or sample 
was added.  The plate was sealed and incubated for 2h with vigorous shaking at 
room temperature.  The plate was washed 3 times with 0.05% Tween-20/PBS.  25µL 
of human proinflammatory-4 II detection antibody (diluted to a final concentration of 
1x in Diluent 100, MSD) was added to each well; the plate was again sealed and 
incubated for 1.5h with vigorous shaking at room temperature.  The plate was 
washed 3 times with 0.05% Tween-20/PBS.  150µL of 2x Read Buffer T (MSD) was 
added to each well and the plate was analysed immediately on the SECTOR® 
Imager 2400.  Data was analysed using the Discovery Workbench® 3.0 Software 
(MSD).  The average sensitivities were 1.4pg/mL (IL-1β), 1.0pg/mL (IL-6), 1.0pg/mL 
(CXCL8/IL-8), 3.3pg/mL (TNF-α). 
 
2.7.3.2 IFN-α2a  
IFN-α2a was quantified with an MSD human IFN-α2a tissue culture kit 
(K151ACB-4, MSD).  The manufacturer’s protocol was followed.  Serial 1:4 dilutions 
of IFN-α2a calibrator stock were made in Diluent 1 (MSD) starting at 10,000pg/mL 
down to 0pg/mL.  25µL/well of calibrator (in duplicate) or sample was added.  The 
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plate was sealed and incubated for 2h with vigorous shaking at room temperature.  
The plate was washed 3 times with 0.05% Tween-20/PBS.  25µL of anti-hIFN-α2a 
antibody (diluted to a final concentration of 1x in Diluent 100, MSD) was added to 
each well; the plate was again sealed and incubated for 1.5h with vigorous shaking 
at room temperature.  The plate was washed 3 times with 0.05% Tween-20/PBS.  
150µL of 2x Read Buffer T (MSD) was added to each well and the plate was 
analysed immediately on the SECTOR® Imager 2400.  Data was analysed using the 
Discovery Workbench® 3.0 Software (MSD).  The average sensitivity was 1.2pg/mL. 
 
2.7.3.3 IFN-β 
IFN-β was quantified with an MSD human IFN-β tissue culture kit (K111ADB-
4, MSD).  The manufacturer’s protocol was followed.  The plate was washed 3 times 
with PBS.  25µL anti-hIFN-β biotinylated capture antibody (diluted to a final 
concentration of 1x in Diluent 100, MSD) was added to each well; the plate was 
sealed and incubated for 1h with vigorous shaking a room temperature, followed by 
3 washes with PBS.  Serial 1:4 dilutions of IFN-β calibrator stock were made in 
Diluent 1 (MSD) starting at 100,000pg/mL down to 0pg/mL.  50µL/well of calibrator 
(in duplicate) or sample was added; 20µL of anti-hIFN-β antibody (diluted to a final 
concentration of 1x in Diluent 100, MSD) was added to each well; the plate sealed 
and incubated for 2h with vigorous shaking a room temperature.  The plate was 
washed 3 times with 0.05% Tween-20/PBS.  150µL of 1x Read Buffer T (MSD) was 
added to each well and the plate was analysed immediately on the SECTOR® 
Imager 2400.  Data was analysed using the Discovery Workbench® 3.0 Software 
(MSD).  The average sensitivity was 8.6pg/mL. 
 
2.7.3.4 IL-29 (IFN-λ1) 
 IL-29 was quantified using the MSD prototype human IL-29 MULTI-SPOT® 96 
4 spot plates as described in section 2.7.2.  Plates were not blocked prior to the 
addition of standard/sample and undiluted standard/sample was used.  The average 
sensitivity was 20.2pg/mL. 
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2.8 Statistical analysis 
Statistical analysis was carried out using non-parametric tests, at a 95% 
confidence interval with the Kruskal-Wallis test (one way ANOVA equivalent); if data 
were significant (p value<0.05), differences were further analysed using Dunn’s 
multiple comparison test.  Statistics were analysed using GraphPad Prism software, 
v4.0 (USA).  
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Chapter 3: RV infection of BAL cells, HBECs and PBMCs, and 
TLR3/7/8 stimulation of HBECs and PBMCs 
 
3.1 Introduction 
 RVs are responsible for a significant proportion of viral-induced asthma 
exacerbations.  AA have increased susceptibility to RV infection, with longer lasting 
and more severe symptoms compared to non-asthmatics 306.  The bronchial 
epithelium has an important role in the innate immune system’s response to viral 
infection, expressing the cell surface receptors for RV, ICAM-1 and LDLR 56, 57.  RV 
results in the production of type I and III IFN and proinflammatory cytokines from the 
bronchial epithelium.  Exposure of BAL cells and PBMCs to RV results in induction of 
type I IFNs 61, 80.  IFN production following RV infection has been reported to be 
defective in AA.  HBECs from AA infected with RV have defective IFN-β production 
60 and HBECs and BAL cells infected with RV have defective IFN-λ production 61.  
The deficient IFN responses may impair an infected cell’s ability to undergo 
apoptosis and thereby allow increased viral replication 60.  Addition of exogenous 
IFN-β to AA cells restores anti-viral responses to levels seen in cells from non-
asthmatics 60.  A more recent study has identified deficient type I IFN production in 
BAL cells from AA and this deficiency may be related to asthma severity 208.  PBMCs 
from adult and child AA have been reported as having deficient IFN-α2 production 
following RSV and NDV infection 82, 206.   
Asthmatics are classed as atopic or non-atopic.  The role of atopy in deficient 
IFN production is unknown, and whether it is the asthmatic or atopic status which 
results in this deficiency is unclear.  Observations have been made identifying IFN-α 
deficiency in cases of atopic disease 234, 307.  A recent study reported deficient IFN-β 
and -λ responses to rhinovirus infection in BECs in asthmatic children irrespective of 
their atopic status and surprisingly, in atopic children without asthma 209.  However, 
these atopic children without asthma had similar degrees of IL-4 staining and 
epithelial damage in their bronchial biopsies as did the children with asthma, thus the 
roles of atopy and asthma in IFN deficiency remain uncertain.  To date whether adult 
NAA and/or ANA have deficient IFN responses has not been identified. 
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 TLR3, TLR7 and TLR8 are receptors linked to viral cell signalling.  TLR3 
recognises dsRNA 260, is important in the recognition of RV 308 and is a potent 
inducer of type I IFNs 260.  It is possible that the defective IFN response to RV in AA 
involves TLR3, and whether this extends to NAA or ANA is of interest.  A 
polymorphism of TLR3 has been identified as a susceptibility gene for asthma and 
atopy 309.  TLR7/8 recognise viral ssRNA 310.  These TLRs are expressed on the 
endolysosomes of HBECs, dendritic cells and monocytes.  TLR7 function has been 
observed to be reduced in adolescents with asthma, with a significant negative 
correlation between total serum IgE and TLR7 stimulated CXCL10/IL-10 production 
311.  Polymorphisms of TLR7 and TLR8 have been linked to asthma and atopic 
diseases 312 and administration of TLR7/8 agonists has been reported to suppress 
inflammation and airway remodelling in rodent models of allergic airways disease, 
postulating the use of TLR7/8 agonists as a treatment modality in asthma 313, 314.   
 
3.1.1 Hypotheses 
 RV infection of BAL cells, HBECs and PBMCs will result in deficient type I and 
III IFN production in AA and NAA, compared to NANA and ANA. 
 Stimulation of TLR3, TLR7 and TLR8 will induce type I and III IFNs and 
proinflammatory cytokines in HBECs and PBMCs and will result in deficient 
type I and III IFN production in AA and NAA, compared to NANA and ANA. 
 
3.1.2 Aims 
 To confirm or refute previous reports of deficient RV induced type I and III IFN 
production in HBECs and PBMCs from a different group of AA and to 
determine whether similar deficiencies are seen in NAA and not in NANA and 
ANA. 
 To confirm or refute previous reports of deficient RV induced type I and III IFN 
production in BAL cells from AA and to determine whether similar deficiencies 
are seen in NAA and not in NANA and ANA. 
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 To characterise the type I and III IFN and proinflammatory cytokine response 
to TLR3, TLR7 and TLR8 stimulation in HBECs and PBMCs (only HBECs and 
PBMCs were used in experiments with the TLR ligands due to the limited 
number of BAL cell samples being collected from the volunteers). 
 To determine whether this response is deficient in AA and NAA compared to 
NANA and ANA. 
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3.2 Results 
3.2.1 Preliminary testing of RV 
 In preparation for the main study, a stock of RV16 and RV1B was made and 
tested in BEAS-2B cells.  IL-6 and CXCL8/IL-8 protein expression was examined 
using ELISA.  Compared to medium- and filtered virus-treated BEAS-2B cells, RV16 
induced expression of IL-6 and CXCL8/IL-8 (figure 3.1 A and B).  Likewise, RV1B 
induced expression of IL-6 and CXCL8/IL-8 (figure 3.1 C and D).  UV-inactivation of 
virus appeared incomplete as CXCL8/IL-8 was comparable to live virus, while filtered 
virus appeared an effective means of inactivation.  Filtered virus was therefore used 
as control virus for subsequent experiments.  
 
Figure 3.1.  Testing the stock rhinovirus. IL-6 and CXCL8/IL-8 production at 24h in BEAS-2B cells 
stimulated with stock RV16 (A and B) and RV1B (C and D) (M = medium, WT = wild type, F = filtered 
virus, UV = UV inactivated virus) (N=1) 
 
 In order to assess the optimal concentration of RV for use in in vitro studies, a 
concentration response study was performed in PBMCs and primary HBECs (figures 
3.2 and 3.3).  Cells were stimulated with varying concentrations of RV16 and RV1B 
(wild type, 1:2, 1:5 and 1:10).  At 24h the supernatants were taken and analysed by 
ELISA for IL-6 and CXCL8/IL-8 protein (figures 3.2 and 3.3).  In PBMCs the optimal 
concentration for RV16 was a 1:2 concentration (Figure 3.2 A and B) and for RV1B 
was a 1:10 concentration (figure 3.2 C and D).  In primary HBECs, wild type RV16 
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(figure 3.3 A and B) and a 1:10 concentration of RV1B (figure 3.3 C and D) were 
optimal.  For all subsequent experiments wild type RV16 and 1:10 RV1B was used. 
 
Figure 3.2.  IL-6 and CXCL8/IL-8 induction at 24h in PBMCs from NANA stimulated with varying 
dilutions of RV16 (A and B) and RV1B (C and D) (M = media, WT = wild type) (N=1) 
 
Figure 3.3.  IL-6 and CXCL8/IL-8 induction at 24h in primary HBECs (Lonza) stimulated with varying 
dilutions of RV16 (A and B) and RV1B (C and D) (M = media, WT = wild type) (N=1) 
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3.2.2 Testing the IFN-λ1/IL-29 MSD prototype 
 A prototype IFN-λ1/IL-29 MSD was developed using R&D IFNλ1/IL-29 duoset 
antibodies and used according to the manufacturer’s instructions.  The efficacy of the 
MSD was analysed and compared to ELISA.  IFN-λ1/IL-29 protein was analysed 
from supernatants from polarised monocyte-derived macrophages stimulated with 
varying MOI of RV16 at 8, 24h and 48h post stimulation (courtesy of A. Nikonova). 
The MSD prototype was compared to standard ELISA using blocked and unblocked 
MSD plates, with diluted and undiluted samples.  Figure 3.4 demonstrates IFN-λ1/IL-
29 production at 8h with RV16 MOI 2 (figure 3.4 A) and 24 and 48h with RV16 MOI 
0.5 and 2 (figure 3.4.B and C).  MSD and ELISA did not produce equivalent 
concentrations of IFN-λ1/IL-29, but the pattern of expression was similar.  No 
marked differences were observed between the use of blocked or unblocked plates 
or using diluted or undiluted samples. 
  
Figure 3.4.  Comparing IFN-λ1/IL-29 MSD prototype to ELISA.  IFN-λ1/IL-29 protein production was 
assessed in polarised monocyte-derived macrophages (MDMs) stimulated with differing MOI of RV16 
at 8h (A), 24h (B) and 48h (C).  Comparisons were made between various set ups of MSD and 
standard ELISA used within the department (N=1).  
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3.2.3 Clinical characteristics of all participants 
 A total of 41 subjects (12 non-atopic non-asthmatics, 13 atopic non-
asthmatics, 4 non-atopic asthmatics and 12 atopic asthmatics) were screened and 
samples obtained.  23 other volunteers were screened but either withdrew from the 
study or were excluded.  Table 3.1 illustrates the numbers of samples obtained from 
the participants.  Recruitment of non-atopic asthmatics proved to be extremely 
difficult so the target N=12 was not reached.  HBECs were prone to contamination, 
at various stages along the culture pathway, hence the reduced numbers of HBEC 
samples, particularly in NAA.  In 3 participants (2 AA, 1 ANA) whose HBECs became 
contaminated a repeat bronchoscopy was performed to gain more samples (days in 
between bronchoscopies - 27, 93 and 150).  On these second bronchoscopies only 
bronchial brushes for HBECs were performed, with no BAL or PBMC sampling.  Of 
the 2 AA subjects who had a repeat bronchoscopy, 1 had an ACQ = 0, normal 
spirometry and PC20 = 4 (very mild disease), the other had ACQ = 1.3, reduced 
spirometry and PC20 = 0.24 (mild disease). 
 
Table 3.1. Samples obtained from participants 
 NANA ANA NAA AA 
Target sample number 12 12 12 12 
BAL samples obtained and 
analysed 
11 13 4 12 
PBMC samples obtained and 
analysed 
11 13 4 12 
HBEC samples obtained and 
analysed 
12 12 2 12 
 
 
 The clinical characteristics of the participants are demonstrated in table 3.2, 
with significant differences being highlighted in figure 3.5. 
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Table 3.2.  Clinical characteristics of all participants.  Values are expressed as median (IQR) 
except sex, treatments and atopic symptoms which are expressed as a percentage of the total in the 
individual groups.  ACQ=asthma control questionnaire score, SABA=short acting β2 agonists, 
ICS=inhaled corticosteroids, LABA=long acting β2 agonists, SPT=number of wheals on skin prick 
testing.  N = NANA-12, ANA-13, NAA-4, AA-12. For p values <0.05 see figure 3.5 for differences 
between groups. 
 
Clinical 
characteristic 
NANA ANA NAA AA p value 
Sex 25% M 75% 
F 
69.2% M 
30.8% F 
25% M 75% 
F 
75% M 25% 
F 
 
Age 25.5 (19.5-
29.5) 
27.0 (24.5-
32.0) 
37.0 (28.0-
44.5) 
29.5 (28.0-
34.0) 
0.1675 
ACQ 0 0 0.75 (0.33-
1.08) 
0.917 (0.417-
1.67) 
<0.001 
SABA alone 0 0 1 (25%) 3 (25%)  
ICS 0 0 3 (75%) 9 (75%)  
ICS and LABA 0 0 1 (25%) 3 (25%)  
Exacerbations/year 0 0 0.5 (0.0-1.0) 0.0 (0.0-1.0) 0.0113 
PEF (L/min) 490.5 (440.5-
561.0) 
586.0 (484.0-
646.5) 
518.5 (449.0-
594.5) 
537.5 (443.5-
585.0) 
0.3907 
PEF % predicted 107.5 (97.5-
112.5) 
102.0 (91.5-
112.0) 
107.5 (106.0-
130.0) 
94.50 (89.5-
99.0) 
0.0869 
FEV1 (L) 3.770 (3.495-
4.410) 
4.310 (3.715-
4.840) 
3.195 (3.115-
3.660) 
3.860 (3.170-
4.290) 
0.0739 
FEV1 % predicted 106.5 (102.0-
112.5) 
103.0 (99.5-
109.5) 
106.5 (101.5-
108.5) 
93.50 (85.0-
103.5) 
0.0205 
FVC (L) 4.250 (3.860-
4.850) 
4.750 (4.445-
5.320) 
3.815 (3.585-
4.400) 
5.065 (3.870-
5.405) 
0.1496 
FVC % predicted 104.5 (96.5-
110.0) 
102.0 (92.5-
110.5) 
107.0 (104.5-
112.0) 
99.00 (93.0-
105.5) 
0.1764 
FEV1/FVC ratio 90.85 (87.0-
92.5) 
88.60 (83.90-
91.65) 
82.35 (81.55-
88.95) 
81.80 (74.20-
84.05) 
0.0044 
PC20 (mg/mL) ≥16 (16-16) ≥16 (16-16) 4.0 (2.12-
6.00) 
3.0  (0.74-
4.00) 
<0.001 
IgE (units/mL) 8.5(5.0-15.5) 90.0 (39.5-
213.5) 
6.0(3.5-14.5) 149.0 (44.5-
235.5) 
<0.001 
SPT (number) 0 (0-0) 2.0  (1.5-3.5) 0 (0-0) 4.0 (2.5-4.5) <0.001 
Atopic symptoms 100% N 46.2% Y 
53.8% N 
100% N 91.7% Y 
8.3% N 
 
% eosinophils in 
BAL 
0 (0-0.6) 0.3 (0-0.55) 0 (0-0.225) 0 (0-1.875) 0.4554 
% neutrophils in 
BAL 
0.6 (0.4-2.4) 0.5 (0.15-
1.95) 
1.11 (0.38-
2.645) 
1.45 (1-
2.475) 
0.3541 
 
 There were no significant differences between all groups for age, sex, PEF, % 
predicted PEF, absolute FEV1 and absolute and % predicted FVC.  Expected 
significant differences were observed in ACQ score between AA and NANA and AA 
and ANA (p<0.001), but no difference between AA and NAA (figure 3.5 A).  Expected 
differences were observed in exacerbation rate in the 4 groups as a whole (p=0.013), 
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but no differences were observed between individual groups (figure 3.5 B).  A 
statistically significant difference in % predicted FEV1 was observed between the 
NANA and AA groups (p<0.05).  No differences were observed between the other 
groups (figure 3.5 C).  A statistically significant difference in FEV1/FVC ratio was 
observed between the NANA and AA groups (p<0.01).  No differences were 
observed between the other groups (figure 3.5 D).  The mean ratio of 79.94% in AA 
does not indicate an obstructive spirometry (FEV1/FVC ratio <70%).  Expected 
differences in PC20 were observed between non-asthmatics and asthmatics, with no 
significant difference between AA and NAA (figure 3.5 E).  Expected significant 
differences were observed in total IgE and number of wheals on skin prick tests 
between atopics and non-atopics (figure 3.5 F and G) with a significant difference in 
the number of wheals on skin prick tests observed between AA and ANA (p<0.01). 
 
Figure 3.5. Clinical characteristics of participants with statistically significant differences between 
groups as a whole.  Asthma control score (A), number of exacerbations per year (B), % predicted 
FEV1 (C), FEV1/FVC ratio (D), PC20 (E), serum total IgE (F) and number of positive wheals on skin 
prick tests(G) ; * = p<0.05, ** = p<0.01, *** = p<0.001, ns = non-significant. 
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3.2.4 BAL cytospin composition in NANA, ANA, NAA and AA 
 To assess which cells were obtained in BAL fluid cytospins were performed 
on each participant.  Figure 3.6 illustrates BAL cell composition.  There was no 
significant difference in total cell number between the 4 groups, though a non-
significant possible reduction in cell number was observed in NAA (figure 3.6 E).  
BAL cells were predominantly macrophages (~95%) There were no significant 
differences in any particular cell type between groups. 
  
Figure 3.6.  BAL cytospins (A, B, C and D).  Data presented as a % of total cell count.  Macrophages 
(A), eosinophils (B), lymphocytes (C), polymorphonuclear cells (D).  Squares denote NANA, circles 
denote ANA, downward triangles denote NAA, upward triangles denote AA.  Total BAL cell count (E).  
No differences were observed between all cell types in all groups.  Within each cell type no significant 
differences were observed between groups.  A non-significant reduction in total cell count in NAA was 
observed (E).  No differences in total cell count were observed between other groups.  
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3.2.5 RV infection of BAL cells: induction of type I and III IFN and 
proinflammatory cytokine mRNA and protein 
 To assess whether the reported deficiency in RV induced IFN induction in 
BAL cells from atopic asthmatic subjects 61, 208 was observed in this newly recruited 
group of atopic asthmatic subjects and whether there is a difference between atopic 
and non-atopic asthmatic and non-asthmatic groups, RV induced IFN-α, IFN-β and 
IFN-λ mRNA and protein production by BAL cells was measured at 8h.  The aim was 
to measure at 24h also, but there were insufficient cells obtained at bronchoscopy for 
this. 
 The primer and probe sets for IFN-α detect IFN-α subtypes 1, 6 and 13, 
named IFN-α(A2).  As the primer and probe pairs span multiple subtypes mRNA 
copy number could not be accurately determined, so data was presented as fold 
induction over medium.  Significant induction of IFN-α mRNA was observed in NANA 
(p<0.001) and AA (p<0.01) with RV16.  Non-significant increases were observed in 
ANA and NAA (figure 3.7 A).  There were no significant differences between groups.  
With RV1B a 10-fold increase in IFN-α mRNA was observed in NANA but this failed 
to reach statistical significance.  Induction was not observed in other groups and 
there were no statistical differences between the 4 groups (figure 3.7 B). 
 IFN-β mRNA was significantly induced by RV16 in NANA and AA (p<0.001).  
Increases were observed in ANA and NAA but these failed to reach statistical 
significance (figure 3.7 C).  Small increases were observed in all groups with RV1B 
but these were not statistically significant (figure 3.7 D).  No differences were 
observed between groups with either virus. 
 IFN-λ2,3/IL-28 mRNA was significantly induced by both viruses in NANA 
(p<0.01) and AA (p<0.001).  Induction was observed in ANA with RV16 (p<0.05) and 
a non-significant increase was observed with RV1B.  Clear induction was observed 
with both viruses in NAA but these failed to reach statistical significance.  No 
differences were observed between groups (figure 3.7 E and F). 
 IFN-λ1/IL-29 mRNA was significantly induced by both viruses in NANA 
(p<0.001 with RV16, p<0.01 with RV1B) and AA (p<0.001).  Clear induction was 
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observed in ANA and NAA but these failed to reach statistical significance.  No 
differences were observed between groups (figure 3.7 G and H). 
   
Figure 3.7.  Interferon mRNA induction in BAL macrophages at 8h post stimulation with RV16 (A, C E 
and G) and RV1B (B, D, F and H).  Squares denote NANA, circles denote ANA, downward triangles 
denote NAA, upward triangles denote AA; open shapes denote medium, grey shapes denote filtered 
virus, black shapes denote virus; * = p<0.05, ** = p<0.01, *** = p<0.001, ns = non-significant.  
Significant induction of type I IFN mRNA was observed in NANA and AA stimulated with RV16 (A and 
C), but not with RV1B (B and D).  A non-significant increase was observed in ANA and NAA.  
Significant induction of IFN-λ2,3/IL-28 mRNA was observed in NANA, ANA and AA in BAL cells 
stimulated with RV-16 (E) and in NANA and AA in cells stimulated with RV1B (F).  Non-significant 
increases were observed in the other groups.  Significant induction of IFN-λ1/IL-29 mRNA in BAL 
cells stimulated with RV16 (G) and RV1B (H) was observed in NANA and AA, with non-significant 
increases in ANA and NAA.  No differences in all IFN mRNA induction were observed between 
groups. 
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 To assess interferon protein production in BAL cell supernatants MSD was 
employed.  The commercially available IFN-α2a and IFN-β MSD assays were used 
as these had been fully assessed and quality controlled by the company.  The 
prototype IFNλ1/IL-29 MSD assay (see section 3.2.2) was used to assess IFNλ1/IL-
29 protein production. 
Type I IFNs were induced by RV16.  Significant induction of IFN-α2a was 
observed in NANA (p<0.01), ANA (p<0.001) and AA (p<0.001).  An increase was 
observed in NAA but this failed to reach statistical significance (figure 3.8 A). 
Significant induction of IFN-β by RV16 was also observed in NANA (p<0.01) and AA 
(p<0.001).  An increase was observed in ANA and NAA but this failed to reach 
statistical significance (figure 3.8 C).  There were no significant differences in the 
production of type I IFNs between any groups.  Type I IFN protein was not 
significantly induced by RV1B (figure 3.8 B and D).  A weak induction of IFN-λ1/IL-29 
was observed in asthmatics following infection with RV16 (figure 3.8 E), but this 
failed to reach statistical significance.  No such induction was observed with RV1B 
(figure 3.8 F). 
 IL-6 and CXCL8/IL-8 mRNA expression in BAL cells, and IL-1β, IL-6, 
CXCL8/IL-8 and TNF-α protein production in BAL cell supernatant was measured at 
8h post stimulation to establish whether any deficiency in proinflammatory cytokines 
was identified in asthmatics, which could lead on to investigation of other innate 
immune responses. 
 IL-6 and CXCL8/IL-8 mRNA was not induced at 8h post stimulation with RV16 
or RV1B (figure 3.9).  High baseline mRNA levels of both cytokines were present 
and no significant difference was observed between any group.  Likewise, production 
of IL-1β, IL-6, CXCL8/IL-8 and TNF-α protein in BAL cell supernatants was not 
observed at 8h post stimulation with both RV16 and RV1B (figure 3.10) and there 
were no differences between the groups.  Similar to mRNA, high baseline levels of 
proinflammatory protein were observed in all groups. 
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Figure 3.8.  Interferon protein induction in BAL macrophages at 8h post stimulation with RV16 (A, C 
and E) and RV1B (B, D and F).  Squares denote NANA, circles denote ANA, downward triangles 
denote NAA, upward triangles denote AA; open shapes denote medium, grey shapes denote filtered 
virus, black shapes denote virus; ** = p<0.01, *** = p<0.001, ns = non-significant.  Induction of IFN-
α2a and IFN-β was observed in all groups stimulated with RV16, with no differences between groups.  
A weak induction of IFN-λ1/IL-29 was observed, but this was non-significant.  There was no induction 
of IFNs in BAL cells stimulated with RV1B. 
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Figure 3.9.  IL-6 and CXCL8/IL-8 mRNA induction in BAL macrophages at 8h post stimulation with 
RV16 (A and C) and RV1B (B and D).  Squares denote NANA, circles denote ANA, downward 
triangles denote NAA, upward triangles denote AA; open shapes denote medium, grey shapes denote 
filtered virus, black shapes denote virus.  Induction of IL-6 and CXCL8/IL-8 mRNA was not observed 
in BAL cells from any group stimulated with RV16 or RV1B at 8h. 
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Figure 3.10.  IL-1β (A and B), IL-6 (C and D), CXCL8/IL-8 (E and F) and TNF-α (G and H) protein 
induction in BAL cells stimulated with RV16 (A, C, E and G) and RV1B (B, D, F and H). Squares 
denote NANA, circles denote ANA, downward triangles denote NAA, upward triangles denote AA; 
open shapes denote medium, grey shapes denote filtered virus, black shapes denote virus.  
Production of proinflammatory cytokine protein was not observed in BAL cells from any group 
stimulated with RV16 or RV1B at 8h. 
 
 Tables 3.3 and 3.4 summarise IFN and proinflammatory cytokine protein and 
mRNA induction in BAL cells at 8h following infection with RV16 and RV1B. 
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Table 3.3 Summary of IFN and proinflammatory cytokine mRNA and protein induction post 
RV16 infection in BAL cells ↑ = significant induction, ns = non-significant increase observed, - = no 
induction 
 8h 
 NANA ANA NAA AA 
IFN-α mRNA ↑ ns ns ↑ 
IFN-α protein ↑ ↑ ns ↑ 
IFN-β mRNA ↑ ns ns ↑ 
IFN-β protein ↑ ns ns ↑ 
IFNλ1/IL-29 mRNA ↑ ns ns ↑ 
IFNλ1/IL-29 protein - - - - 
IFNλ2,3/IL-28 mRNA ↑ ↑ ns ↑ 
IL-6 mRNA - - - - 
CXCL8/IL-8 mRNA - - - - 
IL-1β protein - - - - 
IL-6 protein - - - - 
CXCL8/IL-8 protein - - - - 
TNF-α protein - - - - 
 
Table 3.4 Summary of IFN and proinflammatory cytokine mRNA and protein induction post 
RV1B infection in BAL cells ↑ = significant induction, ns = non-significant increase observed, - = no 
induction 
 8h 
 NANA ANA NAA AA 
IFN-α mRNA ns - - - 
IFN-α protein - - - - 
IFN-β mRNA ns ns ns ns 
IFN-β protein - - - - 
IFNλ1/IL-29 mRNA ↑ ns ns ↑ 
IFNλ1/IL-29 protein - - - - 
IFNλ2,3/IL-28 mRNA ↑ ns ns ↑ 
IL-6 mRNA - - - - 
CXCL8/IL-8 mRNA - - - - 
IL-1β protein - - - - 
IL-6 protein - - - - 
CXCL8/IL-8 protein - - - - 
TNF-α protein - - - - 
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3.2.6 RV infection of HBECs: induction of type I and III IFN and 
proinflammatory cytokines mRNA and protein 
 To establish whether the previously reported defective RV induced IFN-β and 
IFN-λ in AAs was present in HBECs from other patient groups type I and III IFN 
mRNA was measured at 8h and 24h, and protein at 24h and 48h in response to 
RV16 and RV1B.  HBECs have previously been shown not to produce IFN-α 80. 
 RV16 induction of IFN-β mRNA was not observed at 8h (figure 3.11 A), but 
was observed later at 24h (figure 3.11B).  Significant induction was observed in AA 
(p<0.01) and non-significant increases were observed in NANA, ANA and NAA.  No 
differences were observed between groups.  RV1B induction of IFN-β mRNA was 
observed at 8h and 24h (figure 3.12 A and B).  At 8h, significant induction in ANA 
(p<0.01) and AA (p<0.05), and non-significant increases in NANA were observed.  
Induction was not observed in NAA.  At 24h, significant induction in NANA (p<0.05) 
and AA (p<0.001), and non-significant increases in ANA and NAA were observed.  
No differences were observed between groups. 
 RV16 induction of IFN-λ2,3/IL-28 mRNA was observed at 8h and 24h (figure 
3.11 C and D).  At 8h, significant induction was observed in NANA (p<0.01) and AA 
(p<0.05) and non-significant increases were observed in ANA and NAA.  At 24h, 
significant induction was observed in NANA (p<0.05), ANA (p<0.01) and AA 
(p<0.001) and non-significant increases were observed in NAA.  No differences were 
observed between groups.  RV1B induction of IFN-λ2,3/IL-28 mRNA was observed 
at 8h and 24h (figure 3.12 C and D).  At 8h, significant induction was observed in 
NANA (p<0.05) and AA (p<0.01) and non-significant increases were observed in 
ANA and NAA.  At 24h, significant induction was observed in NANA (p<0.01), ANA 
(p<0.01) and AA (p<0.001) and non-significant increases were observed in NAA.  No 
differences were observed between groups.   
RV16 induction of IFN-λ1/IL-29 mRNA was observed at 8h and 24h (figure 
3.11 E and F).  At 8h, significant induction was observed in ANA (p<0.05) and AA 
(p<0.01) and non-significant increases were observed in NANA and NAA.  At 24h, 
significant induction was observed in NANA (p<0.01), ANA (p<0.01) and AA 
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(p<0.001) and non-significant increases were observed in NAA.  No differences were 
observed between groups.  RV1B induction of IFN-λ1/IL-29 mRNA was observed at 
8h and 24h (figure 3.12 E and F).  At 8h, significant induction was observed in NANA 
(p<0.05), ANA (p<0.05) and AA (p<0.01) and non-significant increases were 
observed in NAA.  At 24h, significant induction was observed in NANA (p<0.001), 
ANA (p<0.001) and AA (p<0.001) and non-significant increases were observed in 
NAA.  No differences were observed between groups.   
  
Figure 3.11.  Interferon mRNA induction in HBECs post stimulation with RV16 at 8h (A, C and E) and 
24h (B, D and F).  Squares denote NANA, circles denote ANA, downward triangles denote NAA, 
upward triangles denote AA; open shapes denote medium, grey shapes denote filtered virus, black 
shapes denote virus; * = p<0.05, ** = p<0.01, *** = p<0.001, ns = non-significant.  IFN-β (A and B), 
IFN-λ2,3/IL-28 (C and D), IFN-λ1/IL-29 (E and F).  Induction of IFN-β mRNA by RV16 was observed 
at 24h and type III IFN mRNA at both time points.  No significant differences were observed between 
groups. 
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Figure 3.12.  Interferon mRNA induction in HBECs post stimulation with RV1B at 8h (A, C and E) and 
24h (B, D and F).  Squares denote NANA, circles denote ANA, downward triangles denote NAA, 
upward triangles denote AA; open shapes denote medium, grey shapes denote filtered virus, black 
shapes denote virus; * = p<0.05, ** = p<0.01, *** = p<0.001, ns = non-significant.  IFN-β (A and B), 
IFN-λ2,3/IL-28 (C and D), IFN-λ1/IL-29 (E and F).  Induction of type I and III IFN mRNA by RV1B was 
observed at both time points. No significant differences were observed between groups. 
 
 IFN protein levels in HBEC supernatant were measured using MSD.  At 24h 
RV16 did not induce IFN-β protein (figure 3.13 A).  RV16 induced production of IFN-
β at 48h post stimulation, with significant induction in AA (p<0.05) and non-significant 
increases in NANA, ANA and NAA (figure 3.13 B).  IFN-λ1/IL-29 protein was not 
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observed at 24h (figure 3.13 C), but significant production was observed at 48h in 
NANA (p<0.001), ANA (p<0.01) and AA (p<0.001) with non-significant increases 
observed in NAA (figure 3.13 D).  At both time points no differences were observed 
between groups in the RV16 induced production of type I or III IFNs. 
 Stimulation of HBECs with RV1B resulted in no induction of IFN-β protein at 
24h (figure 3.14 A) and a non-significant increase in IFN-β protein at 48h (figure 3.14 
B).  Increases in IFN-λ1/IL-29 protein were observed at 24h and 48h (figure 3.14 C 
and D) with significance in NANA at 24h (p<0.05), and at 48h in ANA (p<0.01) and 
AA (p<0.001).  At both time points no differences were observed between groups in 
the RV1B induced production of type I or III IFNs. 
 
  
Figure 3.13.  Interferon protein induction in HBECs post stimulation with RV16 at 24h (A and C) and 
48h (B and D).  Squares denote NANA, circles denote ANA, downward triangles denote NAA, upward 
triangles denote AA; open shapes denote medium, grey shapes denote filtered virus, black shapes 
denote virus; * = p<0.05, ** = p<0.01, *** = p<0.001, ns = non-significant.  IFN-β (A and B), IFN-λ1/IL-
29 (C and D).  No production of type I or type III IFN was observed at 24h.  Production was observed 
at 48h, but no significant differences were observed between groups. 
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Figure 3.14.  Interferon protein induction in HBECs post stimulation with RV1B at 24h (A and C) and 
48h (B and D).  Squares denote NANA, circles denote ANA, downward triangles denote NAA, upward 
triangles denote AA; open shapes denote medium, grey shapes denote filtered virus, black shapes 
denote virus ; * = p<0.05, ** = p<0.01, *** = p<0.001, ns = non-significant.  IFN-β (A and B), IFN-λ1/IL-
29 (C and D).  No production of IFN-β protein was observed at 24h or 48h.  Production of IFN-λ1/IL-
29 was observed at 24h in NANA and at 48h in ANA and AA.  No significant differences were 
observed between groups. 
To evaluate differences in HBEC proinflammatory cytokine production 
between NANA, ANA, NAA and AA IL-6 and CXCL8/IL-8 mRNA at 8h and 24h was 
measured post RV16 and RV1B infection (figure 3.15). 
 At 8h induction of IL-6 and CXCL8/IL-8 mRNA was not observed with either 
RV16 or RV1B (figure 3.15 A, C, E and G).  At 24h, increases in IL-6 mRNA in 
HBECs stimulated with RV16 were observed, but these failed to reach statistical 
significance (figure 3.15 B).  Significant increases in CXCL8/IL-8 mRNA, following 
RV16 stimulation were observed in AA (p<0.05) with non-significant increases in 
NANA, ANA and NAA (figure 3.15 D).  With RV1B at 24h, significant increases in IL-
6 mRNA were observed in AA (p<0.05) with non-significant increases in NANA, ANA 
and NAA (figure 3.15 F), and significant increases in CXCL8/IL-8 mRNA were 
observed in NANA (p<0.01), ANA (p<0.01) and AA (p<0.01) with non-significant 
increases in NAA (figure 3.15 H).  No significant differences were observed between 
groups. 
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Figure 3.15.  IL-6 mRNA induction in HBECs post stimulation with RV16 at 8h (A) and 24h (B) and 
RV1B at 8h (E) and 24h (F);  CXCL8/IL-8 mRNA  induction in HBECs post stimulation with RV16 at  
8h (C) and 24h (D) and RV1B at 8h (G) and 24h (H).  Squares denote NANA, circles denote ANA, 
downward triangles denote NAA, upward triangles denote AA; open shapes denote medium, grey 
shapes denote filtered virus, black shapes denote virus; * = p<0.05, ** = p<0.01, ns = non-significant.  
At 8h induction of IL-6 and CXCL8/IL-8 mRNA was not observed.  At 24h, with RV16 non-significant 
increases in IL-6 mRNA were observed (B) and significant increases in CXCL8/IL-8 mRNA were 
observed in AA (D).  At 24h, with RV1B significant increases in IL-6 mRNA in AA and CXCL8/IL-8 
mRNA in NANA, ANA and AA were observed (F and G).  No significant differences were observed 
between groups. 
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To evaluate differences in HBEC proinflammatory cytokine production 
between NANA, ANA, NAA and AA IL-1β, IL-6, CXCL8/IL-8 and TNF-α protein at 
24h and 48h was measured post RV16 and RV1B infection (figure 3.16 and 3.17). 
 IL-1β protein was produced at 24h post RV16 infection, but this failed to reach 
statistical significance (figure 3.16 A).  At 48h, significant increases in IL-1β protein 
were observed in NANA (p<0.01), ANA (p<0.05) and AA (p<0.05) with non-
significant increases in NAA (figure 3.16 B).  IL-6 protein was produced at 24h and 
48h post RV16 infection, but this failed to reach statistical significance (figure 3.16 C 
and D).  CXCL8/IL-8 protein was produced at 24h post RV16 infection in NANA 
(p<0.01), ANA (p<0.05) and AA (p<0.05) with a non-significant increase observed in 
NAA (figure 3.16 E).  At 48h significant increases were observed in NANA (p<0.01), 
ANA (p<0.001) and AA (p<0.05) with a non-significant increase observed in NAA 
(figure 3.16 F).  TNF-α protein was produced at 24h post RV16 infection in NANA, 
ANA, AA and not in NAA, but this failed to reach statistical significance (figure 3.16 
G).  At 48h significant increases were observed in NANA (p<0.05) and AA (p<0.05) 
with a non-significant increase observed in ANA and NAA (figure 3.16 H).  With all 
cytokines and at both time points no differences were observed between groups. 
 IL-1β protein was induced at 24h post RV1B infection, in NANA (p<0.05) and 
ANA (p<0.05) with non-significant increases observed in NAA and AA (figure 3.17 
A).  At 48h, significant increases in IL-1β protein were observed in NANA (p<0.05), 
ANA (p<0.01) and AA (p<0.01) with non-significant increases in NAA (figure 3.17 B).  
IL-6 protein was induced at 24h and 48h post RV1B infection, but this failed to reach 
statistical significance (figure 3.17 C and D).  CXCL8/IL-8 protein was induced at 24h 
post RV1B infection in NANA (p<0.01), ANA (p<0.01) and AA (p<0.05) with a non-
significant increase observed in NAA (figure 3.17 E).  At 48h significant increases 
were observed in ANA (p<0.01) and AA (p<0.05) with a non-significant increase 
observed in NANA and NAA (figure 3.17 F).  TNF-α protein was induced at 24h post 
RV1B infection in NANA (p<0.05), with a non-significant increase observed in ANA 
and AA but not in NAA (figure 3.17 G).  At 48h significant increases were observed 
in AA only (p<0.05) with a non-significant increase observed in NANA, ANA and NAA 
(figure 3.17 H).  With all cytokines and at both time points no differences were 
observed between groups. 
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Figure 3.16.  Proinflammatory cytokine protein induction in HBECs stimulated with RV16 at 24h (A, C, 
E and G) and 48h (B, D, F and H).  IL-1β (A and B), IL-6 (C and D), CXCL8/IL-8 (E and F) and TNF-α 
(G and H).  Squares denote NANA, circles denote ANA, downward triangles denote NAA, upward 
triangles denote AA; open shapes denote medium, grey shapes denote filtered virus, black shapes 
denote virus; * = p<0.05, ** = p<0.01, *** = p<0.001, ns = non-significant.  Proinflammatory cytokine 
protein increases were observed at both time points with all cytokines in all groups.  Significant 
increases in IL-1β were observed in NANA, ANA and AA at 48h.  Significant increases in CXCL8/IL-8 
were observed in NANA, ANA and AA at 24h and 48h.  Significant increases in TNF-α were observed 
in NANA and AA at 48h.  No significant differences were observed between groups. 
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Figure 3.17.  Proinflammatory cytokine protein induction in HBECs stimulated with RV1B at 24h (A, C, 
E and G) and 48h (B, D, F and H).  IL-1β (A and B), IL-6 (C and D), CXCL8/IL-8 (E and F) and TNF-α 
(G and H).  Squares denote NANA, circles denote ANA, downward triangles denote NAA, upward 
triangles denote AA; open shapes denote medium, grey shapes denote filtered virus, black shapes 
denote virus; * = p<0.05, ** = p<0.01, ns = non-significant.  Proinflammatory cytokine protein 
increases were observed at both time points with all cytokines in all groups.  Significant increases in 
IL-1β were observed in NANA and ANA at 24h and in NANA, ANA and AA at 48h.  Significant 
increases in CXCL8/IL-8 were observed in NANA, ANA and AA at 24h and in ANA and AA at 48h.  
Significant increases in TNF-α were observed in AA at 48h.  No significant differences were observed 
between groups. 
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 Tables 3.5 to 3.8 summarise the IFN and proinflammatory cytokine mRNA 
and protein induction in HBECs following RV16 and RV1B infection. 
Table 3.5 Summary of IFN and proinflammatory cytokine mRNA induction post RV16 infection 
in HBECs ↑ = significant induction, ns = non-significant increase observed, - = no induction 
 8h 24h 
 NANA ANA NAA AA NANA ANA NAA AA 
IFN-β - - - - ns ns ns ↑ 
IFNλ2,3/IL-28 ↑ ns ns ↑ ↑ ↑ ns ↑ 
IFNλ1/IL-29 ns ↑ ns ↑ ↑ ↑ ns ↑ 
IL-6 - - - - ns ns ns ns 
CXCL8/IL-8 - - - - ns ns ns ↑ 
 
Table 3.6 Summary of IFN and proinflammatory cytokine protein induction post RV16 infection 
in HBECs ↑ = significant induction, ns = non-significant increase observed, - = no induction  
 
 24h 48h 
 NANA ANA NAA AA NANA ANA NAA AA 
IFN-β - - - - ns ns ns ↑ 
IFNλ1/IL-29 - - - - ↑ ↑ ns ↑ 
IL-1β ns ns ns ns ↑ ↑ ns ↑ 
IL-6 ns ns ns ns ns ns ns ns 
CXCL8/IL-8 ↑ ↑ ns ↑ ↑ ↑ ns ↑ 
TNF-α ns ns - ns ↑ ns ns ↑ 
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Table 3.7 Summary of IFN and proinflammatory cytokine mRNA induction post RV1B infection 
in HBECs ↑ = significant induction, ns = non-significant increase observed, - = no induction 
 8h 24h 
 NANA ANA NAA AA NANA ANA NAA AA 
IFN-β ns ↑ - ↑ ↑ ns ns ↑ 
IFNλ2,3/IL-28 ↑ ns ns ↑ ↑ ↑ ns ↑ 
IFNλ1/IL-29 ↑ ↑ ns ↑ ↑ ↑ ns ↑ 
IL-6 - - - - ns ns ns ↑ 
CXCL8/IL-8 - - - - ↑ ↑ ns ↑ 
 
 
Table 3.8 Summary of IFN and proinflammatory cytokine protein induction post RV1B infection 
in HBECs ↑ = significant induction, ns = non-significant increase observed, - = no induction  
 24h 48h 
 NANA ANA NAA AA NANA ANA NAA AA 
IFN-β - - - - ns ns ns ns 
IFNλ1/IL-29 ↑ ns ns ns ns ↑ ns ↑ 
IL-1β ↑ ↑ ns ns ↑ ↑ ns ↑ 
IL-6 ns ns ns ns ns ns ns ns 
CXCL8/IL-8 ↑ ↑ ns ↑ ns ↑ ns ↑ 
TNF-α ↑ ns - ns ns ns ns ↑ 
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3.2.7 RV infection of PBMCs: induction of type I and III IFN and 
proinflammatory cytokines protein 
 Responses to RV infection were assessed in PBMCs from each of the 
different volunteer groups by measuring type I and III IFN protein, and 
proinflammatory cytokine protein levels in PBMC supernatants at 24h and 48h.  
RV16 infection induced type I and III IFN protein production in PBMCs at 24h and 
48h (figure 3.18), whereas no such induction was observed by RV1B (figure 3.19). 
 RV16 stimulated PBMCs produced significant amounts of IFN-α2a protein at 
24h in NANA, ANA and AA (all p<0.001), with non-significant increases observed in 
NAA (figure 3.18 A).  At 48h significant increases were observed in ANA (p<0.05) 
and AA (p<0.001) with non-significant increases observed in NANA and NAA (figure 
3.18 B).  No differences were observed between groups. 
 RV16 stimulated PBMCs produced significant amounts of IFN-β protein at 24h 
in NANA (p<0.01), ANA (p<0.01) and AA (p<0.001), with non-significant increases 
observed in NAA (figure 3.18 C).  At 48h significant increases were observed in AA 
(p<0.01) with non-significant increases observed in NANA, ANA and NAA (figure 
3.18 D).  No differences were observed between groups. 
 RV16 stimulated PBMCs produced significant amounts of IFN-λ1/IL-29 protein 
at 24h in ANA (p<0.05) and AA (p<0.001), with non-significant increases observed in 
NANA and NAA (figure 3.18 E).  At 48h significant increases were observed in AA 
(p<0.001) with non-significant increases observed in NANA, ANA and NAA (figure 
3.18 F).  No differences were observed between groups. 
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Figure 3.18.  Interferon protein induction in PBMCs stimulated with RV16 at 24h (A, C and E) and 48h 
(B, D and F).  IFN-α2a (A and B), IFN-β (C and D) and IFN-λ1/IL-29 (E and F).  Squares denote 
NANA, circles denote ANA, downward triangles denote NAA, upward triangles denote AA; open 
shapes denote medium, grey shapes denote filtered virus, black shapes denote virus; * = p<0.05, ** = 
p<0.01, *** = p<0.001, ns = non-significant.  RV16 induced type I and III IFN production at 24h and 
48h.  Significant induction of IFN-α2a was observed in NANA, ANA and AA at 24h, and in ANA and 
AA at 48h. Significant induction of IFN-β was observed in NANA, ANA and AA at 24h, and in AA at 
48h.  Significant induction of IFN-λ1/IL-29 was observed in ANA and AA at 24h, and in AA at 48h.  No 
significant differences were observed in type I or III IFN protein production between groups. 
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Figure 3.19.  Interferon protein induction in PBMCs stimulated with RV1B at 24h (A, C and E) and 48h 
(B, D and F).  IFN-α2a (A and B), IFN-β (C and D) and IFN-λ1/IL-29 (E and F).  Squares denote 
NANA, circles denote ANA, downward triangles denote NAA, upward triangles denote AA; open 
shapes denote medium, grey shapes denote filtered virus, black shapes denote virus.  RV1B did not 
induce type I or III IFN protein production at 24h or 48h. 
 
To evaluate differences in PBMC proinflammatory cytokine production 
between NANA, ANA, NAA and AA IL-1β, IL-6, CXCL8/IL-8 and TNF-α protein at 
24h and 48h was measured post RV16 and RV1B infection (figure 3.20 and 3.21).  
Very high baseline levels of all the proinflammatory cytokines measured were 
observed in medium-treated cells, with the CXCL8/IL-8 data being at the top of the 
standard curve.  There were no significant differences in the baseline levels of 
cytokines between groups though there was non-significant log difference lower in 
the virus stimulated cells in the NAA group.  Both RV16 (figure 3.20) and RV1B 
(figure 3.21) failed to significantly induce the production of proinflammatory cytokines 
at 24h or 48h in PBMCs in all the volunteer groups.  No differences were observed 
between groups. 
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Figure 3.20.  Proinflammatory cytokine protein induction in PBMCs stimulated with RV16 at 24h (A, C, 
E and G) and 48h (B, D, F and H).  IL-1β (A and B), IL-6 (C and D), CXCL8/IL-8 (E and F) and TNF-α 
(G and H).  Squares denote NANA, circles denote ANA, downward triangles denote NAA, upward 
triangles denote AA; open shapes denote medium, grey shapes denote filtered virus, black shapes 
denote virus.  RV16 did not induce proinflammatory cytokine production in PBMCs at 24h or 48h.  
High baseline levels of all cytokines were observed. 
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Figure 3.21.  Proinflammatory cytokine protein induction in PBMCs stimulated with RV1B at 24h (A, 
C, E and G) and 48h (B, D, F and H).  IL-1β (A and B), IL-6 (C and D), CXCL8/IL-8 (E and F) and 
TNF-α (G and H).  Squares denote NANA, circles denote ANA, downward triangles denote NAA, 
upward triangles denote AA; open shapes denote medium, grey shapes denote filtered virus, black 
shapes denote virus.  RV1B did not induce proinflammatory cytokine production in PBMCs at 24h or 
48h.  High baseline levels of all cytokines were observed. 
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 Tables 3.9 and 3.10 summarise the IFN and proinflammatory cytokine protein 
induction in PBMCs following RV16 and RV1B infection. 
Table 3.9 Summary of IFN and proinflammatory cytokine protein induction post RV16 infection 
in PBMCs ↑ = significant induction, ns = non-significant increase observed, - = no induction 
 24h 48h 
 NANA ANA NAA AA NANA ANA NAA AA 
IFN-α2a ↑ ↑ ns ↑ ns ↑ ns ↑ 
IFN-β ↑ ↑ ns ↑ ns ns ns ↑ 
IFNλ1/IL-29 ns ↑ ns ↑ ns ns ns ↑ 
IL-1β - - - - - - - - 
IL-6 - - - - - - - - 
CXCL8/IL-8 - - - - - - - - 
TNF-α - - - - - - - - 
 
Table 3.10 Summary of IFN and proinflammatory cytokine protein induction post RV1B 
infection in PBMCs - = no induction  
 
 24h 48h 
 NANA ANA NAA AA NANA ANA NAA AA 
IFN-α2a - - - - - - - - 
IFN-β - - - - - - - - 
IFNλ1/IL-29 - - - - - - - - 
IL-1β - - - - - - - - 
IL-6 - - - - - - - - 
CXCL8/IL-8 - - - - - - - - 
TNF-α - - - - - - - - 
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3.2.8 RV infection induced RV replication and viral release 
 RV infection of HBECs from AA has been reported to result in significantly 
increased viral RNA (vRNA) production and virus release into cell supernatants 
when compared to NANA 60.  In order to assess whether cells from all the volunteer 
groups had increased RV replication and release, and to see whether there was a 
difference between asthmatic and atopic status, vRNA was measured in cell lysates 
and live virus release was measured in cell supernatants using a virus titration assay 
in TCID50/mL. 
RV replication at individual time points is demonstrated in figure 3.22, with the 
time course illustrated in figure 3.23.  Although cells were washed following the initial 
stimulation with virus, high levels of RV vRNA were observed at 0h (figure 3.22 A 
and B).  With RV16, vRNA expression peaked at 24h in NANA, NAA and AA and at 
48h in ANA (figure 3.22 C, E and G, and figure 3.23 A).  With RV1B, vRNA 
expression peaked at 48h (figure 3.22 D, F and H, and figure 3.23 B).  No significant 
differences in vRNA expression following stimulation with RV16 or RV1B were 
observed between all volunteer groups. 
Virus release into cell supernatants at individual time points in demonstrated 
in figure 3.24, with the time course illustrated in figure 3.25.  Peak viral release was 
at 24h with RV16 (figure 3.24 A, C, E and G, and figure 3.25 A) and at 48h with 
RV1B (figure B, D, F and H, and figure 3.25 B).  No significant differences in virus 
release following stimulation with RV16 or RV1B were observed between all 
volunteer groups. 
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Figure 3.22.  RV vRNA induction in HBECs after inoculation with RV16 (A, C, E and G) and RV1B (B, 
D, F and H) at 0h (A and B), 8h (C and D), 24h (E and F) and 48h (G and H)).  Squares denote 
NANA, circles denote ANA, downward triangles denote NAA, upward triangles denote AA.  No 
significant differences in vRNA were observed between groups. 
 
Figure 3.23.  Time courses demonstrating RV vRNA induction in HBECs after inoculation with RV16 
(A) and RV1B (B).  Squares denote NANA, circles denote ANA, downward triangles denote NAA, 
upward triangles denote AA.  No significant differences in vRNA were observed between groups. 
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Figure 3.24.  RV release in supernatants of HBECs after inoculation with RV16 (A, C, E and G) and 
RV1B (B, D, F and H) measured by TCID50/mL at 0h (A and B), 8h (C and D), 24h (E and F) and 48h 
(G and H).  Squares denote NANA, circles denote ANA, downward triangles denote NAA, upward 
triangles denote AA.  No significant differences were observed between groups, though a trend for 
increased RV release in asthmatics was observed at 24h after inoculation with RV16. 
 
Figure 3.25.  Time courses demonstrating RV release in supernatants of HBECs after inoculation with 
RV16 (A) and RV1B (B) measured by TCID50/mL.  Squares denote NANA, circles denote ANA, 
downward triangles denote NAA, upward triangles denote AA.  Peak viral release was at 24h with 
RV16 and 48h with RV1B.  No differences were observed between groups. 
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3.2.9 TLR 3, 7, 8 ligands stimulation of HBECs: induction of type I and III IFN 
and proinflammatory cytokines mRNA and protein 
 TLR3 recognises viral dsRNA.  TLR7 and TLR8 recognise viral ssRNA.  In 
order to characterise the IFN and proinflammatory cytokine response to “viral TLR” 
stimulation and to clarify whether the response is different depending on asthmatic 
and atopic status, HBECs from volunteers were stimulated with poly(IC) (TLR3) and 
R848 (TLR7/8).  Type I and III IFN and IL-6 and CXCL8/IL-8 mRNA was measured 
at 8h and 24h post stimulation and type I and III IFN and IL-1β, IL-6, CXCL8/IL-8 and 
TNF-α protein was measured at 24h post stimulation. 
 IFN-β mRNA was induced by poly(IC) at 8h in NANA (p<0.01), ANA (p<0.01) 
and AA (p<0.01) with a non-significant increase observed in NAA (figure 3.26 A).  At 
24h a significant increase was observed in NANA (p<0.05), with non-significant 
increases observed in ANA, NAA and AA (figure 3.26 B).  No significant differences 
were observed between groups. IFN-β mRNA was not significantly induced by R848 
in any group, but small increases were observed (figure 3.27 A and B).  No 
differences were observed between groups. 
 IFN-λ2,3/IL-28 mRNA was induced by poly(IC) at 8h in NANA (p<0.01), ANA 
(p<0.01) and AA (p<0.001) with a non-significant increase observed in NAA (figure 
3.26 C).  At 24h a significant increase was observed in NANA (p<0.001), ANA 
(p<0.001) and AA (p<0.01) with non-significant increases observed in NAA (figure 
3.26 D).  No significant differences were observed between groups. IFN-λ2,3/IL-28 
mRNA was induced by R848 at 8h in ANA and AA (both p<0.05), with a non-
significant increase in NANA and NAA (figure 3.27 C).  At 24h, significant increases 
were observed in ANA (p<0.001) and AA (p<0.01), with non-significant increases in 
NANA and NAA (figure 3.28 D).  No significant differences were observed between 
groups. 
 IFN-λ1/IL-29 mRNA was induced by poly(IC) at 8h in NANA (p<0.01), ANA 
(p<0.01) and AA (p<0.001) with a non-significant increase observed in NAA (figure 
3.26 E).  At 24h a significant increase was observed in NANA (p<0.001), ANA 
(p<0.001) and AA (p<0.01) with non-significant increases observed in NAA (figure 
124 
 
3.26 F).  No significant differences were observed between groups. IFN-λ1/IL-29 
mRNA was induced by R848 at 8h in AA (p<0.01), with a non-significant increase in 
NANA, ANA and NAA (figure 3.27 E).  At 24h, significant increases were observed in 
NANA, ANA and AA (all p<0.01), with non-significant increases in NAA (figure 3.28 
F).  No significant differences were observed between groups. 
 
 
Figure 3.26.  Interferon mRNA induction in HBECs post stimulation with poly(IC) at 8h (A, C and E) 
and 24h (B, D and F).  Squares denote NANA, circles denote ANA, downward triangles denote NAA, 
upward triangles denote AA; open shapes denote medium, black shapes denote poly(IC) ; * = p<0.05, 
** = p<0.01, *** = p<0.001, ns = non-significant.  IFN-β (A and B), IFN-λ2,3/IL-28 (C and D), IFN-λ1/IL-
29 (E and F).  Type I and III IFN mRNA was induced by poly (IC) at both time points.  No significant 
differences were observed between groups. 
 
101
102
103
104
105
106
NANA ANA NAA AA
ns** *** **
IF
N
-
 m
R
N
A
 e
x
p
re
s
s
io
n
(l
o
g
1
0
/ 
L
 c
D
N
A
)
100
101
102
103
104
105
106
NANA ANA NAA AA
ns ns ns*
IF
N
-
 m
R
N
A
 e
x
p
re
s
s
io
n
(l
o
g
1
0
/ 
L
 c
D
N
A
)
10 -2
10 -1
100
101
102
103
104
105
106
NANA ANA NAA AA
ns
** **
***
IF
N
-
2
,3
/I
L
-2
8
 m
R
N
A
e
x
p
re
s
s
io
n
 (
lo
g
1
0
/ 
L
 c
D
N
A
)
10 -2
10 -1
100
101
102
103
104
105
106
107
108
NANA ANA NAA AA
ns
***
*** **
IF
N
-
2
,3
/I
L
-2
8
 m
R
N
A
e
x
p
re
s
s
io
n
 (
lo
g
1
0
/ 
L
 c
D
N
A
)
10 -1
100
101
102
103
104
105
106
107
NANA ANA NAA AA
ns** **
***
IF
N
-
1
/I
L
-2
9
 m
R
N
A
e
x
p
re
s
s
io
n
 (
lo
g
1
0
/ 
L
 c
D
N
A
)
10 -1
100
101
102
103
104
105
106
107
108
109
NANA ANA NAA AA
ns
***
***
**
IF
N
-
1
/I
L
-2
9
 m
R
N
A
e
x
p
re
s
s
io
n
 (
lo
g
1
0
/ 
L
 c
D
N
A
)
A B
C D
E F
8h 24h
125 
 
 
Figure 3.27.  Interferon mRNA induction in HBECs post stimulation with R848 at 8h (A, C and E) and 
24h (B, D and F).  Squares denote NANA, circles denote ANA, downward triangles denote NAA, 
upward triangles denote AA; open shapes denote medium, black shapes denote R848; * = p<0.05, ** 
= p<0.01, *** = p<0.001, ns = non-significant.  IFN-β (A and B), IFN-λ1/IL-28 (C and D), IFN-λ1/IL-29 
(E and F).  IFN-β mRNA was not significantly induced by R848.  Type III IFN mRNA was induced by 
R848 at both time points.  No significant differences were observed between groups. 
  
Stimulation of HBECs with poly(IC) resulted in non-significant increases in 
IFN-β protein at 24h in all groups (figure 3.28 A).  Increases in IFN-λ1/IL-29 protein 
were observed at 24h (figure 3.28 B) with significance in NANA (p<0.001), ANA 
(p<0.01) and AA (p<0.001) and a non-significant increase in NAA.  No differences 
were observed between groups in the poly(IC) induced production of type I or III IFN 
protein.  Stimulation of HBECs with R848 did not induce type I or III IFN protein at 
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24h (figure 3.28 C and D).  An unexplained reduction in IFN-β protein was observed 
with R848 in AA only, with no significant differences between groups. 
 
 
Figure 3.28.  Interferon protein induction in HBECs post stimulation with poly(IC) (A and B) and R848 
(C and D) at 24h.  Squares denote NANA, circles denote ANA, downward triangles denote NAA, 
upward triangles denote AA; open shapes denote medium, black shapes denote ligand; * = p<0.05, ** 
= p<0.01, *** = p<0.001, ns = non-significant.  IFN-β (A and C), IFN-λ1/IL-29 (B and D).  Increases in 
type I and III protein were observed following stimulation with poly(IC), with no differences between 
groups.  No increases were seen following stimulation with R848.  An unexplained reduction in IFN-β 
protein was observed in AA only, with no significant differences between groups. 
  
IL-6 and CXCL8/IL-8 mRNA was measured in HBECs at 8h and 24h post 
TLR3 and TLR7/8 stimulation.  Significant induction of IL-6 mRNA was observed at 
8h following stimulation with poly(IC) in NANA (p<0.01), ANA (p<0.001) and AA 
(p<0.01) with a non-significant increase observed in NAA (figure 3.29 A).  At 24h, 
significant induction was observed in NANA, ANA and AA (all p<0.01) with a non-
significant increase observed in NAA (figure 3.29 B).  Likewise, at 8h, significant 
induction of CXCL8/IL-8 mRNA was observed in NANA (p<0.05), ANA (p<0.001) and 
AA (p<0.01) with a non-significant induction observed in NAA (figure 3.29 C) and at 
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24h induction was observed in NANA (p<0.01), ANA (p<0.01) and AA (p<0.001), 
with a non-significant induction observed in NAA (figure 3.29 D).  With both IL-6 and 
CXCL8/IL-8 mRNA no significant differences were observed between groups at both 
time points. 
Following stimulation of HBECs with R848 no induction of IL-6 mRNA was 
observed at 8h or 24h in all groups (figure 3.29 E and F).  Significant induction of 
CXCL8/IL-8 mRNA was observed at 8h in NANA (p<0.01), ANA (p<0.001) and AA 
(p<0.001), with a non-significant induction observed in NAA (figure 3.29 G).  At 24h, 
significant induction of CXCL8/IL-8 mRNA was observed in ANA (p<0.001) and AA 
(p<0.01), with a non-significant induction observed in NANA and NAA (figure 3.29 
H).  With both IL-6 and CXCL8/IL-8 mRNA no significant differences were observed 
between groups at both time points. 
128 
 
 
Figure 3.29.  IL-6 mRNA induction in HBECs post stimulation with poly(IC) at  8h (A) and 24h (B) and 
R848 at 8h (E) and 24h (F);  CXCL8/IL-8 mRNA  induction in HBECs post stimulation with poly(IC) at  
8h (C) and 24h (D) and R848 at 8h (G) and 24h (H).  Squares denote NANA, circles denote ANA, 
downward triangles denote NAA, upward triangles denote AA; open shapes denote medium, grey 
shapes denote filtered virus, black shapes denote virus; * = p<0.05, ** = p<0.01, *** = p<0.001, ns = 
non-significant.  Following stimulation with poly(IC) significant induction of IL-6 and CXCL8/IL-8 
mRNA was observed at both 8h and 24h with no significant difference between groups.  Following 
stimulation with R848, no induction of IL-6 mRNA was observed, but significant induction of 
CXCL8/IL-8 mRNA was observed at both time points, with no significant differences between groups. 
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Proinflammatory cytokine proteins were measured in HBECs at 24h following 
stimulation of TLR3 and TLR7/8.  Significant production of IL-1β, IL-6, CXCL8/IL-8 
and TNF-α protein from HBECs stimulated with poly(IC) was observed at 24h in 
NANA, ANA and AA with non-significant increases observed in NAA (figure 3.30 A-
D).  No differences were observed between the four volunteer groups. 
Following stimulation with R848 non-significant weak production of IL-1β 
protein was observed in all groups (figure 3.30 E).  Production of IL-6 protein was not 
observed (figure 3.30 F).  Non-significant production of CXCL8/IL-8 protein was 
observed in ANA only (figure 3.30 G).  Significant production of TNF-α protein was 
observed in ANA (p<0.05), with non-significant increases in NAA (figure 3.30 H).  
Increases were not observed in NANA or AA.  With all cytokines measured, no 
differences were observed between groups. 
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Figure 3.30.  Proinflammatory cytokine protein induction in HBECs stimulated with poly(IC) (A, B, C 
and D) and R848 (E, F, G and H) at 24h.  IL-1β (A and E), IL-6 (B and F), CXCL8/IL-8 (C and G) and 
TNF-α (D and H).  Squares denote NANA, circles denote ANA, downward triangles denote NAA, 
upward triangles denote AA; open shapes denote medium, grey shapes denote filtered virus, black 
shapes denote virus; * = p<0.05, ** = p<0.01, *** = p<0.001, ns = non-significant.  Significant 
production of all cytokines was observed following stimulation with poly(IC).  At 24h post stimulation 
with R848, weak production of IL-1β in all groups, no production of IL-6, production of CXCL8/IL-8 in 
ANA and of TNF-α in ANA and NAA, was observed.  No differences were observed between groups. 
 
 Tables 3.11 and 3.12 summarise the IFN and proinflammatory cytokine 
mRNA and protein induction in HBECs following poly(IC) and R848 stimulation. 
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Table 3.11 Summary of IFN and proinflammatory cytokine mRNA and protein induction post 
poly(IC) stimulation in HBECs ↑ = significant induction, ns = non-significant increase observed, 
black squares = not performed 
 8h 24h 
 NANA ANA NAA AA NANA ANA NAA AA 
IFN-β mRNA ↑ ↑ ns ↑ ↑ ns ns ns 
IFN-β protein     ns ↑ ns ns 
IFNλ2,3/IL-28 mRNA ↑ ↑ ns ↑ ↑ ↑ ns ↑ 
IFNλ1/IL-29 mRNA ↑ ↑ ns ↑ ↑ ↑ ns ↑ 
IFNλ1/IL-29 protein     ↑ ↑ ns ↑ 
IL-6 mRNA ↑ ↑ ns ↑ ↑ ↑ ns ↑ 
CXCL8/IL-8 mRNA ↑ ↑ ns ↑ ↑ ↑ ns ↑ 
IL-1β protein     ↑ ↑ ns ↑ 
IL-6 protein     ↑ ↑ ns ↑ 
CXCL8/IL-8 protein     ↑ ↑ ns ↑ 
TNF-α protein     ↑ ↑ ns ↑ 
 
Table 3.12 Summary of IFN and proinflammatory cytokine mRNA and protein induction post 
R848 stimulation in HBECs ↑ = significant induction, ns = non-significant increase observed, - = no 
induction, ↓ = significant reduction, black squares = not performed 
 8h 24h 
 NANA ANA NAA AA NANA ANA NAA AA 
IFN-β mRNA - - - - - - - - 
IFN-β protein     - - - ↓ 
IFNλ2,3/IL-28 mRNA ns ↑ ns ↑ ns ↑ ns ↑ 
IFNλ1/IL-29 mRNA ns ns ns ↑ ↑ ↑ ns ↑ 
IFNλ1/IL-29 protein     - - - - 
IL-6 mRNA - - - - - - - - 
CXCL8/IL-8 mRNA ↑ ↑ ns ↑ ns ↑ ns ↑ 
IL-1β protein     ns ns ns ns 
IL-6 protein     - - - - 
CXCL8/IL-8 protein     - ns - - 
TNF-α protein     - ↑ ns - 
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3.2.10 TLR 3, 7, 8 ligands stimulation of PBMCs: induction of type I and III IFN 
and proinflammatory cytokines protein 
 In order to characterise the IFN and proinflammatory cytokine response to 
“viral TLR” stimulation, to clarify whether the response is different depending on 
asthmatic and atopic status and to investigate whether other cell types were 
involved, PBMCs from volunteers were stimulated with poly(IC) (TLR3) and R848 
(TLR7/8).  Type I and III IFN and IL-1β, IL-6, CXCL8/IL-8 and TNF-α protein was 
measured at 24h and 48h post stimulation (figures 3.31-3.35). 
 Responses to TLR3 and TLR7/8 stimulation were assessed in PBMCs from 
each of the different volunteer groups.  TLR3 stimulation did not induce type I and III 
IFN protein production in PBMCs at 24h and 48h (figure 3.31).  TLR7/8 stimulated 
PBMCs produced significant amounts of IFN-α2a protein at 24h in NANA (p<0.05), 
ANA (p<0.01) and AA (all p<0.01), with non-significant increases observed in NAA 
(figure 3.32 A).  At 48h non-significant increases were observed in all groups (figure 
3.32 B).  No differences were observed between groups.  Small increases in IFN-β 
and IFN-λ1/IL-29 protein at 24h and 48h were observed in all groups but these failed 
to reach statistical significance (figure 3.32 C-F).  No differences were observed 
between groups. 
 Production of proinflammatory cytokines in PBMCs following TLR3 and 
TLR7/8 stimulation was assessed in each of the volunteer groups (figures 3.33-
3.35).  TLR3 stimulation resulted in significant induction of IL-1β and IL-6 protein at 
24h in AA (p<0.01) with non-significant increases in NANA, ANA and NAA (figure 
3.33 A and C).  In AA significant induction of CXCL8/IL-8 (p<0.05) and TNF-α 
(p<0.001) was observed at 24h with non-significant increases observed in NANA, 
ANA and NAA (figure 3.33 E and G).  No significant differences were observed 
between groups.  At 48h non-significant increases were observed in all 4 
proinflammatory cytokines measured in all groups (figure 3.33 B, D, F and H).  No 
significant differences were observed between groups.  To assess the significance of 
proinflammatory cytokine production at 48h and having established no significant 
difference between individual groups, all groups were combined.  Significant 
induction of IL-1β protein (p<0.001), IL-6 protein (p<0.001), CXCL8/IL-8 protein 
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(p<0.01) and TNF-α protein (p<0.001) was observed at 48h following TLR3 
stimulation of PBMCs from all volunteer groups combined (figure 3.35 A-D). 
 TLR7/8 stimulation resulted in significant induction of IL-1β and IL-6 protein at 
24h in AA (p<0.01) with non-significant increases in NANA, ANA and NAA (figure 
3.34 A and C).  Induction of CXCL8/IL-8 protein was not observed (figure 3.34 E).  
Weak induction of TNF-α protein was observed in AA (p<0.01) at 24h with non-
significant increases observed in NANA, ANA and NAA (figure 3.34 G).  No 
significant differences were observed between groups.  At 48h non-significant 
increases were observed in IL-1β in all groups (figure 3.34 B).  Non-significant 
induction of IL-6 was observed in NANA and NAA (figure 3.34 D).  Non-significant 
induction of CXCL8/IL-8 protein was observed in NAA only (figure 3.34 F).  Non-
significant induction of TNF-α protein was observed in NANA, ANA and NAA (figure 
3.34 H). No significant differences were observed between groups.  To assess the 
significance of proinflammatory cytokine production at 48h and having established 
no significant difference between individual groups, all groups were combined.  
Significant induction of IL-1β protein (p<0.001) and TNF-α protein (p<0.05) was 
observed at 48h following TLR7/8 stimulation of PBMCs (figure 3.35 E and H).  
Induction of IL-6 and CXCL8/IL-8 protein was not observed in PBMCs following 
TLR7/8 stimulation (figure 3.35 F and G). 
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Figure 3.31.  Interferon protein induction in PBMCs stimulated with poly(IC) at 24h (A, C and E) and 
48h (B, D and F).  IFN-α2a (A and B), IFN-β (C and D) and IFN-λ1/IL-29 (E and F).  Squares denote 
NANA, circles denote ANA, downward triangles denote NAA, upward triangles denote AA; open 
shapes denote medium, black shapes denote poly(IC).  No production of type I or III IFN was 
observed in PBMCs stimulated with poly(IC). 
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Figure 3.32.  Interferon protein induction in PBMCs stimulated with R848 at 24h (A, C and E) and 48h 
(B, D and F).  IFN-α2a (A and B), IFN-β (C and D) and IFN-λ1/IL-29 (E and F).  Squares denote 
NANA, circles denote ANA, downward triangles denote NAA, upward triangles denote AA; open 
shapes denote medium, black shapes denote R848; * = p<0.05, ** = p<0.01, ns = non-significant.  
Significant increases in IFN-α2a protein were observed in PBMCs stimulated with R848 at 24h with 
non-significant increases observed at 48h.  Small increases in IFN-β and IFN-λ1/IL-29 protein were 
observed at 24h and 48h but these did not reach statistical significance.  No significant differences 
were observed between groups. 
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Figure 3.33.  Proinflammatory cytokine protein induction in PBMCs stimulated with poly(IC) at 24h (A, 
C, E and G) and 48h (B, D, F and H).  IL-1β (A and B), IL-6 (C and D), CXCL8/IL-8 (E and F) and 
TNF-α (G and H).  Squares denote NANA, circles denote ANA, downward triangles denote NAA, 
upward triangles denote AA; open shapes denote medium, black shapes denote poly(IC) ; * = p<0.05, 
** = p<0.01, *** = p<0.001, ns = non-significant.  Induction of proinflammatory cytokine protein was 
observed in all groups at 24h and 48h, with significant results observed in AA.  At 48h increases were 
observed but these failed to reach statistical significance.  No significant differences were observed 
between groups. 
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Figure 3.34.  Proinflammatory cytokine protein induction in PBMCs stimulated with R848 at 24h (A, C, 
E and G) and 48h (B, D, F and H).  IL-1β (A and B), IL-6 (C and D), CXCL8/IL-8 (E and F) and TNF-α 
(G and H).  Squares denote NANA, circles denote ANA, downward triangles denote NAA, upward 
triangles denote AA; open shapes denote medium, black shapes denote R848; ** = p<0.01, ns = non-
significant.  Significant induction of IL-1β, IL-6 and TNF-α protein were observed at 24h in AA with 
non-significant increases observed in other groups.  Induction of CXCL8/IL-8 was not observed.  At 
48h, non-significant increases in IL-1β and TNF-α were observed in all groups and in IL-6 in NANA 
and NAA.  No significant differences were observed between groups. 
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Figure 3.35.  Proinflammatory cytokine protein induction at 48h in PBMCs from all groups combined 
stimulated with poly(IC) (A, B, C and D) and R848 (E, F, G and H).  IL-1β (A and E), IL-6 (B and F), 
CXCL8/IL-8 (C and G) and TNF-α (D and H).  Open squares denote medium (M); black squares 
denote poly(IC) or R848; * = p<0.05, ** = p<0.01, *** = p<0.001, ns = non-significant.  Non-significant 
induction of proinflammatory cytokine protein had been observed in all groups, with no apparent 
difference between groups.  Groups were therefore combined.  Significant induction of all 
proinflammatory cytokines measured was observed when PBMCs from all groups stimulated with 
poly(IC) were combined.  Likewise, significant induction of IL-1β and TNF-α protein but not IL-6 and 
CXCL8/IL-8 was observed in PBMCs from all groups stimulated with R848. 
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 Tables 3.13 and 3.14 summarise the IFN and proinflammatory cytokine 
protein induction in PBMCs following poly(IC) and R848 stimulation. 
Table 3.13 Summary of IFN and proinflammatory cytokine protein induction post poly(IC) 
stimulation in PBMCs ↑ = significant induction, ns = non-significant increase observed, - = no 
induction 
 24h 48h 
 NANA ANA NAA AA NANA ANA NAA AA 
IFN-α2a - - - - - - - - 
IFN-β - - - - - - - - 
IFNλ1/IL-29 - - - - - - - - 
IL-1β ns ns ns ↑ ns ns ns ns 
IL-6 ns ns ns ↑ ns ns ns ns 
CXCL8/IL-8 ns ns ns ↑ ns ns ns ns 
TNF-α ns ns ns ↑ ns ns ns ns 
 
 
Table 3.14 Summary of IFN and proinflammatory cytokine protein induction post R848 
stimulation in PBMCs ↑ = significant induction, ns = non-significant increase observed, - = no 
induction 
 24h 48h 
 NANA ANA NAA AA NANA ANA NAA AA 
IFN-α2a ↑ ↑ ns ↑ ns ns ns ns 
IFN-β ns ns ns ns ns ns ns ns 
IFNλ1/IL-29 ns ns ns ns ns ns ns ns 
IL-1β ns ns ns ↑ ns ns ns ns 
IL-6 ns ns ns ↑ ns - ns - 
CXCL8/IL-8 - - - - - - ns - 
TNF-α ns ns ns ↑ ns ns ns - 
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3.3 Discussion 
 
 Previous studies have identified defective type I and III IFN production in 
HBECs and type III IFN in BAL cells 60, 61.  A more recent study has identified 
deficient type I IFN production in BAL cells from AA and this deficiency may be 
related to asthma severity 208.  Defective IFN-α2 production has been observed in 
PBMCs from AA following RSV and NDV infection 82, 206.  The only report of the role 
of atopy in deficient IFN production in asthmatics prior to initiation of this study was 
that of Bufe et al. which demonstrated significantly lower amounts of virus-induced 
IFN-α production in AA compared to NANA and NAA and that the number of 
eosinophils (a marker for allergic inflammation) negatively correlated with IFN-α 
levels 206.  While this study was ongoing, a recent study reported deficient IFN-β and 
-λ responses to rhinovirus infection in BECs in childhood in both atopic and non-
atopic asthmatic subjects and surprisingly, in atopic children without asthma 209.  
These atopic children without asthma, however, had similar degrees of IL-4 staining 
and epithelial damage in their bronchial biopsies as did the children with asthma, 
thus the roles of atopy and asthma in IFN deficiency remain uncertain.  Another 
recent study examined innate immune responses in plasmacytoid dendritic cells 
(pDCs) to RV in allergic asthmatic children finding significant differences between 
allergic non-asthmatic and non-allergic non-asthmatic children 315.  Another study 
identified deficient IFN-α secretion from pDCs stimulated with influenza viruses from 
allergic asthmatics which was inversely correlated with serum IgE levels 205. 
The experiments reported in this chapter aimed to investigate type I and III 
IFN and proinflammatory cytokine responses in atopics and non-atopics, asthmatics 
and non-asthmatics to determine whether the previously reported IFN deficiency 
observed in atopic asthmatic subjects is asthma- or atopy-specific.  It also aimed to 
investigate whether deficiency was observed to similar degrees in several different 
cell types – BAL cells, HBECs and PBMCs sampled simultaneously from the same 
subjects, as with the exception of Contoli et al, who reported on IFN-λ deficiency in 
both BAL cells and BECs, but did not report PBMCs 61, and Sykes et al who reported 
type I IFN deficiency in BAL cells and PBMCs, but who did not report BECs 208, 
previous reports of IFN deficiency in asthma have only reported results in single cell 
types. 
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3.3.1 Rhinoviruses 
3.3.1.1 BAL cells & RV 
This study demonstrated differences between major and minor group RVs in 
their abilities to induce type I and III IFNs in BAL cells (tables 3.3 and 3.4), with both 
type I and III IFNs being induced by RV16 and only type III IFN being induced by 
RV1B.  Indeed neither type I or III IFN protein was produced at 8h following 
stimulation with RV1B, although this may have been observed at a later time point, if 
sufficient cells had been acquired at bronchoscopy.  The reason for these 
differences is unclear.  Although titres of RV16 and RV1B stocks were not identical, 
as measured by TCID50 assays (RV16 2x10
7, RV1B 8.43x106), RV1B is a more 
potent virus, as determined by the fact that more diluted virus was required to 
produce similar effects in PBMCs, which was translated to experiments with BAL 
cells (figure 3.2).  
Deficiencies in IFN production, both mRNA and protein were not observed in 
asthmatics (figures 3.7 and 3.8), meaning the question of whether asthma or atopy is 
important in IFN deficiency remains unanswered.  The lack of observed deficiency 
differs from another study where type I IFN production was reduced in atopic 
asthmatics, compared to non-atopic non-asthmatics 208.  The differences between 
the two studies may be a result of this study having a group of less severe 
asthmatics; as although ACQ score for the asthmatic subjects reported in this study 
and that of Sykes et al were similar (0.917 vs 0.8), the subjects in Sykes et al. had 
more exacerbations/year (0.0 vs 1.5), and more severe airway hyperresponsiveness 
(PC20 3.0 vs 2.0), i.e. this study’s group of asthmatics, had well controlled disease, 
were not exacerbation prone and had normal lung function.  In analysis of the 
severity of asthmatics, it would have been of interest to determine the median dose 
of inhaled corticosteroid and the peripheral eosinophil and neutrophil counts (data 
not available).   
It is possible that the lack of identified IFN-λ deficiency was due to only an 8h 
time point being used, due to the limited number of cells obtained at bronchoscopy 
and the desire to investigate responses to Spn also.  The previous studies in BAL 
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cells observed deficient IFN-λ protein production at 48h after RV16 infection 61 and 
type I IFN deficiency at both 8 and 24hrs 208.   
It is of interest, and perhaps surprise that RV failed to induce production of 
proinflammatory cytokine mRNA and protein.  High baseline levels of these 
cytokines was observed in media treated cells, suggesting the acquisition of BAL 
cells at bronchoscopy itself resulted in the production of proinflammatory cytokines, 
an inherent problem with an ex vivo model of infection. 
 
3.3.1.2 HBECs & RV 
 IFN production in HBECs was different for major and minor group RVs.  IFN-β 
and type III IFN mRNA was observed for both groups, though protein production 
differed.  With RV16 both type I and III IFN protein was produced at 48h, but with 
RV1B only type III IFN protein was observed.  This is in agreement with previous 
studies suggesting diversity in IFN responses to different RV strains 201.  This 
previous study however noted different HBEC responses to different RV infections in 
that major group RVs produce a more intense inflammatory mediator release and 
minor group RVs produce a marked IFN-β response.  Proinflammatory cytokine 
release, both mRNA and protein, was observed in all groups with both RV16 and 
RV1B, reaching significance with certain cytokines and certain groups, but with no 
significant difference between the different volunteer groups (tables 3.5 - 3.8). 
 The lack of difference in IFN production from HBECs between asthmatics and 
non-asthmatics is somewhat surprising given the previous studies identifying IFN 
deficiencies in cells stimulated with different RV strains 60, 61.  Given the lack of 
difference in BAL cells in this study, however, it may not be surprising that 
differences were not observed in HBECs, perhaps due to the mild nature of the 
disease in atopic asthmatics.  Other studies failed to reproduce the findings of 
deficient IFN production by Wark et al. and Contoli et al. 203, 204.  The Lopez-Souza et 
al. study differed however in that the HBECs were cultured using an air liquid 
interface (ALI) and the sample size (5 NANA and 6 AA) was small.  ALI cultures 
allow the development of tight junctions and cilia, which may resemble the in vivo 
appearance of the airway more closely 203.  The Bochkov et al. study used 
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microarrays and qPCR and discovered no difference in type I or III IFN expression 
between NANA and AA 204.  These other studies support the finding from the results 
reported in this chapter in that an IFN deficiency was not identified in asthmatics.  
More recent studies have identified deficient IFN responses in children with asthma, 
both atopic and non-atopic, and in atopic patients without asthma, with airway Th2 
inflammatory profile and epithelial damage correlating with decreased IFN production 
209.  Similarly, a study in severe therapy resistant asthmatic children had impaired 
type I and III IFN mRNA and protein in response to RV 316.  These studies support 
the conclusion that the reason why there was no IFN deficiency identified in this 
study was that the asthmatic subjects had too mild disease.  Due to problems of 
NAA volunteer recruitment, and that only 2 volunteers’ HBECs were experimented 
on (the other 2 being lost to contamination), sample size was insufficient to 
determine whether a difference might be seen in NAA.  Certainly the small numbers 
of NAA recruited would have had an impact on the robustness of the data, had a 
difference been identified.  Another potential flaw in the study design was that more 
severe asthmatics were not sought out, but the study used a similar template and 
inclusion/exclusion criteria to other studies which identified IFN deficiency 208.  A 
potential explanation for the lack deficient IFN production in asthmatics observed in 
this study and other studies 203, 204 may be that this group of asthmatics had a more 
mild form of the disease and that there are subgroups of asthmatics which have IFN 
deficiency. 
 Why might there have been a difference between the different cells 
experimented upon?  The nature of the experiments in HBECs is very different 
compared to BAL cells and PBMCs, in that HBECs undergo several weeks of growth 
whereas BAL cells and PBMCs were stimulated immediately after being obtained.  If 
any difference in IFN expression had been observed, given the different 
experimental conditions, it may have been difficult to extrapolate findings between 
the different cell types.  The different cells received the same viruses as virus was 
produced in one batch, confirmed by neutralisation assay and titrated, so the cells 
received the same multiplicity of infection (MOI=1.0). 
 Previous studies have identified increased RV replication in AA compared to 
NANA 60, 61.  In this study, differences were observed between the 2 viruses.  vRNA 
and RV release (measured by TCID50/mL) peaked at 24h with RV16 and at 48h with 
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RV1B (figures 3.22-3.25).  More vRNA was produced by RV1B which is of interest in 
the degree of potency of the virus, given a 1 in 10 dilution of RV1B was used.  These 
findings again highlight the differences between major and minor group viruses.  RV 
replication studies did not identify differences between asthmatics and non-
asthmatics, atopics and non-atopics.  This may not be surprising given no 
differences in IFN production had been observed and previous studies reported the 
increase viral replication in AA correlating with IFN-β mRNA levels at 8h and protein 
at 48h 60. 
 
3.3.1.3 PBMCs & RV 
PBMCs were studied as previous studies have identified deficient IFN-α in 
asthmatics with viruses other than RV 82, 206.  The aim was to identify whether IFN 
deficiencies were observed following stimulation by RV and whether these 
deficiencies were also observed in HBECs and BAL cells from the same individual.  
This would allow a less invasive way to identify deficiencies in IFN production, 
thereby avoiding the need for bronchoscopy.  However this was not found to be the 
case. 
 These experiments identified that major group RV (RV16) but not minor group 
(RV1B) resulted in the production of type I and III IFN.  It is of interest that RV1B 
induced IFNs in BAL cells, but not PBMCs.  The different responses may be due to 
the different cell types having differing levels receptor expression, different 
efficiencies of viral replication or different intracellular responses.  No significant 
differences were observed between asthmatics or non-asthmatics, atopics or non-
atopics.  Indeed the only group where significant induction of type I and III IFNs was 
observed at both 24h and 48h after RV stimulation was the AA.  This differs from a 
recent study where asthmatic youths aged 7-19 were identified as having impaired 
IFN-α production in PBMCs stimulated with RV14, though this was not observed in 
adults, as in this study 81.   
 As with BAL cells, induction of proinflammatory cytokines was not observed in 
PBMCs stimulated with RV16 or RV1B, hence comments regarding differences 
between the different groups could not be made.  This is in contrast to the study 
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where IL-6 and TNF-α was induced in PBMCs and was significantly lower in an 
asthmatic youth (but not adult) group compared to non-asthmatics 81. 
 
3.3.2 “Viral” TLR ligands 
 In order to attempt to explain the signalling pathways for viral stimulation of 
various cell types the experiments reported in this chapter used various TLR ligands 
to determine whether type I and III IFNs were induced and whether differences were 
observed between the various volunteer groups.  In the experiments where IFN was 
expressed no differences were observed between asthmatics or non-asthmatics, 
atopics or non-atopics.  This may not be surprising in that differences were not 
observed in cells stimulated with rhinoviruses.  Due to the limited numbers of BAL 
cells obtained at bronchoscopy only HBECs and PBMCs were experimented upon.  
It would be of interest to observe whether IFNs were expressed in BAL cells 
following stimulation with these TLR ligands. 
3.3.2.1 TLR3 stimulation 
 Induction of type I and III IFN mRNA and protein was observed in HBECs 
stimulated with poly(IC) in all groups, with significance in NANA, ANA and AA, and 
trends for induction in NAA (table 3.11).  Significant induction of proinflammatory 
cytokine mRNA and protein was also observed in the same groups.  No significant 
difference was observed between any groups.  Induction of both type I and III IFNs 
was not observed in PBMCs stimulated with poly(IC) (table 3.13).  Induction of 
proinflammatory cytokine protein was observed at 24h and 48h, reaching 
significance only in AA.  At 48h, in all groups combined highly significant expression 
of proinflammatory cytokine protein was observed.  The experiments reported in this 
chapter suggest there may be a difference in the expression/function of TLR3 in 
different cell types.  TLR3 has variable expression in vivo.  CNS cells from humans 
with a dominant-negative allele of TLR3 which predisposes to HSV encephalitis have 
been shown to have a deficient TLR3 response whereas epithelial cells and PBMCs 
from the same individuals have normal type I and II IFN responses 261.   
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3.3.2.2 TLR7/8 stimulation 
 Induction of type III IFN mRNA only, and not type I IFNs, was observed in 
HBECs stimulated with R848.  No differences were observed between groups.  
Induction of CXCL8/IL-8 and not IL-6 mRNA was observed.  Only non-significant 
increases in IL-1β and TNF-α protein were observed at 24h (table 3.12).  The 
findings of induction of IFNs and proinflammatory cytokines in HBECs by TLR7/8 
stimulation supports the previously conflicting reports for TLR7/8 expression in 
HBECs 317, 318 in favour of the presence of TLR7/8 in HBECs. 
 In PBMCs stimulated with R848 significant induction of IFN-α2a protein was 
observed at 24h, with non-significant increases at 48h and in the other IFNs 
measured at 24h and 48h (table 3.14).  No differences were observed between 
groups.  This is in contrast to the study which identified reduced TLR7 function in 
PBMCs from asthmatic adolescents with mild-moderate disease 311.  Increases in 
proinflammatory cytokine protein (other than CXCL8/IL-8) were observed in all 
groups, with significance only in AA.  However no significant differences were 
observed between groups.  Having identified no difference, in order to determine 
significance of the 48h time point all groups were combined.  Significant IL-1β and 
TNF-α protein was observed (figure 3.35).   
 
3.4 Conclusions 
 
 This is the first report of type I and III IFN and proinflammatory cytokine 
responses to stimulation with rhinoviruses and TLR3 and TLR7/8 ligands in cells 
from adult asthmatics and non-asthmatics, atopics and non-atopics.  The 
hypothesised deficiencies in IFN production in asthmatic subjects were not observed 
in BAL cells, HBECs or PBMCs stimulated with RV, or HBECs and PBMCs 
stimulated with TLR3 and TLR7/8.  The most likely cause for this deficiency not 
being identified is the mild nature of the disease in the asthmatics recruited.  Indeed, 
it may be the propensity to exacerbate which is a key factor in IFN deficiency.  Due 
to difficulties in recruitment of NAA volunteers it is impossible to say whether 
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deficiencies would have been identified, but there were no trends to suggest a 
deficiency. The study hypothesis should therefore be rejected. 
 
3.5 Summary 
 
IFN was produced in BAL cells, HBECs or PBMCs following stimulation with 
rhinoviruses, TLR3 and TLR7/8 but no difference in IFN production was observed 
between asthmatics or non-asthmatics, or atopics or non-atopics. 
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Chapter 4: Streptococcus pneumoniae infection of BAL cells, 
HBECs and PBMCs 
 
4.1 Introduction 
 There is increasing evidence for the role of bacteria, particularly atypical 
bacteria such as Cpn and mycoplasma in asthma, both in the development of 
asthma and in exacerbations.  Lately the role for typical bacteria such as Spn has 
been questioned.  Neonates colonised by Spn have an increased risk of later 
development of wheeze and asthma 88.  Pneumococcal colonisation of the 
oropharynx is more common in asthmatics 93.  Asthma is a risk factor for invasive 
pneumococcal disease 104, 319.  The mechanism for the increased susceptibility to 
Spn in asthmatics is unknown, but asthmatics have lower pneumococcal antibodies 
than non-asthmatics 105.  Studies have identified deficiencies in the innate immune 
response in asthmatics, particularly in response to viral infection, and in particular 
deficiencies in type I and III IFN production.  BAL macrophages from asthmatics 
have deficient IFN-λ production in response to the gram negative bacterial cell wall 
product LPS 61.   
IFNs have classically been considered antiviral cytokines.  Studies have 
identified extracellular bacteria inducing IFNs.  In particular, Spn has been shown to 
activate type I IFNs in airway epithelial cells 223 and Spn colonisation of mice leads to 
type I IFN mRNA induction 222.  Human BAL macrophages have been identified as 
producers of type I IFN upon infection with Spn 224.  Whether the previously identified 
IFN deficiency in asthmatics in response to viruses can be extrapolated to Spn 
infection has not been investigated.  If a deficiency were identified the role of atopy in 
this deficiency could be evaluated further.  Similarly, investigation of anti-bacterial 
cytokines such as IL-1β, IL-6, CXCL8/IL-8 and TNF-α may identify deficiency in 
asthmatics, a finding that has only been recently observed, and published after the 
commencement of the project 320. 
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4.1.1 Hypothesis 
 Spn infection will induce type I and III IFNs and proinflammatory cytokines in 
BAL cells, HBECs and PBMCs and will result in deficient type I and III IFN 
production in AA and NAA, compared to NANA and ANA. 
 
4.1.2 Aims 
 To establish whether Spn infection of BAL cells, HBECs and PBMCs results in 
type I and III IFN production. 
 To further characterise whether Spn infection of BAL cells, HBECs and 
PBMCs results in production of proinflammatory cytokines important in host 
defence against bacterial infections. 
 To establish whether Spn infection of BAL cells, HBECs and PBMCs results in 
deficient type I and III IFN production in AA and NAA, compared to NANA and 
ANA. 
 To establish whether Spn infection of BAL cells, HBECs and PBMCs results in 
deficient anti-bacterial cytokine production in AA and NAA, compared to 
NANA and ANA. 
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4.2 Results 
 
4.2.1 Pre-study investigation of Spn 
 Prior to the assessment of the effects of Spn in interferon and 
proinflammatory cytokine production in cells acquired from volunteers, and to the 
investigation as to whether there were any differences depending on the atopic 
and/or asthmatic status of volunteers, the effects of Spn was analysed in BEAS-2B 
cells, primary HBECs and PBMCs.  Concentration-time experiments were performed 
in these cell types and type I and III IFN and IL-6 and CXCL8/IL-8 mRNA was 
measured in cell lysates (figure 4.1).  Serial 10-fold dilutions from 1x106 colony 
forming units/mL (cfu/mL) to 1x100 cfu/mL were made.  Cells were stimulated with 
varying concentrations of Spn and were harvested at various times following 
stimulation. 
 In BEAS-2B cells a non-significant induction of IL-6 and CXCL8/IL-8 mRNA 
was observed at 24h post stimulation with Spn (figure 4.1 A and B).  Weak induction 
of IFN-β mRNA was observed at 4h post stimulation with a concentration of 1x104 
cfu/mL but this failed to reach statistical significance (figure 4.1 C).  At other time 
points no induction was observed.  No induction of type III IFN mRNA was observed 
in BEAS-2B cells following stimulation with Spn (data not shown). 
In primary HBECs induction of IL-6 and CXCL8/IL-8 mRNA was not observed 
(figure 4.1 D and E).  A non-significant weak induction of IFN-β mRNA was observed 
at 48h with Spn at 1x104 cfu/mL (figure 4.1 F). No induction of type III IFN mRNA 
was observed in primary HBECs following stimulation with Spn (data not shown). 
In PBMCs a non-significant induction of IL-6 and CXCL8/IL-8 was seen with 
all 3 concentrations of Spn at 8h, 24h and 48h (figure 4.1 G and H).  A non-
significant weak induction of IFN-β mRNA was observed at 24 and 48h (figure 4.1 I).  
No induction of type III IFN mRNA was observed in PBMCs following stimulation with 
Spn (data not shown).   For all cell types the concentration of Spn chosen for 
subsequent experiments on samples from volunteers was 1x104 cfu/mL (in view of 
there being no marked difference between this concentration and the higher 
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concentrations, and the need to re-test any further Spn stocks prior to use in 
volunteers’ samples). 
 
Figure 4.1.  Concentration and time course response of S. pneumoniae (Spn) in BEAS-2B cells (A, B 
and C, N=3), primary HBECs (D, E and F, N=3) and PBMCs (G, H and I, N=3).  Concentrations from 
1x10
6 
cfu/mL to 1x10
0 
cfu/mL were used.  Only the highest 3 dilutions are shown.  Poly(IC) was used 
as a positive control.  □ = medium, ○ = filtered Spn, ● = Spn 1x106 cfu/mL, ● = Spn 1x105 cfu/mL, ● = 
Spn 1x10
4 
cfu/mL, ■ = poly(IC) 10µg/mL for epithelial cells, 100µg/mL for PBMCs. In BEAS-2B cells a 
non-significant induction of IL-6 and CXCL8/IL-8 mRNA at 24h was observed (A and B).  Weak 
induction of IFN-β mRNA at 4h with Spn at 1x10
4 
cfu/mL was observed, but this was non-significant 
(C).  In primary HBECs induction of IL-6 and CXCL8/IL-8 was not observed (D and E).  A non-
significant weak induction of IFN-β mRNA was observed at 48h with Spn at 1x10
4 
cfu/mL (F).  In 
PBMCs a non-significant induction of IL-6 and CXCL8/IL-8 was seen in all 3 doses of Spn at 8h, 24h 
and 48h (G and H).  A non-significant weak induction of IFN-β mRNA was observed in IFN-β mRNA 
induction at 24 and 48h (I).   Induction of IFN-λ2,3/IL-28 or IFN-λ1/IL-29 mRNA was not observed (not 
shown). 
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4.2.2 Spn infection of BAL cells: induction of type I and III IFN and 
proinflammatory cytokine mRNA and protein 
 
 In order to assess whether IFN production was a characteristic of the innate 
immune response to infection with Spn and to observe whether there is a difference 
between asthmatic/atopic and non-asthmatic/atopic groups, IFN-α, IFN-β and IFN-λ 
mRNA and protein production by BAL cells was measured at 8h following infection 
with Spn.  Only an 8h time point was chosen due to other aims of the project, 
particularly the investigation of rhinoviruses and the limited number of BAL cells 
obtained. The BAL cell composition and clinical characteristics of volunteers are 
described in chapter 3.  No significant induction of type I or III IFN mRNA or protein 
was observed at 8h in BAL cells (figures 4.2 and 4.3).  No differences were observed 
between groups. 
 
Figure 4.2.  Interferon mRNA induction in BAL macrophages at 8h post stimulation with Spn.  Squares 
denote NANA, circles denote ANA, downward triangles denote NAA, upward triangles denote AA; 
open shapes denote medium, grey shapes denote filtered Spn, black shapes denote Spn.  IFN-α(A2) 
(A), IFN-β (B), IFN-λ2,3/IL-28 (C), IFN-λ1/IL-29 (D).  No significant induction of type I or III IFN mRNA 
was observed in BAL cells stimulated with Spn. 
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Figure 4.3.  Interferon protein induction in BAL macrophages at 8h post stimulation with Spn.  
Squares denote NANA, circles denote ANA, downward triangles denote NAA, upward triangles 
denote AA; open shapes denote medium, grey shapes denote filtered Spn, black shapes denote Spn.  
IFN-α2a (A), IFN-β (B), IFN-λ1/IL-29 (C).  No IFN protein production at 8h was observed. 
 
In order to assess the model of Spn infection of BAL cells proinflammatory 
cytokine production was measured.  Following 8h incubation the BAL cells 
stimulated with media alone (containing no supplementary antibiotics) was visibly 
cloudy, suggestive of a bacterial contamination, possibly from the upper airway.  
Proinflammatory cytokine production in BAL cells stimulated with Spn was therefore 
examined and compared to cells treated to media alone, with and without antibiotic 
supplementation.   There were no differences in induction of IL-6 mRNA in cells 
stimulated with Spn compared to cells treated with media without antibiotics (figure 
4.4 A).  When compared to media which was supplemented with antibiotics a weak 
induction of IL-6 mRNA was observed but this failed to reach statistical significance 
(figure 4.4 B).  No induction of CXCL8/IL-8 mRNA was observed in BAL cells when 
compared to either type of medium (figure 4.4 C and D).  No differences were 
observed between the individual volunteer groups. 
Proinflammatory cytokine protein production was also measured in BAL cell 
supernatants stimulated with Spn and media alone (with and without supplementary 
antibiotics, due to the observed visible contamination of the media without 
supplementary antibiotics-treated BAL cells).  When comparing cells stimulated with 
Spn to those stimulated with media without supplementary antibiotics no production 
of IL-1β, IL-6, CXCL8/IL-8 or TNF-α protein was observed (figure 4.5 A, C, E and G).  
Weak induction of IL-1β was observed in cells stimulated with Spn compared to cells 
stimulated with media with supplementary antibiotics, but this failed to reach 
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statistical significance (figure 4.5 B).  There was a suggestion for lower amounts of 
IL-1β protein produced in asthmatics compared to non-asthmatics, but this was not 
statistically different.  A non-significant induction of TNF-α protein was observed in 
NAA, though sample size was small.  Induction was not observed in other groups 
(figure 4.5 H).  No induction of IL-6 or CXCL8/IL-8 protein was observed in any group 
(figure 4.5 D and F). 
 
 
Figure 4.4.  Proinflammatory cytokine mRNA induction in BAL macrophages at 8h post stimulation 
with Spn.  Squares denote NANA, circles denote ANA, downward triangles denote NAA, upward 
triangles denote AA; open shapes denote medium, grey shapes denote filtered Spn, black shapes 
denote Spn.  IL-6 (A and B), CXCL8/IL-8 (C and D).  A and C compared to medium without 
supplementary antibiotics (medium –P/S); B and D compared to medium with supplementary 
antibiotics (medium +P/S).  No induction of IL-6 or CXCL8/IL-8 mRNA was observed.  After 8h the 
medium was visibly cloudy in all conditions.  When compared to medium with supplementary 
antibiotics a non-significant induction of IL-6 mRNA was observed.  This was not observed for 
CXCL8/IL-8 mRNA. 
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Figure 4.5.  Proinflammatory cytokine protein induction in BAL macrophages at 8h post stimulation 
with Spn.  Squares denote NANA, circles denote ANA, downward triangles denote NAA, upward 
triangles denote AA; open shapes denote medium, grey shapes denote filtered Spn, black shapes 
denote Spn.  IL-1β (A and B), IL-6 (C and D), CXCL8/IL-8 (E and F), TNF-α (G and H).  A, C, E and G 
compared to medium without supplementary antibiotics; B, D, F and H compared to medium with 
supplementary antibiotics.  At 8h cells treated to medium without supplementary antibiotics alone had 
evidence of bacterial contamination, presumably from the upper airway at bronchoscopy.  No 
induction of IL-1β, IL-6, CXCL8/IL-8 and TNF-α was observed when comparing to medium without 
supplementary antibiotics (A, C, E and G).  When comparing to medium with supplementary 
antibiotics cells stimulated with Spn had a non-significant production of IL-1β protein.  Although no 
significant difference was observed between groups there was a suggestion for reduced production in 
asthmatics compared to non-asthmatics. No production of IL-6 or CXCL8/IL-8 protein was observed 
(D and F).  In the small sample size of NAA a non-significant production of TNF-α was observed with 
no production observed in other groups (H). 
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Table 4.1 summarises IFN and proinflammatory cytokine protein and mRNA 
induction in BAL cells at 8h following infection with Spn. 
 
Table 4.1 Summary of IFN and proinflammatory cytokine mRNA and protein induction post 
Spn infection in BAL cells - = no induction  
 8h 
 NANA ANA NAA AA 
IFN-α mRNA - - - - 
IFN-α protein - - - - 
IFN-β mRNA - - - - 
IFN-β protein - - - - 
IFNλ1/IL-29 mRNA - - - - 
IFNλ1/IL-29 protein - - - - 
IFNλ2,3/IL-28 mRNA - - - - 
IL-6 mRNA - - - - 
CXCL8/IL-8 mRNA - - - - 
IL-1β protein - - - - 
IL-6 protein - - - - 
CXCL8/IL-8 protein - - - - 
TNF-α protein - - - - 
 
 
 
4.2.3 Spn infection of HBECs: induction of type I and III IFN and 
proinflammatory cytokine mRNA and protein 
 To establish whether the previously reported defective IFN-β and IFN-λ 
production in AAs following infection with RV was also observed following infection 
with Spn, HBECs from the four patient groups were stimulated with Spn and type I 
and III IFN mRNA was measured at 8h and 24h, and protein at 24h and 48h.  
Induction of IFN-β, IFN-λ2,3/IL-28 and IFN-λ1/IL-29 mRNA was not observed at 8h 
or 24h in HBECs stimulated with Spn (figure 4.6).  A high baseline level of IFN-β 
mRNA was observed.  Production of IFN-β and IFN-λ1/IL-29 protein was not 
157 
 
observed in HBEC supernatants at 24h or 48h post stimulation with Spn (figure 4.7).  
No differences were observed between groups.  
 
 
Figure 4.6.  Interferon mRNA induction in HBECs at 8h (A, C and E) and 24h (B, D and F) post 
stimulation with Spn.  Squares denote NANA, circles denote ANA, downward triangles denote NAA, 
upward triangles denote AA; open shapes denote medium, grey shapes denote filtered Spn, black 
shapes denote Spn.  IFN-β (A and B), IFN-λ2,3/IL-28 (C and D), IFN-λ1/IL-29 (E and F).  No 
significant IFN mRNA induction was observed at 8 or 24h.  High levels of IFN-β mRNA were observed 
in medium treated cells, with no increased induction in Spn treated cells. 
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Figure 4.7 Interferon protein induction in HBECs at 24h (A and C) and 48h (B and D) post stimulation 
with Spn.  Squares denote NANA, circles denote ANA, downward triangles denote NAA, upward 
triangles denote AA; open shapes denote medium, grey shapes denote filtered Spn, black shapes 
denote Spn.  IFN-β (A and B), IFN-λ1/IL-29 (C and D).  No significant IFN protein production was 
observed. 
  
 In order to examine whether stimulation of HBECs with Spn resulted in 
induction of proinflammatory cytokines and to observe whether there were 
differences between the asthmatic or atopic status of the volunteers from whom the 
cells were obtained, IL-6 and CXCL8/IL-8 mRNA was measured at 8h and 24h, and 
IL-1β, IL-6, CXCL8/IL-8 and TNF-α protein was measured at 24h and 48h.  Induction 
of IL-6 and CXCL8/IL-8 mRNA was not observed at either time point in HBECs 
stimulated with Spn (figure 4.8).  Induction of IL-1β, IL-6, CXCL8/IL-8 and TNF-α 
protein from HBECs stimulated with Spn was not observed at 24 or 48h (figure 4.9).  
No differences were observed between the four volunteer groups. 
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Figure 4.8.  Proinflammatory cytokine mRNA induction in HBECs at 8h (A and C) and 24h (B and D) 
post stimulation with Spn.  Squares denote NANA, circles denote ANA, downward triangles denote 
NAA, upward triangles denote AA; open shapes denote medium, grey shapes denote filtered Spn, 
black shapes denote Spn.  IL-6 (A and B), CXCL8/IL-8 (C and D).  No significant induction of 
proinflammatory cytokine mRNA was observed at 8 or 24h. 
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Figure 4.9.  Proinflammatory cytokine protein induction in HBECs at 24h (A, C, E and G) and 48h (B, 
D, F, H) post stimulation with Spn.  Squares denote NANA, circles denote ANA, downward triangles 
denote NAA, upward triangles denote AA; open shapes denote medium, grey shapes denote filtered 
Spn, black shapes denote Spn.  IL-1β (A and B), IL-6 (C and D), CXCL8/IL-8 (E and F), TNF-α (G and 
H).  No significant production of proinflammatory cytokines was observed. 
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Tables 4.2 and 4.3 summarise IFN and proinflammatory cytokine protein and 
mRNA induction in HBECs at 8h following infection with Spn. 
Table 4.2 Summary of IFN and proinflammatory cytokine mRNA induction post Spn infection in 
HBECs - = no induction 
 8h 24h 
 NANA ANA NAA AA NANA ANA NAA AA 
IFN-β - - - - - - - - 
IFNλ2,3/IL-28 - - - - - - - - 
IFNλ1/IL-29 - - - - - - - - 
IL-6 - - - - - - - - 
CXCL8/IL-8 - - - - - - - - 
 
Table 4.3 Summary of IFN and proinflammatory cytokine protein induction post Spn infection 
in HBECs - = no induction  
 24h 48h 
 NANA ANA NAA AA NANA ANA NAA AA 
IFN-β - - - - - - - - 
IFNλ1/IL-29 - - - - - - - - 
IL-1β - - - - - - - - 
IL-6 - - - - - - - - 
CXCL8/IL-8 - - - - - - - - 
TNF-α - - - - - - - - 
 
 
4.2.4 Spn infection of PBMCs: induction of type I and III IFN and 
proinflammatory cytokine protein 
 The effect of Spn stimulation on PBMCs, as a further cell type, was 
examined in order to establish whether the IFNs were produced following infection 
with Spn and if they were produced, whether the asthmatic or atopic status of 
volunteers was important.  The production of type I and III IFN protein was assessed 
at 24h and 48h post stimulation.  As previously discussed, unlike HBECs, PBMCs 
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produce IFN-α as well as the other type I and III IFNs.  IFN-α, IFN-β and IFN-λ1/IL-
29 protein production was not observed in PBMCs stimulated with Spn at 24h and 
48h with no differences between the volunteer groups(figure 4.10). 
 
 
Figure 4.10.  Interferon protein induction in PBMCs at 24h (A, C and E) and 48h (B, D and F) post 
stimulation with Spn.  Squares denote NANA, circles denote ANA, downward triangles denote NAA, 
upward triangles denote AA; open shapes denote medium, grey shapes denote filtered Spn, black 
shapes denote Spn.  IFN-α2a (A and B), IFN-β (C and D), IFN-λ1/IL-29 (E and F).  No significant IFN 
protein production was observed. 
  
 In order to establish whether Spn results in production of proinflammatory 
cytokines from PBMCs and to examine whether the different asthmatic and atopic 
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phenotype of volunteers resulted in different proinflammatory cytokine expression 
from PBMCs simulated with Spn IL-1β, IL-6, CXCL8/IL-8 and TNF-α protein was 
measured in PBMC supernatants at 24h and 48h. 
 IL-1β was produced at 24h and 48h in PBMCs stimulated with Spn.  At 24h 
significant production was observed in all 4 groups of volunteers (figure 4.11 A); 
NANA (p<0.01), ANA (p<0.05), NAA (p<0.05) and AA (p<0.001).  No significant 
difference was observed between groups.  At 48h significant production of IL-1β was 
observed in asthmatic subjects; NAA (p<0.05) and AA (p<0.001).  Non-significant 
increases in IL-1β protein were observed in NANA and ANA (figure 4.11 B).  No 
differences were observed between groups. 
 Increases in IL-6 and CXCL8/IL-8 protein were not observed in PBMCs 
stimulated with Spn at either 24h or 48h other than in the small sample of NAA 
(figure 4.11 C-F). 
 TNF-α protein was produced at 24h and 48h in PBMCs stimulated with 
Spn.  At 24h significant production was observed in AA only (p<0.01) with non-
significant increases observed in NANA, ANA and NAA (figure 4.11 G).  At 48h 
significant production was observed in AA only (p<0.001) with non-significant 
increases observed in NANA, ANA and NAA (figure 4.11 H).  No significant 
differences were observed between groups at either time point.  
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Figure 4.11.  Proinflammatory cytokine protein induction in PBMCs at 24h (A, C, E and G) and 48h (B, 
D, F, H) post stimulation with Spn.  Squares denote NANA, circles denote ANA, downward triangles 
denote NAA, upward triangles denote AA; open shapes denote medium, grey shapes denote filtered 
Spn, black shapes denote Spn; * = p<0.05, ** = p<0.01, *** = p<0.001, ns = non-significant.  IL-1β (A 
and B), IL-6 (C and D), CXCL8/IL-8 (E and F), TNF-α (G and H).  Significant increases in IL-1β protein 
were observed in all groups at 24h.  At 48h increases were observed which reached statistical 
significance in asthmatic volunteers.  No significant increases were observed in IL-6 or CXCL8/IL-8 
protein at either 24h or 48h.  Increases in TNF-α protein were observed at 24h and 48h, with 
statistical significance reached in AA only.  No differences were observed between in any of the 
cytokines measured at either time point. 
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 Table 4.4 summarises the IFN and proinflammatory cytokine protein induction 
in PBMCs following Spn infection. 
 
Table 4.4 Summary of IFN and proinflammatory cytokine protein induction post Spn infection 
in PBMCs ↑ = significant induction, ns = non-significant increase observed, - = no induction  
 24h 48h 
 NANA ANA NAA AA NANA ANA NAA AA 
IFN-α2a - - - - - - - - 
IFN-β - - - - - - - - 
IFNλ1/IL-29 - - - - - - - - 
IL-1β ↑ ↑ ↑ ↑ ns ns ↑ ↑ 
IL-6 - - ns - - - ns - 
CXCL8/IL-8 - - ns - - - ns - 
TNF-α ns ns ns ↑ ns ns ns ↑ 
 
 
4.3 Discussion 
 
 There is increasing evidence to suggest a role for bacteria in asthma.  Asthma 
is a risk factor for invasive pneumococcal disease 104, 319 and Spn colonisation has 
been reported more common in asthmatics 93.   The aim of the experiments 
performed in this chapter were to examine whether Spn infection of BAL cells, 
HBECs and PBMCs resulted in production of type I and III IFNs and whether there 
were any differences observed between asthmatics and non-asthmatics, atopics and 
non-atopics. 
 In the experiments reported in this chapter Spn failed to induce type I or III 
IFN mRNA or protein in any of the cell types examined.  In BAL cells no induction 
was observed at 8h.  It could be that 8h was too early a time point to detect IFN 
mRNA expression, especially in view of the suggestion from the preliminary 
experiments in PBMCs that IFN-β mRNA was detected at 24h and 48h.  Previous 
studies have identified type I IFN expression in human alveolar macrophages co-
166 
 
cultured with alveolar epithelial cells infected with Spn for 16h 224.  This induction of 
type I IFN was mediated by a cytosolic DNA-sensing pathway involving the adaptor 
molecule STING and IRF-3 and was dependent on the pore-forming toxin 
pneumolysin.  The production of proinflammatory cytokine mRNA and protein was 
also examined in BAL cells, again using 8h as a time point, to be in line with 
experiments performed on RV.  Protocols developed in the department have 
routinely used medium supplemented with antibiotics for experiments with RV in BAL 
cells and PBMCs.  This seemed counterintuitive for experiments with bacteria, so 
medium without supplementary antibiotics was used.  However, visible 
contamination of BAL cell samples was observed in medium-only treated cells, 
presumably from airway commensal bacteria acquired at bronchoscopy.  Hence no 
difference in proinflammatory cytokine production was observed between Spn- and 
medium-treated BAL cells.  In an attempt to clarify proinflammatory cytokine 
induction, Spn-treated cells were compared to medium with supplementary 
antibiotics.  Only non-significant induction of IL-1β was observed, with no differences 
between groups.  If a later time point had been used, more significant results may 
have been found.  Previous studies have identified the alveolar macrophage as 
important sources for early proinflammatory cytokine release in response to Spn 
infection 132, which was not replicated in this chapter. 
 Although a high level of baseline IFN-β mRNA was observed in HBECs, no 
increased induction of type I or III IFNs was observed in HBECs treated with Spn at 
any of the time points examined.  Some studies have not identified alveolar epithelial 
cells infected with Spn as a source of type I IFN production 224, whereas other 
studies using mouse models of Spn infection have identified type I IFN induction 
from the airway epithelium 223.  In the initial dose-time experiments weak induction of 
IL-6 and CXCL8/IL-8 mRNA was observed at 24h in BEAS-2B cells, but not primary 
HBECs.  This disparity between different types of BECs made further examination in 
the volunteer groups of interest.  Experimental conditions were identical, yet no 
significant induction of proinflammatory cytokine mRNA or protein was observed at 
any time point.  The reason for this may have been insufficient stimulation time for 
the Spn.  There is variation in other studies with the stimulation time of Spn – 2h 123, 
6h 321 and up to 16h 287 with the latter two studies observing production of CXCL8/IL-
8 from BECs stimulated with Spn.  In the preliminary experiments performed in this 
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chapter, 24h stimulation with Spn lead to marked cell death (observed with light 
microscopy).  In this study, with the experiments on RV being performed at the same 
time as those reported in this chapter and the initial experiments suggesting 
induction after 1h of stimulation, this timing was thought sufficient.  There was 
insufficient evidence obtained from the experiments reported in this chapter to 
suggest Spn induces type I or III IFNs from HBECs, meaning observations between 
asthmatics and non-asthmatics, atopics and non-atopics could not be made. 
 PBMCs were the only cell type stimulated with Spn in which clear 
inflammatory responses were observed.  Significant production of IL-1β protein was 
observed at 24h in all groups and at 48h in AA and NAA, with non-significant 
increases observed in NANA and ANA.  No differences were observed between 
groups.  With TNF-α protein, significant increases were observed in AA at 24h and 
48h, with non-significant production in the other groups at both time points.  Less 
convincing production of IL-6 and CXCL8/IL-8 protein was observed.  Several other 
anti-bacterial cytokines could also be involved in host defence against bacteria, 
particularly IFN-γ.  This has a role in anti-bacterial immunity, though it appears to be 
microbe-specific 322.  Due to time and financial constraints of the project and the 
multiplex used not having IFN-γ as a cytokine to measure, the production of IFN-γ 
was not analysed.   
Production of proinflammatory cytokines from PBMCs stimulated by Spn has 
been known for some years 323, and the data presented in this chapter support this.  
However no difference was observed between asthmatic and/or atopic nature of the 
cells.  As with the other cell types experimented upon in this chapter, no induction of 
type I or III IFN mRNA or protein was observed, suggesting Spn leads to an 
inflammatory response and not IFN production. 
 It may be that IFN signalling is not an important part of the innate immune 
response to Spn infection.  Other components of the innate immune system may be 
important, and, in future, deficiencies could be identified in asthmatics.  One such 
system could be the anti-microbial peptides such as defensins.  These are present in 
airway secretions and expressed in the airway epithelium, and have direct 
antimicrobial action, modulate innate and adaptive immunity and play a role in 
wound repair 324.  Recently Spn has been identified as an inducer of β-defensins in 
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lung epithelium 325.  Although beyond the scope of this study, it would be interesting 
to examine whether Spn resulted in the expression of such a system in the cells 
obtained in this study, and to determine whether a difference between asthmatic and 
non-asthmatics, atopics and non-atopics was observed.  It was for this reason that, 
despite Spn not clearly inducing IFNs in any cell type investigated in the preliminary 
investigations, a decision was made to continue with the investigation of Spn in the 
volunteers’ samples, and to investigate the proinflammatory responses to Spn in the 
various cell types. 
 
4.4 Conclusions 
 
 This is the first report of the investigation of type I and III and 
proinflammatory cytokine responses to stimulation Spn in cells from adult asthmatics 
and non-asthmatics, atopics and non-atopics.  Induction of type I and III IFN mRNA 
and protein was not observed in BAL cells, HBECs or PBMCs stimulated with Spn.  
Induction of proinflammatory cytokines was observed in PBMCs stimulated with Spn, 
but there was no difference identified between asthmatics and non-asthmatics, 
atopics and non-atopics.  The study hypothesis should therefore be rejected. 
 
4.5 Summary 
 
 Type I and III IFN was not produced from BAL cells, HBECs or PBMCs 
stimulated with Spn.  Induction of anti-bacterial cytokines was observed in PBMCs 
stimulated with Spn but no differences were observed between asthmatics or control 
groups. 
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Chapter 5: TLR 1/2/6/4/5/9 stimulation of HBECs and PBMCs 
 
5.1 Introduction 
 TLRs 1, 2, 6, 4, 5 and 9 recognise products of bacterial infection.  Asthmatics 
have an increased susceptibility to atypical bacterial infection 326 and invasive 
pneumococcal disease 104, 319.  Recent data suggest these “bacterial” TLRs may be 
involved in IFN signalling pathways.  With studies demonstrating IFN deficiency in 
asthmatics, further clarification of TLR stimulation may highlight potential therapeutic 
targets. 
 TLR2 forms heterodimers with TLR1 or TLR6 to recognise bacterial triacyl or 
diacyl lipoproteins.  Administration of the TLR1/2 ligand Pam3CSK4 reduces total 
inflammatory cell infiltrates and BAL eosinophilia in a mouse model of allergic 
airways disease 327 .  Upregulation of TLR2 has been identified in the nasal mucosa 
of humans with allergic rhinitis 328 and a polymorphism of TLR2 has been associated 
with allergic asthma 329.  TLR1, 2 and 6 signalling is largely understood to result in 
the induction of proinflammatory cytokines, through the MyD88 dependent pathway.  
Recent data, however, suggests TLR2 activation resulting in the induction of type I 
IFNs 257, 258.  Further investigation is required to characterise the role of TLR1, 2 and 
6 in IFN induction and to determine whether deficiencies in asthma or atopy are 
identified. 
 TLR4 recognises the bacterial ligands LPS and pneumolysin.  For this study 
LPS was used as a previous study identified macrophages from asthmatics 
stimulated with LPS ex-vivo having a deficient IFN-λ response which correlated with 
exacerbation severity in vivo 61.  TLR4 polymorphisms have been associated with 
asthma and atopy in humans, with decreased LPS-induced IL-12 and IL-10 in 
PBMCs 330.  TLR4 is also important for IFN signalling 264.  Further study therefore 
needs to be done on the role of TLR4 and IFN deficiency in asthma and/or atopy. 
 TLR5 is expressed by epithelial cells, monocytes and immature dendritic cells 
and recognises the flagellar element of motile bacteria.  A recent study has 
suggested that the TLR5 ligand flagellin promotes the development of allergic 
asthma by priming allergic responses to indoor allergens 331.  Data is limited, but 
170 
 
TLR5 stimulation had been shown to stimulate IFN expression in mouse 
macrophages 268.  Whether TLR5 is important in IFN signalling in asthma and atopy 
has not yet been elucidated. 
 TLR9 recognises CpG motifs found in bacterial DNA and is important for the 
clearance of bacteria from the lower respiratory tract of mice 270.  Administration of 
CpG-ODN in mouse models of asthma and allergy results in reduction of Th2 
responses, eosinophilic inflammation and airway hyperreactivity 332 and is effective in 
treatment of ragweed rhinitis in humans 333.  TLR9 stimulation results in induction of 
type I IFNs in human primary cells via the MyD88 dependent pathway 272 and TLR9 
is known to be expressed in bronchial epithelial cells 317.  TLR9 therefore may be of 
relevance in the further characterisation of IFN deficiency in asthma. 
 In this chapter type I and III IFNs and proinflammatory cytokines were 
investigated in HBECs and PBMCs from NANA, ANA, NAA and AA.  Experiments 
were not carried out in BAL cells due to the limited number of cells acquired at 
bronchoscopy.   
  
5.1.1 Hypothesis 
 TLRs sensing products of bacterial infection (TLR1, TLR2, TLR4, TLR5, TLR6 
and TLR9) will induce type I and III IFNs and proinflammatory cytokines in 
HBECs and PBMCs and will result in deficient type I and III IFN induction in 
AA and NAA, compared to NANA and ANA. 
5.1.2 Aims 
 To establish whether TLR1, TLR2, TLR4, TLR5, TLR6 and TLR9 stimulation 
of HBECs and PBMCs results in type I and III IFN and proinflammatory 
cytokine induction. 
 To determine whether this response is deficient in AA and NAA compared to 
NANA and ANA. 
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5.2 Results 
 
5.2.1 Preliminary experiments: time course and concentration responses to 
TLR ligands in BEAS-2B cells, primary HBECs and PBMCs 
 Prior to the assessment of the effects of different TLR ligands in interferon 
and proinflammatory cytokine induction in cells acquired from volunteers, and to the 
investigation as to whether there were any differences depending on the atopic 
and/or asthmatic status of volunteers, the effects of different TLR ligands was 
analysed in BEAS-2B cells, primary HBECs and PBMCs.  Dose-time experiments 
were performed in these cell types and type I and III IFN and IL-6 and CXCL8/IL-8 
mRNA was measured in cell lysates (figures 5.1-5.5).  10-fold dilutions of each 
ligand were made.  Cells were stimulated with varying concentrations of TLR ligand 
and were harvested at various times following stimulation. 
 
5.2.1.1 Pam3CSK4 (PAM) (TLR1/2 ligand)  
 In BEAS-2B cells a concentration dependent induction of IL-6 mRNA at 8h, 
24h and 48h, and CXCL8/IL-8 mRNA at 8h and 24h was observed following 
stimulation with Pam3CSK4 (figure 5.1 A and B).  This failed to reach statistical 
significance.  A non-significant weak induction of IFN-β mRNA was observed at 24h 
with a concentration of 10µg/mL (figure 5.1 C).  Induction of IFN-λ2,3/IL-28 or IFN-
λ1/IL-29 mRNA was not observed (not shown).  In primary HBECs a non-significant 
induction of IL-6 and CXCL8/IL-8 mRNA was observed at 8h and 24h (figure 5.1 D 
and E).  A non-significant induction IFN-β mRNA was observed at 8h and 24h with a 
concentration of 10µg/mL and at 24h with a concentration of 1µg/mL (figure 5.1 F).  
Induction of IFN-λ2,3/IL-28 or IFN-λ1/IL-29 mRNA was not observed (not shown).  In 
PBMCs induction of IL-6 and IFN-β mRNA was not observed (figure 5.1 G and I).  
Non-significant induction of CXCL8/IL-8 mRNA was observed at 48h (figure 5.1 H).  
Induction of IFN-λ2,3/IL-28 or IFN-λ1/IL-29 mRNA was not observed (not shown).  In 
each cell type, Pam3CSK4 at a concentration of 10µg/mL was used for subsequent 
experiments in participants’ samples. 
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Figure 5.1.  Concentration and time course response of Pam3CSK4 (PAM) in BEAS-2B cells (A, B and 
C, N=2), primary HBECs (D, E and F, N=3) and PBMCs (G, H and I, N=2) (□ = medium, ● = PAM 
10µg/mL, ● = PAM 1µg/mL, ● = PAM 0.1µg/mL, ■ = poly(IC) 10µg/mL for epithelial cells, 100µg/mL 
for PBMCs). Poly(IC) was used as a positive control.  In BEAS-2B cells non-significant concentration 
dependent induction of IL-6 mRNA at all time points (A) and CXCL8/IL-8 mRNA at 8h and 24h was 
observed (B).  Non-significant weak induction of IFN-β mRNA was observed at 24h for 10µg/mL(C).  
In primary HBECs a non-significant induction of IL-6 mRNA and CXCL8/IL-8 mRNA at 8h and 24h 
was observed (D and E).  Non-significant weak induction of IFN-β mRNA at 8 and 24h for 10µg/mL 
and 24h for 1µg/mL was observed (F).  In PBMCs induction of IL-6 mRNA was not observed (G).  
Non-significant induction of CXCL8/IL-8 mRNA at 48h was observed (H).  Induction of IFN-β mRNA 
was not observed (I).  Induction of IFN-λ2,3/IL-28 or IFN-λ1/IL-29 mRNA was not observed in any cell 
type (not shown). 
 
5.2.1.2 Lipoteichoic acid (LTA) (TLR2/6 ligand) 
 In BEAS-2B cells a concentration dependent induction of IL-6 and 
CXCL8/IL-8 mRNA was observed following stimulation with LTA (figure 5.2 A and B).  
This failed to reach statistical significance.  Induction of IFN-β mRNA was not 
observed (figure 5.2 C).  Induction of IFN-λ2,3/IL-28 or IFN-λ1/IL-29 mRNA was not 
observed (not shown).  In primary HBECs induction of IL-6, CXCL8/IL-8 and IFN-β 
mRNA was not observed (figure 5.2 D-F).  Likewise, induction of IFN-λ2,3/IL-28 or 
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IFN-λ1/IL-29 mRNA was not observed (not shown).  In PBMCs induction of IL-6 and 
CXCL8/IL-8 mRNA was observed in a concentration dependent manner following 
stimulation with LTA (figure 5.2 G and H).  This failed to reach statistical significance.  
A non-significant induction of IFN-β mRNA was observed at 8h (figure 5.2 I).  
Induction of IFN-λ2,3/IL-28 or IFN-λ1/IL-29 mRNA was not observed (not shown).  A 
dose of 25µg/mL was found to be optimal in BEAS-2Bs and PBMCs and was used 
for subsequent experiments in participants’ samples. 
 
  
Figure 5.2.  Concentration and time course response of Lipoteichoic acid (LTA) in BEAS-2B cells (A, 
B and C, N=3), primary HBECs (D, E and F, N=3) and PBMCs (G, H and I, N=2) (□ = medium, ● = 
LTA 25µg/mL, ● = LTA 10µg/mL, ● = LTA 1µg/mL, ■ = poly(IC) 10µg/mL). In epithelial cells poly(IC) 
was used as a positive control.  In BEAS-2B cells non-significant concentration dependent induction 
of IL-6 and CXCL8/IL-8 mRNA was observed (A and B); induction of IFN-β mRNA was not observed 
(C). In primary HBECs induction of IL-6 mRNA (D), CXCL8/IL-8 mRNA (E) and IFN-β mRNA (F) was 
not observed. In PBMCs a non-significant induction of IL-6 and CXCL8/IL-8 mRNA at 8, 24 and 48h 
for the higher concentrations of LTA was observed (G and H).  A non-significant weak induction of 
IFN-β mRNA was observed at 8h (I). Induction of IFN-λ2,3/IL-28 or IFN-λ1/IL-29 mRNA was not 
observed in any cell type (not shown). 
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5.2.1.3 Synthetic lipoprotein (FSL) (TLR2/6 ligand) 
 In BEAS-2B cells a concentration dependent induction of IL-6 and 
CXCL8/IL-8 mRNA was observed following stimulation with FSL (figure 5.3 A and B).  
This failed to reach statistical significance.  Induction of IFN-β mRNA was not 
observed (figure 5.3 C).  Induction of IFN-λ2,3/IL-28 or IFN-λ1/IL-29 mRNA was not 
observed (not shown).  In primary HBECs induction of IL-6 and CXCL8/IL-8 mRNA 
was observed at 8h (figure 5.3 D and E).  Induction of IFN-β mRNA was not 
observed (figure 5.3 F).  Likewise, induction of IFN-λ2,3/IL-28 or IFN-λ1/IL-29 mRNA 
was not observed (not shown).  In PBMCs weak induction of IL-6 mRNA at all time 
points, and CXCL8/IL-8 mRNA at 48h was observed following stimulation with FSL 
(figure 5.3 G and H).  This failed to reach statistical significance.  Induction of IFN-β 
mRNA was not observed (figure 5.3 I).  Induction of IFN-λ2,3/IL-28 or IFN-λ1/IL-29 
mRNA was not observed (not shown).  A concentration of 1µg/mL was found to be 
optimal in BEAS-2Bs, HBECs and PBMCs and was used for subsequent 
experiments in participants’ samples.  
 
5.2.1.4 Peptidoglycan (PGN) (TLR2/6 ligand) 
 In BEAS-2B cells induction of IL-6 and IFN-β mRNA was not observed 
following stimulation with PGN (figure 5.4 A and C).  Non-significant weak induction 
of CXCL8/IL-8 mRNA was observed at 8h and 24h (figure 5.4 B).  In primary HBECs 
non-significant induction of IL-6 mRNA was observed (figure 5.4 D).  Induction of 
CXCL8/IL-8 and IFN-β mRNA was not observed (figure 5.4 E and F).  In PBMCs a 
non-significant induction of IL-6 mRNA at 8, 24 and 48h (figure 5.4 G), and 
CXCL8/IL-8 mRNA at 24 and 48h was observed (figure 5.4 H).  A non-significant 
induction of IFN-β mRNA was observed at 8h (figure 5.4 I). Induction of IFN-λ2,3/IL-
28 or IFN-λ1/IL-29 mRNA was not observed in any cell type (data not shown).  A 
concentration of 25µg/mL was found to be optimal in HBECs and PBMCs and was 
used for subsequent experiments in participants’ samples. 
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Figure 5.3.  Concentration and time course response of Synthetic lipoprotein (FSL) in BEAS-2B cells 
(A, B and C, N=3), primary HBECs (D, E and F, N=3) and PBMCs (G, H and I, N=3) (□ = medium, ● 
= FSL 10µg/mL, ● = FSL 1µg/mL, ● = FSL 0.1µg/mL, ○ = FSL 0.01µg/mL, ■ = poly(IC) 10µg/mL for 
epithelial cells, 100µg/mL for PBMCs).  Poly(IC) was used as a positive control.  In BEAS-2B cells a 
non-significant induction of IL-6 mRNA and CXCL8/IL-8 mRNA at 8, 24 and 48h was observed (A and 
B) with the optimal concentration being 1µg/mL.  IFN-β mRNA induction not observed (C). In primary 
HBECs induction of IL-6 mRNA at 8h (D), and CXCL8/IL-8 mRNA at 8h with the higher 2 
concentrations (E) was observed.  Induction of IFN-β mRNA (F) was not observed.  In PBMCs a non-
significant weak induction of IL-6 mRNA at 8, 24 and 48h, and CXCL8/IL-8 mRNA at 48h for the 
higher concentrations of FSL was observed (G and H).  IFN-β mRNA induction in FSL treated cells 
over that of medium treated cells was not observed (I)  Induction of IFN-λ2,3/IL-28 or IFN-λ1/IL-29 
mRNA was not observed (not shown). 
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Figure 5.4.  Concentration and time course response of Peptidoglycan (PGN) in BEAS-2B cells (A, B 
and C, N=3), primary HBECs (D, E and F, N=3) and PBMCs (G, H and I, N=2) (□ = medium, ● = 
PGN 25µg/mL, ● = PGN 10µg/mL, ● = PGN 1µg/mL, ■ = poly(IC) 10µg/mL). In epithelial cells 
poly(IC) was used as a positive control.  In BEAS-2B cells induction of IL-6 mRNA was not observed 
(A).  Weak induction of CXCL8/IL-8 mRNA, at 8h with PGN 10µg/mL and at 24h with PGN 25µg/mL, 
was observed (B).  Induction of IFN-β mRNA was not observed (C). In primary HBECs a non-
significant induction of IL-6 mRNA at 8h was observed (D).  Induction of CXCL8/IL-8 mRNA and IFN-
β mRNA was not observed (E and F). In PBMCs a non-significant induction of IL-6 mRNA at 8, 24 
and 48h (G), and CXCL8/IL-8 mRNA at 24 and 48h was observed (H).  A non-significant induction of 
IFN-β mRNA was observed at 8h (I). Induction of IFN-λ2,3/IL-28 or IFN-λ1/IL-29 mRNA was not 
observed in any cell type (not shown). 
 
5.2.1.5 Flagellin (FLA) (TLR5 ligand) 
 In BEAS-2B cells a concentration dependent induction of IL-6 and 
CXCL8/IL-8 mRNA was observed following stimulation with FLA.  This failed to reach 
statistical significance (figure 5.5 A and B).  Induction of IFN-β mRNA was not 
observed (figure 5.5 C).  In primary HBECs induction of IL-6 and IFN-β mRNA was 
not observed (figure 5.5 D and F).  A non-significant weak induction of CXCL8/IL-8 
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mRNA was observed at 8h (figure 5.5 E).  In PBMCs a non-significant induction of 
IL-6 mRNA was observed for 100ng/mL FLA and of CXCL8/IL-8 mRNA for each 
concentration of FLA at 8h (figure 5.5G and H).  Induction of IFN-β mRNA was not 
observed (figure 5.5 I).  Induction of IFN-λ2,3/IL-28 or IFN-λ1/IL-29 mRNA was not 
observed in any cell type (data not shown).  A concentration of 100ng/mL was found 
to be optimal in BEAS-2Bs, HBECs and PBMCs and was used for subsequent 
experiments in participants’ samples.  
 
Figure 5.5.  Concentration and time course response of Flagellin (FLA) in BEAS-2B cells (A, B and C, 
N=3), primary HBECs (D, E and F, N=3) and PBMCs (G, H and I, N=2) (□ = medium, ● = FLA 
100ng/mL, ● = FLA 25ng/mL, ● = FLA 10ng/mL, ■ = poly(IC) 10µg/mL). In epithelial cells poly(IC) 
was used as a positive control.  In BEAS-2B cells non-significant concentration dependent induction 
of IL-6 and CXCL8/IL-8 mRNA was observed (A and B); induction of IFN-β mRNA was not observed 
(C). In primary HBECs induction of IL-6 mRNA (D) and IFN-β mRNA (F) was not observed.  A non-
significant concentration dependent weak induction of CXCL8/IL-8 mRNA was observed at 8h (E). In 
PBMCs a non-significant induction of IL-6 mRNA with 100ng/mL at 8 and 48h and a half log increase 
in CXCL8/IL-8 mRNA at 8h for each concentration of FLA was observed (G and H).  Induction of IFN-
β mRNA was not observed at (I). Induction of IFN-λ2,3/IL-28 or IFN-λ1/IL-29 mRNA was not observed 
in any cell type (not shown). 
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5.2.1.6 Lipopolysaccharide (LPS) (TLR4) and CpG-C (TLR9) 
 The concentrations of LPS and CpG-C were used from already established 
protocols within the department (A. Sykes, unpublished data/thesis 334).  No 
preliminary experiments were performed with LPS or CpG-C. 
 
5.2.2 TLR1, 2 and 6 stimulation of HBECs: type I and III IFN and 
proinflammatory cytokine mRNA and protein induction 
As discussed in chapter 3, stimulation of TLR3 leads to the induction of type I 
and III IFNs in HBECs.  In order to establish whether other TLRs were involved in 
type I and III IFN signalling, particularly those TLRs stimulated by ligands which are 
bacterial components, each TLR was evaluated using different TLR ligands.  For the 
purposes of discussion they were grouped into TLR1, 2 and 6, TLR4, TLR5 and 
TLR9.  Whether there was a difference between the asthmatic or atopic nature of 
volunteers’ samples was investigated.  Cells were stimulated with different TLR 
ligands and type I and III IFN and proinflammatory cytokines were measured; mRNA 
at 8h and 24h, and protein at 24h post stimulation. 
 
5.2.2.1 Pam3CSK4 
IFN-β mRNA was not induced by Pam3CSK4 at 8h or 24h (figure 5.6 A and B).  
At 8h IFN-λ2,3/IL-28 mRNA was not significantly induced by Pam3CSK4.  There was 
a suggestion of induction in the NAA group but sample size was small (figure 5.6 C).  
At 24h a weak increase was observed in NANA and ANA but this failed to reach 
statistical significance (figure 5.6 D).  There was a suggestion that IFN-λ1/IL-29 
mRNA was induced by Pam3CSK4 at 8h in NAA (the sample size was small), but not 
in the other groups (figure 5.6 E).  At 24h a non-significant increase was observed in 
NANA only (figure 5.6 F).  With type I and III IFN mRNA induction there were no 
significant differences were observed between groups. 
No significant induction of IFN-β protein was observed at 24h post stimulation 
with Pam3CSK4 in any group, with a significant difference observed between ANA 
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and AA (figure 5.7 A).  A non-significant weak increase in IFN-λ1/IL-29 protein 
induction in NANA was observed, with no induction in other groups (figure 5.7 B). 
  
Figure 5.6.  Interferon mRNA induction in HBECs post stimulation with Pam3CSK4 at 8h (A, C and E) 
and 24h (B, D and F).  Squares denote NANA, circles denote ANA, downward triangles denote NAA, 
upward triangles denote AA; open shapes denote medium, black shapes denote Pam3CSK4.  IFN-β 
(A and B), IFN-λ2,3/IL-28 (C and D), IFN-λ1/IL-29 (E and F). No significant induction of IFN-β mRNA 
was observed in any group.  In NAA induction of IFN-λ2,3/IL-28 and IFN-λ1/IL-29 mRNA was 
observed at 8h.  A non-significant induction of IFN-λ2,3/IL-28 and IFN-λ1/IL-29 mRNA was observed 
in NANA at 24h.  No significant differences were observed between groups. 
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Figure 5.7.  Interferon protein induction in HBECs post stimulation with Pam3CSK4 at 24h.  Squares 
denote NANA, circles denote ANA, downward triangles denote NAA, upward triangles denote AA; 
open shapes denote medium, black shapes denote Pam3CSK4; ** = p<0.01.  IFN-β (A), IFN-λ1/IL-29 
(B). A trend for IFN-β protein induction was observed in NANA, NAA and AA, with a significant 
difference between ANA and AA.  A non-significant weak increase in IFN-λ1/IL-29 protein induction in 
NANA was observed, with no induction in other groups. 
 
In order to examine whether stimulation of HBECs with Pam3CSK4 resulted in 
induction of proinflammatory cytokines and to observe whether there were 
differences between the asthmatic or atopic status of the volunteers from whom the 
cells were obtained, IL-6 and CXCL8/IL-8 mRNA was measured at 8h and 24h, and 
IL-1β, IL-6, CXCL8/IL-8 and TNF-α protein was measured at 24h.  Non-significant 
induction of IL-6 mRNA was observed at 8h in NAA, with no induction observed in 
other groups (figure 5.8 A).  Induction was not observed at 24h (figure 5.8 B).  At 8h, 
significant induction of CXCL8/IL-8 mRNA was observed in NANA (p<0.05), with a 
non-significant induction observed in ANA, NAA and AA (figure 5.8 C).  Induction 
was not observed at 24h (figure 5.8 D).  With both IL-6 and CXCL8/IL-8 mRNA no 
significant differences were observed between groups at both time points. 
Weak induction of CXCL8/IL-8 protein from HBECs stimulated with 
Pam3CSK4 was observed at 24h but this failed to reach statistical significance (figure 
5.9 C).  Induction of IL-1β, IL-6 and TNF-α protein was not observed (figure 5.9 A, B 
and D).  No differences were observed between the four volunteer groups. 
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Figure 5.8.  IL-6 and CXCL8/IL-8 mRNA induction in HBECs post stimulation with Pam3CSK4 at 8h (A 
and C) and 24h (B and D).  Squares denote NANA, circles denote ANA, downward triangles denote 
NAA, upward triangles denote AA; open shapes denote medium, black shapes denote Pam3CSK4; * = 
p<0.05, ns = non-significant.  IL-6 (A and B), CXCL8/IL-8 (C and D).  Non-significant induction of IL-6 
mRNA at 8h was observed in NAA only, with no induction at 24h.  Significant induction of CXCL8/IL-8 
mRNA was observed in NANA at 8h with non-significant increases in other groups.  No induction was 
observed at 24h.  No significant differences were observed between groups. 
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Figure 5.9.  Proinflammatory cytokine protein induction in HBECs post stimulation with Pam3CSK4 at 
24h.  Squares denote NANA, circles denote ANA, downward triangles denote NAA, upward triangles 
denote AA; open shapes denote medium, black shapes denote Pam3CSK4.  IL-1β (A), IL-6 (B), 
CXCL8/IL-8 (C), TNF-α (D). Non-significant weak induction of CXCL8/IL-8 protein was observed in all 
groups.  Induction of IL-1β, IL-6 and TNF-α was not observed.  There were no differences between 
groups. 
 
5.2.2.2 Lipoteichoic Acid (LTA) 
As with Pam3CSK4, the type I and III IFN and proinflammatory cytokine 
response to LTA was assessed in HBECs. IFN-β mRNA was not induced by LTA at 
8h or 24h but high basal levels of IFN-β mRNA were observed (figure 5.10 A and B).  
At 8h and 24h IFN-λ2,3/IL-28 mRNA was weakly induced by LTA in NAA but sample 
size was small (figure 5.10 C and D).  At 24h a weak increase was observed in 
NANA, ANA and NAA but this failed to reach statistical significance (figure 5.10 D).  
IFN-λ1/IL-29 mRNA was not induced by LTA at 8h in any group (figure 5.10 E).  At 
24h a non-significant increase was observed in all groups (figure 5.10 F).  With type I 
and III IFN mRNA induction there were no significant differences were observed 
between groups. 
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No significant induction of IFN-β or IFN-λ1/IL-29 protein was observed at 24h 
post stimulation with LTA in any group (appendix A, figure A1). 
 
 
Figure 5.10.  Interferon mRNA induction in HBECs post stimulation with LTA at 8h (A, C and E) and 
24h (B, D and F).  Squares denote NANA, circles denote ANA, downward triangles denote NAA, 
upward triangles denote AA; open shapes denote medium, black shapes denote LTA.  IFN-β (A and 
B), IFN-λ2,3/IL-28 (C and D), IFN-λ1/IL-29 (E and F).  Induction of IFN-β mRNA was not observed. 
Non-significant weak induction of IFN-λ2,3/IL-28 mRNA was observed at 8h in NAA and in NANA, 
ANA and NAA at 24h.  Non-significant induction of IFN-λ1/IL-29 mRNA was observed in all groups at 
24h.  No differences were observed between groups at both time points and with all IFNs measured. 
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Proinflammatory cytokines were measured in HBECs stimulated with LTA.  
Induction of IL-6 mRNA was not observed at 8h or 24h in any group (figure 5.11 A 
and B).  At 8h, non-significant induction of CXCL8/IL-8 mRNA was observed in all 
groups (figure 5.11 C).  Induction was not observed at 24h (figure 5.11 D).  With both 
IL-6 and CXCL8/IL-8 mRNA no significant differences were observed between 
groups. 
At 24h following stimulation with LTA non-significant weak induction of IL-1β, 
and CXCL8/IL-8 was observed in all groups and IL-6 and TNF-α protein in NANA 
and ANA (figure 5.12).  No differences were observed between the four volunteer 
groups. 
 
Figure 5.11.  IL-6 and CXCL8/IL-8 mRNA induction in HBECs post stimulation with LTA at 8h (A and 
C) and 24h (B and D).  Squares denote NANA, circles denote ANA, downward triangles denote NAA, 
upward triangles denote AA; open shapes denote medium, black shapes denote LTA.  IL-6 (A and B), 
CXCL8/IL-8 (C and D).  Induction of IL-6 mRNA was not observed in any group.  Non-significant 
induction of CXCL8/IL-8 mRNA was observed in all groups at 8h.  No differences were observed 
between groups. 
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Figure 5.12.  Proinflammatory cytokine protein induction in HBECs post stimulation with LTA at 24h.  
Squares denote NANA, circles denote ANA, downward triangles denote NAA, upward triangles 
denote AA; open shapes denote medium, black shapes denote LTA.  IL-1β (A), IL-6 (B), CXCL8/IL-8 
(C), TNF-α (D). Non-significant increases of IL-1β, IL-6, CXCL8/IL-8 and TNF-α protein were 
observed.  Induction of TNF-α was not observed in NAA or AA.  There were no differences between 
groups. 
 
5.2.2.3 Peptidoglycan (PGN) 
Type I and III IFN and proinflammatory cytokine response to PGN was 
assessed in HBECs.  IFN-β and IFN-λ2,3/IL-28 mRNA was not induced by PGN at 
8h or 24h (figure 5.13 A-D).  IFN-λ1/IL-29 mRNA was non-significantly induced by 
PGN at 8h and 24h in NAA only (figure 5.13 E and F) but sample size was small.  No 
significant differences were observed between groups. 
No significant induction of IFN-β protein was observed at 24h post stimulation 
with PGN in any group (appendix A, figure A2, A). In NAA induction of IFN-λ1/IL-29 
protein was observed (appendix A, figure A2, B), but this failed to reach statistical 
significance with a small sample size.  No statistically significant differences were 
observed between groups. 
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Figure 5.13.  Interferon mRNA induction in HBECs post stimulation with PGN at 8h (A, C and E) and 
24h (B, D and F).  Squares denote NANA, circles denote ANA, downward triangles denote NAA, 
upward triangles denote AA; open shapes denote medium, black shapes denote PGN.  IFN-β (A and 
B), IFN-λ2,3/IL-28 (C and D), IFN-λ1/IL-29 (E and F).  Induction of IFN-β and IFN-λ2,3/IL-28 mRNA 
was not observed.  Non-significant induction of IFN-λ1/IL-29 mRNA was observed in NAA only.  No 
significant differences were observed between groups. 
 
Proinflammatory cytokines were measured in HBECs stimulated with PGN.  
Induction of IL-6 mRNA was not observed at 8h or 24h in any group (figure 5.14 A 
and B).  At 8h, non-significant induction of CXCL8/IL-8 mRNA was observed in NAA 
(figure 5.14 C).  Induction was not observed at 24h (figure 5.14 D).  No significant 
differences were observed between groups. 
At 24h following stimulation with PGN non-significant weak induction of IL-1β, 
IL-6, CXCL8/IL-8 and TNF-α protein was observed in NAA only (figure 5.15).  No 
differences were observed between the four volunteer groups. 
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Figure 5.14.  IL-6 and CXCL8/IL-8 mRNA induction in HBECs post stimulation with PGN at 8h (A and 
C) and 24h (B and D).  Squares denote NANA, circles denote ANA, downward triangles denote NAA, 
upward triangles denote AA; open shapes denote medium, black shapes denote PGN.  IL-6 (A and 
B), CXCL8/IL-8 (C and D).  Induction of IL-6 mRNA was not observed in any group.  At 8h a non-
significant induction of CXCL8/IL-8 mRNA was observed in the NAA group, with no induction in other 
groups or at 24h.  No significant differences were observed between groups. 
 
Figure 5.15.  Proinflammatory cytokine protein induction in HBECs post stimulation with PGN at 24h.  
Squares denote NANA, circles denote ANA, downward triangles denote NAA, upward triangles 
denote AA; open shapes denote medium, black shapes denote PGN.  IL-1β (A), IL-6 (B), CXCL8/IL-8 
(C), TNF-α (D). Non-significant weak induction of IL-1β, IL-6, CXCL8/IL-8 and TNF-α protein was 
observed in NAA.  Induction of proinflammatory cytokines was not observed in other groups.  There 
were no differences between groups. 
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5.2.2.4 Synthetic lipoprotein (FSL) 
Type I and III IFN and proinflammatory cytokine response to FSL was 
assessed in HBECs.  IFN-β and IFN-λ2,3/IL-28 mRNA was not induced by FSL at 8h 
or 24h (figure 5.16 A-D).  IFN-λ1/IL-29 mRNA was non-significantly induced by FSL 
at 8h in NAA only (figure 5.16 E).  No significant differences were observed between 
groups. 
No significant induction of IFN-β or IFN-λ1/IL-29 protein was observed at 24h 
post stimulation with FSL in any group (appendix A, figure A3).  No statistically 
significant differences were observed between groups. 
 
Figure 5.16.  Interferon mRNA induction in HBECs post stimulation with FSL at 8h (A, C and E) and 
24h (B, D and F).  Squares denote NANA, circles denote ANA, downward triangles denote NAA, 
upward triangles denote AA; open shapes denote medium, black shapes denote FSL.  IFN-β (A and 
B), IFN-λ2,3/IL-28 (C and D), IFN-λ1/IL-29 (E and F).  No induction of IFN-β or IFN-λ2,3/IL-28 mRNA 
was observed.  Non-significant induction of IFN-λ1/IL-29 mRNA was observed in NAA at 8h.  No 
significant differences were observed between groups. 
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Proinflammatory cytokines were measured in HBECs stimulated with FSL.  
Non-significant induction of IL-6 mRNA was observed at 8h in NANA, ANA and NAA 
and in ANA at 24h (figure 5.17 A and B).  At 8h, significant induction of CXCL8/IL-8 
mRNA was observed in NANA, ANA and AA (all p<0.05), with a non-significant 
increase observed in NAA (figure 5.17 C).  Induction was less marked at 24h (figure 
5.17 D).  No significant differences were observed between groups. 
At 24h following stimulation with FSL non-significant weak induction of IL-1β, 
IL-6 protein was observed in all groups (figure 5.18 A and B).  Induction of 
CXCL8/IL-8 protein was observed in all groups, with statistical significance reached 
in ANA (p<0.01) and AA (p<0.05) (figure 5.18 C).  TNF-α protein induction was 
observed in all groups with statistical significance reached in ANA only (p<0.05) 
(figure 5.18 D).  No differences were observed between the four volunteer groups. 
 
 
Figure 5.17.  IL-6 and CXCL8/IL-8 mRNA induction in HBECs post stimulation with FSL at 8h (A and 
C) and 24h (B and D).  Squares denote NANA, circles denote ANA, downward triangles denote NAA, 
upward triangles denote AA; open shapes denote medium, black shapes denote FSL; * = p<0.05, ns 
= non-significant.  IL-6 (A and B), CXCL8/IL-8 (C and D).  Non-significant induction of IL-6 mRNA was 
observed at 8h in NANA, ANA and NAA and in ANA at 24h.  Significant induction of CXCL8/IL-8 
mRNA was observed at 8h.  No significant differences were observed between groups. 
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Figure 5.18.  Proinflammatory cytokine protein induction in HBECs post stimulation with FSL at 24h.  
Squares denote NANA, circles denote ANA, downward triangles denote NAA, upward triangles 
denote AA; open shapes denote medium, black shapes denote FSL; * = p<0.05, ** = p<0.01, ns = 
non-significant.  IL-1β (A), IL-6 (B), CXCL8/IL-8 (C), TNF-α (D). Non-significant increases in induction 
of IL-1β and IL-6 protein were observed in all groups.  Significant induction of CXCL8/IL-8 protein was 
observed in ANA and AA, with non-significant increases observed in NANA and NAA.  Significant 
induction of TNF-α protein was observed in ANA, with non-significant increases in induction in other 
groups.  There were no differences between groups. 
 
5.2.3 TLR4 stimulation of HBECs: type I and III IFN and proinflammatory 
cytokine mRNA and protein induction 
 Macrophages from asthmatics stimulated ex vivo with the TLR4 ligand 
lipopolysaccharide (LPS) have been shown to have a deficient IFN-λ response and 
IFN-λ responses correlated with exacerbation severity in vivo 61.  In order to further 
investigate this type I and III IFN and proinflammatory cytokine expression was 
examined in HBECs in order to assess whether other cell types were involved and 
whether the asthmatic or atopic status of the volunteer had an impact.  Cells were 
stimulated with LPS and type I and III IFN and proinflammatory cytokines were 
measured; mRNA at 8h and 24h, and protein at 24h post stimulation. 
IFN-β and IFN-λ2,3/IL-28 mRNA was not induced by LPS at 8h or 24h (figure 
5.19 A-D).  IFN-λ1/IL-29 mRNA was non-significantly induced by LPS at 8h in NAA 
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only but induction at 24h was not observed (figure 5.19 E and F).  No significant 
differences were observed between groups. 
No significant induction of IFN-β or IFN-λ1/IL-29 protein was observed at 24h 
post stimulation with LPS in any group (appendix A, figure A4).  No differences were 
observed between groups. 
 
Figure 5.19.  Interferon mRNA induction in HBECs post stimulation with LPS at 8h (A, C and E) and 
24h (B, D and F).  Squares denote NANA, circles denote ANA, downward triangles denote NAA, 
upward triangles denote AA; open shapes denote medium, black shapes denote LPS.  IFN-β (A and 
B), IFN-λ2,3/IL-28 (C and D), IFN-λ1/IL-29 (E and F).  Induction of IFN-β and IFN-λ2,3/IL-28 mRNA 
was not observed. Weak, non-significant induction of IFN-λ1/IL-29 mRNA was observed at 8h in NAA 
only.  No differences were observed between groups. 
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Proinflammatory cytokines were measured in HBECs stimulated with LPS.  
Non-significant weak induction of IL-6 mRNA was observed at 8h in all groups, but 
not at 24h (figure 5.20 A and B).  At 8h, non-significant induction of CXCL8/IL-8 
mRNA was observed in all groups other than ANA (figure 5.20 C).  Induction was not 
observed at 24h (figure 5.20 D).  No significant differences were observed between 
groups. 
At 24h following stimulation with LPS non-significant weak induction of IL-1β, 
IL-6 and CXCL8/IL-8 protein was observed in NANA, ANA and NAA (figure 5.21).  
No differences were observed between the groups. 
 
 
Figure 5.20.  IL-6 and CXCL8/IL-8 mRNA induction in HBECs post stimulation with LPS at 8h (A and 
C) and 24h (B and D).  Squares denote NANA, circles denote ANA, downward triangles denote NAA, 
upward triangles denote AA; open shapes denote medium, black shapes denote LPS.  IL-6 (A and B), 
CXCL8/IL-8 (C and D).  Non-significant weak induction of IL-6 and CXCL8/IL-8 mRNA was observed 
at 8h in all groups.  No induction was observed at 24h.  No differences were observed between 
groups. 
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Figure 5.21.  Proinflammatory cytokine protein induction in HBECs post stimulation with LPS at 24h.  
Squares denote NANA, circles denote ANA, downward triangles denote NAA, upward triangles 
denote AA; open shapes denote medium, black shapes denote LPS.  IL-1β (A), IL-6 (B), CXCL8/IL-8 
(C), TNF-α (D). Non-significant weak induction of IL-1β, IL-6 and CXCL8/IL-8 protein was observed 
NANA, ANA and NAA.  There were no differences between groups. 
 
5.2.4 TLR5 stimulation of HBECs: type I and III IFN and proinflammatory 
cytokine mRNA and protein induction 
The type I and III IFN and proinflammatory cytokine response to the TLR5 
ligand, flagellin (FLA), was assessed in HBECs.  IFN-β mRNA was not induced by 
FLA at 8h or 24h (figure 5.22 A and B).  IFN-λ2,3/IL-28 and IFN-λ1/IL-29 mRNA was 
non-significantly weakly induced by FLA at 8h in NAA only albeit with a small sample 
size (figure 5.22 C and E).  Induction at 24h was not observed (figure 5.22 D and F).  
No significant differences were observed between groups. 
No significant induction of IFN-β or IFN-λ1/IL-29 protein was observed at 24h 
post stimulation with FLA in any group (appendix A, figure A5).  No differences were 
observed between groups. 
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Figure 5.22.  Interferon mRNA induction in HBECs post stimulation with FLA at 8h (A, C and E) and 
24h (B, D and F).  Squares denote NANA, circles denote ANA, downward triangles denote NAA, 
upward triangles denote AA; open shapes denote medium, black shapes denote FLA.  IFN-β (A and 
B), IFN-λ2,3/IL-28 (C and D), IFN-λ1/IL-29 (E and F).  Induction of IFN-β mRNA was not observed.  A 
weak non-significant induction of IFN-λ2,3/IL-28 and IFN-λ1/IL-29 mRNA was observed at 8h in NAA 
only with no induction in other groups or at 24h.  No differences were observed between groups. 
 As with the other TLR ligands proinflammatory cytokine mRNA and protein 
was measured in HBECs stimulated with FLA.  No significant induction of IL-6 mRNA 
was observed at 8h or 24h, though there was a suggestion of induction in NAA at 8h  
(figure 5.23 A and B).  More convincing induction of CXCL8/IL-8 mRNA was 
observed at 8h, though this failed to reach statistical significance (figure 5.23 C).  
Induction of CXCL8/IL-8 mRNA was not observed at 24h (figure 5.23 D).  No 
differences were observed between groups. 
 Proinflammatory cytokine protein was measured at 24h post stimulation with 
FLA.  Non-significant induction of IL-6 and CXCL8/IL-8 protein was observed in all 
groups (figure 5.24 B and C).  Induction of IL-1β and TNF-α was less convincing.  No 
differences were observed between groups. 
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Figure 5.23.  IL-6 and CXCL8/IL-8 mRNA induction in HBECs post stimulation with FLA at 8h (A and 
C) and 24h (B and D).  Squares denote NANA, circles denote ANA, downward triangles denote NAA, 
upward triangles denote AA; open shapes denote medium, black shapes denote FLA.  IL-6 (A and B), 
CXCL8/IL-8 (C and D).  No significant induction of IL-6 mRNA was observed.  Non-significant 
induction of CXCL8/IL-8 mRNA was observed at 8h and not 24h.  No differences were observed 
between groups. 
 
Figure 5.24.  Proinflammatory cytokine protein induction in HBECs post stimulation with FLA at 24h.  
Squares denote NANA, circles denote ANA, downward triangles denote NAA, upward triangles 
denote AA; open shapes denote medium, black shapes denote FLA.  IL-1β (A), IL-6 (B), CXCL8/IL-8 
(C), TNF-α (D). Non-significant induction of IL-6 and CXCL8/IL-8 protein was observed in all groups.  
There were no differences between groups. 
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5.2.5 TLR9 stimulation of HBECs: type I and III IFN and proinflammatory 
cytokine mRNA and protein induction 
 TLR9 has been shown to induce IFN via the MyD88 pathway 317.  This IFN 
signalling pathway may be of importance in IFN deficiency in asthma.  HBECs were 
stimulated with the TLR9 ligand CpG-C to assess whether type I and III IFNs and 
proinflammatory cytokines were expressed and whether the asthmatic and/or atopic 
status of the cells had any impact on expression.  
 No significant induction of type I or III IFN mRNA was observed in HBECs 
stimulated with CpG-C at 8h or 24h (appendix A, figure A6).  Similarly, no induction 
of type I or III protein was observed at 24h post stimulation (appendix A, figure A7). 
 Proinflammatory cytokines were measured in HBECs stimulated with CpG-C.  
No significant induction of IL-6 or CXCL8/IL-8 mRNA was observed in HBECs at 8h 
or 24h (appendix A, figure A8).  No increases in IL-1β, IL-6, CXCL8/IL-8 and TNF-α 
protein were observed (figure 5.25).  There was a non-significant reduction in 
CXCL8/IL-8 protein levels in NANA, ANA and AA (figure 5.25 C).  No significant 
differences were observed between the 4 volunteer groups. 
 
Figure 5.25.  Proinflammatory cytokine protein induction in HBECs post stimulation with CpG-C at 
24h.  Squares denote NANA, circles denote ANA, downward triangles denote NAA, upward triangles 
denote AA; open shapes denote medium, black shapes denote CpG-C.  IL-1β (A), IL-6 (B), CXCL8/IL-
8 (C), TNF-α (D).  Induction of IL-1β, IL-6, CXCL8/IL-8 and TNF-α protein was not observed in all 
groups.  Indeed a suggestion of lower levels of CXCL8/IL-8 in CpG-C treated cells compared to 
medium treated cells was observed in all groups other than NAA.  There were no differences between 
groups. 
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5.2.6 Summary of type I and III IFN and proinflammatory cytokine induction in 
HBECs stimulated with TLR1/2/4/5/6/9 ligands 
 
Tables 5.1 to 5.7 summarise the induction of type I and III IFNs and 
proinflammatory cytokines in HBECs stimulated with “bacterial” TLR ligands. 
 
Table 5.1 Summary of IFN and proinflammatory cytokine mRNA and protein induction post 
PAM stimulation in HBECs ↑ = significant induction, ns = non-significant increase observed, - = no 
induction, black squares = not performed 
 8h 24h 
 NANA ANA NAA AA NANA ANA NAA AA 
IFN-β mRNA - - - - - - - - 
IFN-β protein     - - - - 
IFNλ2,3/IL-28 mRNA - - - - ns ns - - 
IFNλ1/IL-29 mRNA - - ns - ns - - - 
IFNλ1/IL-29 protein     ns - - - 
IL-6 mRNA - - ns - - - - - 
CXCL8/IL-8 mRNA ↑ ns ns ns - - - - 
IL-1β protein     - - - - 
IL-6 protein     - - - - 
CXCL8/IL-8 protein     ns ns ns ns 
TNF-α protein     - - - - 
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Table 5.2 Summary of IFN and proinflammatory cytokine mRNA and protein induction post 
LTA stimulation in HBECs ns = non-significant increase observed, - = no induction, black squares = 
not performed 
 8h 24h 
 NANA ANA NAA AA NANA ANA NAA AA 
IFN-β mRNA - - - - - - - - 
IFN-β protein     - - - - 
IFNλ2,3/IL-28 mRNA - - ns - ns ns ns - 
IFNλ1/IL-29 mRNA - - ns - ns ns ns ns 
IFNλ1/IL-29 protein     - - - - 
IL-6 mRNA - - - - - - - - 
CXCL8/IL-8 mRNA ns ns ns ns - - - - 
IL-1β protein     ns ns ns ns 
IL-6 protein     ns ns ns - 
CXCL8/IL-8 protein     ns ns ns ns 
TNF-α protein     ns ns - - 
 
Table 5.3 Summary of IFN and proinflammatory cytokine mRNA and protein induction post 
PGN stimulation in HBECs ns = non-significant increase observed, - = no induction, black squares = 
not performed 
 8h 24h 
 NANA ANA NAA AA NANA ANA NAA AA 
IFN-β mRNA - - - - - - - - 
IFN-β protein     - - - - 
IFNλ2,3/IL-28 mRNA - - - - - - - - 
IFNλ1/IL-29 mRNA - - ns - - - ns - 
IFNλ1/IL-29 protein     - - ns - 
IL-6 mRNA - - - - - - - - 
CXCL8/IL-8 mRNA - - ns - - - - - 
IL-1β protein     - - ns - 
IL-6 protein     - - ns - 
CXCL8/IL-8 protein     - - ns - 
TNF-α protein     - - ns - 
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Table 5.4 Summary of IFN and proinflammatory cytokine mRNA and protein induction post 
FSL stimulation in HBECs ↑ = significant induction, ns = non-significant increase observed, - = no 
induction, black squares = not performed 
 8h 24h 
 NANA ANA NAA AA NANA ANA NAA AA 
IFN-β mRNA - - - - - - - - 
IFN-β protein     - - - - 
IFNλ2,3/IL-28 mRNA - - - - - - - - 
IFNλ1/IL-29 mRNA - - ns - - - - - 
IFNλ1/IL-29 protein     - - - - 
IL-6 mRNA ns ns ns - ns - - - 
CXCL8/IL-8 mRNA ↑ ↑ ns ↑ - - - - 
IL-1β protein     ns ns ns ns 
IL-6 protein     ns ns ns ns 
CXCL8/IL-8 protein     ns ↑ ns ↑ 
TNF-α protein     ns ↑ ns ns 
 
Table 5.5 Summary of IFN and proinflammatory cytokine mRNA and protein induction post 
LPS stimulation in HBECs ns = non-significant increase observed, - = no induction, black squares = 
not performed 
 8h 24h 
 NANA ANA NAA AA NANA ANA NAA AA 
IFN-β mRNA - - - - - - - - 
IFN-β protein     - - - - 
IFNλ2,3/IL-28 mRNA - - - - - - - - 
IFNλ1/IL-29 mRNA - - ns - - - - - 
IFNλ1/IL-29 protein     - - - - 
IL-6 mRNA ns ns ns ns - - - - 
CXCL8/IL-8 mRNA ns ns ns ns - - - - 
IL-1β protein     ns ns ns - 
IL-6 protein     ns ns ns - 
CXCL8/IL-8 protein     ns ns ns - 
TNF-α protein     - - - - 
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Table 5.6 Summary of IFN and proinflammatory cytokine mRNA and protein induction post 
FLA stimulation in HBECs ns = non-significant increase observed, - = no induction, black squares = 
not performed 
 8h 24h 
 NANA ANA NAA AA NANA ANA NAA AA 
IFN-β mRNA - - - - - - - - 
IFN-β protein     - - - - 
IFNλ2,3/IL-28 mRNA - - ns - - - - - 
IFNλ1/IL-29 mRNA - - ns - - - - - 
IFNλ1/IL-29 protein     - - - - 
IL-6 mRNA - - - - - - - - 
CXCL8/IL-8 mRNA ns ns ns ns - - - - 
IL-1β protein     - - - - 
IL-6 protein     ns ns ns ns 
CXCL8/IL-8 protein     ns ns ns ns 
TNF-α protein     - - - - 
 
Table 5.7 Summary of IFN and proinflammatory cytokine mRNA and protein induction post 
CpG stimulation in HBECs - = no induction, black squares = not performed 
 8h 24h 
 NANA ANA NAA AA NANA ANA NAA AA 
IFN-β mRNA - - - - - - - - 
IFN-β protein     - - - - 
IFNλ2,3/IL-28 mRNA - - - - - - - - 
IFNλ1/IL-29 mRNA - - - - - - - - 
IFNλ1/IL-29 protein     - - - - 
IL-6 mRNA - - - - - - - - 
CXCL8/IL-8 mRNA - - - - - - - - 
IL-1β protein     - - - - 
IL-6 protein     - - - - 
CXCL8/IL-8 protein     - - - - 
TNF-α protein     - - - - 
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5.2.7 TLR1, 2 and 6 stimulation of PBMCs: type I and III IFN and 
proinflammatory cytokine protein induction 
 As with other viral and bacterial stimuli, PBMCs were stimulated with 
“bacterial” TLR ligands to investigate whether type I and III IFNs were induced by 
these ligands, and to observe any differences between the atopic and asthmatic 
phenotype of volunteers’ samples.  As in the HBEC section above, results were 
grouped into the 4 groups of bacterial TLR.  Cells were stimulated with different TLR 
ligands and type I and III IFN and proinflammatory cytokine protein induction was 
measured at 24h and 48h post stimulation.  mRNA was not analysed due to time 
constraints of the project. 
 
5.2.7.1 Pam3CSK4 
 Type I and III IFNs were not significantly induced following stimulation with 
Pam3CSK4 (figure 5.26).  IFN-α2a was not induced (figure 5.26 A and B).  IFN-β 
protein induction was only observed in a small number of ANA, though this failed to 
reach statistical significance (figure 5.26 C and D).  IFN-λ1/IL-29 protein was induced 
in a small number of AA and NAA, but this was not significant (figure 5.26 E and F).  
No statistically significant differences were observed between the 4 volunteer 
groups. 
Marginal increases in proinflammatory cytokine protein induction were 
observed at 24h post stimulation of PBMCs with Pam3CSK4 (figure 5.27 A, C, E and 
G).  At 48h non-significant increases in IL-1β protein were observed in NANA, ANA 
and NAA (figure 5.27 B), in IL-6 protein in NANA, NAA and AA (figure 5.27 D), in 
CXCL8/IL-8 protein in NANA, ANA and NAA (figure 5.27 F) and in TNF-α protein in 
NANA and NAA (figure 5.27 H).  No significant differences were observed between 
the volunteer groups.  As non-significant trends for induction were observed at both 
24h and 48h all groups were combined in order to establish whether PBMCs 
stimulated with Pam3CSK4 had significant proinflammatory cytokine induction.  At 
24h significant increases in all proinflammatory cytokines was observed (figure 5.28 
A, C, E and G; p<0.001 for all).  No increase in IL-1β protein was observed at 48h 
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(figure 5.28 B).  Significant increases in IL-6 (p<0.01), CXCL8/IL-8 (p<0.01) and 
TNF-α (p<0.05) protein was observed in PBMCs at 48h (figure 5.28 D, F and H). 
 
 
Figure 5.26.  Interferon protein induction in PBMCs post stimulation with Pam3CSK4 at 24h (A, C and 
E) and 48h (B, D and F).  Squares denote NANA, circles denote ANA, downward triangles denote 
NAA, upward triangles denote AA; open shapes denote medium, black shapes denote Pam3CSK4.  
IFN-α2a (A and B), IFN-β (C and D), IFN-λ1/IL-29 (E and F). No significant IFN-α2a induction was 
observed.  No IFN-β protein induction was observed other than in a small number of ANA participants’ 
samples.  In a small number of NAA and AA participants’ samples IFN-λ1/IL-29 protein was observed, 
but this was non-significant. 
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Figure 5.27.  Proinflammatory cytokine protein induction in PBMCs post stimulation with Pam3CSK4 at 
24h (A, C, E and G) and 48h (B, D, F and H).  Squares denote NANA, circles denote ANA, downward 
triangles denote NAA, upward triangles denote AA; open shapes denote medium, black shapes 
denote Pam3CSK4.  IL-1β (A and B), IL-6 (C and D), CXCL8/IL-8 (E and F), TNF-α (G and H).  Non-
significant marginal increases were observed in proinflammatory cytokine protein induction at 24h.  At 
48h non-significant increases in all proinflammatory cytokines measured in varying groups was 
observed (see text).  No significant differences were observed between groups. 
 
100
101
102
103
104
NANA ANA NAA AA
IL
-1

 (
p
g
/m
L
)
100
101
102
103
104
NANA ANA NAA AA
IL
-1

 (
p
g
/m
L
)
102
103
104
105
NANA ANA NAA AA
IL
-6
 (
p
g
/m
L
)
101
102
103
104
105
NANA ANA NAA AA
IL
-6
 (
p
g
/m
L
)
102
103
104
105
NANA ANA NAA AA
C
X
C
L
8
/I
L
-8
 (
p
g
/m
L
)
103
104
105
NANA ANA NAA AA
C
X
C
L
8
/I
L
-8
 (
p
g
/m
L
)
102
103
104
105
NANA ANA NAA AA
T
N
F
- 
 (
p
g
/m
L
)
101
102
103
104
NANA ANA NAA AA
T
N
F
- 
 (
p
g
/m
L
)
A B
C D
E F
G H
24h 48h
204 
 
 
Figure 5.28.  Proinflammatory cytokine protein induction at 24h (A, C, E and G) and 48h (B, D, F and 
H) in PBMCs from all groups combined stimulated with Pam3CSK4.  IL-1β (A and B), IL-6 (C and D), 
CXCL8/IL-8 (E and F) and TNF-α (G and H).  Open squares denote medium (M); black squares 
denote Pam3CSK4; * = p<0.05, ** = p<0.01, *** = p<0.001, ns = non-significant.  Highly significant 
induction of all proinflammatory cytokines was observed at 24h in all groups combined.  No significant 
induction of IL-1β was observed at 48h.  Significant induction of IL-6, CXCL8/IL-8 and TNF-α protein 
induction was observed at 48h. 
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5.2.7.2 LTA 
 Type I and III IFNs were not significantly induced following stimulation with 
LTA (figure 5.29).  IFN-α2a was not induced (figure 5.29 A and B).  IFN-β protein 
induction was only observed at 24h in a small number of NAA and AA, though this 
failed to reach statistical significance (figure 5.29 C).  No induction was observed at 
48h (figure 5.29 D).  IFN-λ1/IL-29 protein was induced in a single AA volunteer at 
24h, but not in other groups or at 48h (figure 5.29 E and F).  No statistically 
significant differences were observed between groups. 
 Induction of all proinflammatory cytokine protein was observed in all groups at 
24h and 48h (figure 5.30).  At 24h significant induction of IL-1β and IL-6 was 
observed in ANA (p<0.05) and AA (p<0.001), with non-significant induction observed 
in NANA and NAA (figure 5.30 A and C).  Significant induction of CXCL8/IL-8 protein 
was observed in ANA (p<0.05) and AA (p<0.01), with non-significant induction 
observed in NANA and NAA (figure 5.30 E).   Significant induction of TNF-α protein 
was observed in AA only (p<0.001), with non-significant induction observed in other 
groups (figure 5.30 G).  At 48h trends towards induction of IL-1β, IL-6, CXCL8/IL-8 
and TNF-α protein were observed in all groups but these failed to reach statistical 
significance (figure 5.30 B, D, F and H).  Both at 24h and 48h no significant 
difference in proinflammatory cytokine induction was observed between groups.  As 
a result, in order to determine whether cytokine induction at 24h and 48h was 
significant, all groups were combined.  Highly significant induction of IL-1β, IL-6, 
CXCL8/IL-8 and TNF-α protein as observed in all groups combined at both 24h and 
48h (p<0.001 for all; figure 5.31). 
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Figure 5.29.  Interferon protein induction in PBMCs post stimulation with LTA at 24h (A, C and E) and 
48h (B, D and F).  Squares denote NANA, circles denote ANA, downward triangles denote NAA, 
upward triangles denote AA; open shapes denote medium, black shapes denote LTA.  IFN-α2a (A 
and B), IFN-β (C and D), IFN-λ1/IL-29 (E and F). No significant IFN-α2a induction was observed.  A 
non-significant weak increase in IFN-β protein induction was observed in NAA and AA at 24h but not 
at 48h.  In a single AA participant’s sample IFN-λ1/IL-29 protein at 24h was observed, but this was 
non-significant. 
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Figure 5.30.  Proinflammatory cytokine protein induction in PBMCs post stimulation with LTA at 24h 
(A, C, E and G) and 48h (B, D, F and H).  Squares denote NANA, circles denote ANA, downward 
triangles denote NAA, upward triangles denote AA; open shapes denote medium, black shapes 
denote LTA; * = p<0.05, ** = p<0.01, *** = p<0.001, ns = non-significant.  IL-1β (A and B), IL-6 (C and 
D), CXCL8/IL-8 (E and F), TNF-α (G and H).  Induction of all proinflammatory cytokines measured 
was observed in all groups at 24h, reaching statistical significance in ANA and AA for IL-1β, IL-6 and 
CXCL8/IL-8 and in AA for TNF-α, with non-significant increases in other groups.  At 48h increases 
were observed, but these failed to reach statistical significance.  No differences were observed 
between groups. 
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Figure 5.31.  Proinflammatory cytokine protein induction at 24h (A, C, E and G) and 48h (B, D, F and 
H) in PBMCs from all groups combined stimulated with LTA.  IL-1β (A and B), IL-6 (C and D), 
CXCL8/IL-8 (E and F) and TNF-α (G and H).  Open squares denote medium (M); black squares 
denote LTA; *** = p<0.001.  Significant increases in all proinflammatory cytokines measured were 
observed in PBMCs at both 24h and 48h from all groups combined. 
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5.2.7.3 PGN 
 As with Pam3CSK4 and LTA, type I and III IFN and proinflammatory cytokine 
protein was measured in PBMCs stimulated with PGN.  No induction of IFN-α2a was 
observed at 24h or 48h post stimulation (figure 5.32 A and B).  A non-significant 
increase in IFN-β protein induction was observed in ANA and AA at 24h, but not at 
48h other than in a single ANA participant’s sample (figure 5.32 C and D).  A non-
significant trend for induction of IFN-λ/IL-29 was observed in NAA at 48h (figure 5.32 
E and F).  No significant difference was observed between groups. 
Induction of proinflammatory cytokine protein was observed in all groups, 
reaching statistical significance at 24h in AA with IL-1β (p<0.01), IL-6 (p<0.01), 
CXCL8/IL-8 (p<0.05) and TNF-α (p<0.01) and non-significant trends in all other 
groups (figure 5.33 A, C, E and G).  No statistically significant differences were 
observed between groups.  At 48h trends for an increase in induction were observed 
in all groups but these failed to reach statistical significance (figure 5.33 B, D, F and 
H).  As no differences were observed between groups and as there was a small 
sample size of samples obtained at 48h, in order to observe whether PGN stimulated 
PBMCs induced significant amounts of proinflammatory cytokines at 48h, all groups 
were combined.  Likewise all groups were combined at 24h.  Significant amounts of 
proinflammatory cytokines was observed at 24h and 48h with all groups combined 
(p<0.001 for all at 24h; p<0.01 for all at 48h, figure 5.34). 
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Figure 5.32.  Interferon protein induction in PBMCs post stimulation with PGN at 24h (A, C and E) and 
48h (B, D and F).  Squares denote NANA, circles denote ANA, downward triangles denote NAA, 
upward triangles denote AA; open shapes denote medium, black shapes denote PGN.  IFN-α2a (A 
and B), IFN-β (C and D), IFN-λ1/IL-29 (E and F). No significant IFN-α2a induction was observed.  A 
non-significant increase in IFN-β protein induction was observed in ANA and AA at 24h, but not at 48h 
other than in a single ANA participant’s sample.  A non-significant increase in IFN-λ1/IL-29 protein 
induction was observed in NAA at 48h 
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Figure 5.33.  Proinflammatory cytokine protein induction in PBMCs post stimulation with PGN at 24h 
(A, C, E and G) and 48h (B, D, F and H).  Squares denote NANA, circles denote ANA, downward 
triangles denote NAA, upward triangles denote AA; open shapes denote medium, black shapes 
denote PGN; * = p<0.05, ** = p<0.01, ns = non-significant.  IL-1β (A and B), IL-6 (C and D), 
CXCL8/IL-8 (E and F), TNF-α (G and H).  Increases in proinflammatory cytokine protein were 
observed in all groups at 24h, reaching statistical significance in AA.  Increases were also observed at 
48h, but this failed to reach statistical significance.  No differences were observed between volunteer 
groups at both time points. 
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Figure 5.34.  Proinflammatory cytokine protein induction at 24h (A, C, E and G) and 48h (B, D, F and 
H) in PBMCs from all groups combined stimulated with PGN.  IL-1β (A and B), IL-6 (C and D), 
CXCL8/IL-8 (E and F) and TNF-α (G and H).  Open squares denote medium (M); black squares 
denote PGN; ** = p<0.01, *** = p<0.001.  Significant induction of all proinflammatory cytokines was 
observed in all groups combined. 
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5.2.7.4 FSL 
 The final TLR 2/6 ligand to be examined in PBMCs was FSL.  As with the 
other ligands, type I and III IFN and proinflammatory cytokine protein was measured 
at 24h and 48h.  Induction of IFN-α2a was not observed (figure 5.35 A and B).  A 
non-significant trend for induction of IFN-β protein was observed in ANA and AA at 
24h only (figure 5.35 C).  An increased induction of IFN-λ1/IL-29 protein was 
observed in single volunteers in the NAA and AA groups at 48h (figure 5.35 F).  No 
significant difference was observed between groups. 
 No significant induction of proinflammatory cytokine protein was observed in 
PBMCs at 24h post stimulation with FSL (figure 5.36 A, C, E and G).  A trend for 
induction of TNF-α was observed in ANA only (figure 5.36 G).  At 48h trends for 
induction of proinflammatory cytokines was observed in NANA, ANA and NAA, with 
less obvious induction in AA (figure 5.36 B, D, F and H).  These failed to reach 
statistical significance.  No differences were observed between groups.  As no 
differences were observed between groups, as with the other ligands, all groups 
were combined at 24h and 48h, in order to observe whether FSL stimulated PBMCs 
induced significant amounts of proinflammatory cytokines.  Significant amounts of IL-
1β (p<0.01 at 24h; non-significant at 48h), IL-6 (p<0.001 for 24h; p<0.05 for 48h), 
CXCL8/IL-8 (p<0.01 at both 24h and 48h) and TNF-α (p<0.01 at 24h; p<0.05 at 48h) 
was observed with all groups combined (figure 5.37). 
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Figure 5.35.  Interferon protein induction in PBMCs post stimulation with FSL at 24h (A, C and E) and 
48h (B, D and F).  Squares denote NANA, circles denote ANA, downward triangles denote NAA, 
upward triangles denote AA; open shapes denote medium, black shapes denote FSL.  IFN-α2a (A 
and B), IFN-β (C and D), IFN-λ1/IL-29 (E and F). No significant IFN-α2a induction was observed.  A 
non-significant trend in IFN-β protein induction was observed in ANA and AA at 24h, but not at 48h.  
An increase in IFN-λ1/IL-29 protein induction was observed in a single volunteer in the NAA and AA 
groups at 48h. 
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Figure 5.36.  Proinflammatory cytokine protein induction in PBMCs post stimulation with FSL at 24h 
(A, C, E and G) and 48h (B, D, F and H).  Squares denote NANA, circles denote ANA, downward 
triangles denote NAA, upward triangles denote AA; open shapes denote medium, black shapes 
denote FSL.  IL-1β (A and B), IL-6 (C and D), CXCL8/IL-8 (E and F), TNF-α (G and H).  No induction 
of proinflammatory cytokines was observed at 24h.  A trend for induction of TNF-α in ANA was 
observed.  At 48h, trends for induction were observed in NANA, ANA and NAA. 
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Figure 5.37.  Proinflammatory cytokine protein induction at 24h (A, C, E and G) and 48h (B, D, F and 
H) in PBMCs from all groups combined stimulated with FSL.  IL-1β (A and B), IL-6 (C and D), 
CXCL8/IL-8 (E and F) and TNF-α (G and H).  Open squares denote medium (M); black squares 
denote FSL; * = p<0.05, ** = p<0.01, *** = p<0.001, ns = non-significant.  Significant amounts of IL-6, 
CXCL8/IL-8 and TNF-α were observed.  Induction of IL-1β was observed at 24h and not 48h. 
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5.2.8 TLR 4 stimulation of PBMCs: type I and III IFN and proinflammatory 
cytokine protein induction 
 PBMCs were stimulated with the TLR 4 ligand LPS and induction of type I and 
III IFN and proinflammatory cytokine protein was assessed at 24h and 48h post 
stimulation.  Induction of IFN-α2a was not observed (figure 5.38 A and B).  A trend 
for induction of IFN-β was observed at 24h in NAA and AA, but this was not 
statistically significant (figure 5.38 C).  No induction was observed at 48h (figure 5.38 
D).  Induction of IFN-λ1/IL-29 was not observed other than in single NAA and AA 
participants’ samples at 48h (figure 5.38 E and F).  No significant differences were 
observed between the 4 volunteer groups. 
 In order to establish whether stimulation of PBMCs with LPS resulted in 
induction of proinflammatory cytokines, cell supernatants were assessed for cytokine 
protein and 24h and 48h.  At 24h induction of IL-1β, IL-6, CXCL8/IL-8 and TNF-α 
was observed, reaching statistical significance in ANA and AA and with trends for 
induction observed in NANA and NAA (figure 5.39 A, C, E and G).  Non-significant 
trends for induction of proinflammatory cytokine protein were observed at 48h (figure 
5.39 B, D, F and H).  No significant differences were observed between groups at 
24h or 48h.  As with the other TLR ligands examined, as no significant difference 
had been identified between volunteer groups, all the groups were combined.  Highly 
significant induction of IL-1β, IL-6, CXCL8/IL-8 and TNF-α protein were observed at 
both 24h and 48h post LPS-stimulation of PBMCs in all groups combined (all 
p<0.001, figure 5.40). 
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Figure 5.38.  Interferon protein induction in PBMCs post stimulation with LPS at 24h (A, C and E) and 
48h (B, D and F).  Squares denote NANA, circles denote ANA, downward triangles denote NAA, 
upward triangles denote AA; open shapes denote medium, black shapes denote LPS.  IFN-α2a (A 
and B), IFN-β (C and D), IFN-λ1/IL-29 (E and F). No significant IFN-α2a induction was observed.  A 
non-significant trend in IFN-β protein induction was observed in NAA and AA at 24h, but not at 48h.  
In a single NAA and AA participants’ samples IFN-λ1/IL-29 protein was observed at 48h, but this was 
non-significant.  No significant differences were observed between groups. 
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Figure 5.39.  Proinflammatory cytokine protein induction in PBMCs post stimulation with LPS at 24h 
(A, C, E and G) and 48h (B, D, F and H).  Squares denote NANA, circles denote ANA, downward 
triangles denote NAA, upward triangles denote AA; open shapes denote medium, black shapes 
denote LPS; * = p<0.05, ** = p<0.01, *** = p<0.001, ns = non-significant.  IL-1β (A and B), IL-6 (C and 
D), CXCL8/IL-8 (E and F), TNF-α (G and H).  At 24h induction of all proinflammatory cytokines was 
observed, reaching statistical significance in ANA and AA.  At 48h, non-significant trends for induction 
were observed.  No significant differences were observed between groups. 
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Figure 5.40.  Proinflammatory cytokine protein induction at 24h (A, C, E and G) and 48h (B, D, F and 
H) in PBMCs from all groups combined stimulated with LPS.  IL-1β (A and B), IL-6 (C and D), 
CXCL8/IL-8 (E and F) and TNF-α (G and H).  Open squares denote medium (M); black squares 
denote LPS; *** = p<0.001.  Highly significant induction of all proinflammatory cytokine protein was 
observed in all groups combined at both 24h and 48h. 
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5.2.9 TLR 5 stimulation of PBMCs: type I and III IFN and proinflammatory 
cytokine protein induction 
 Induction of type I and III IFN and proinflammatory cytokine protein was 
examined in PBMC supernatants stimulated with FLA.  No significant induction of 
type I or III IFNs was observed at 24h or 48h (appendix A, figure A9).  In 2 separate 
AA volunteers induction of IFN-β protein at 24h and IFN-λ1/IL-29 protein at 48h was 
observed (appendix A, figure A9, C and F). 
 Proinflammatory cytokine induction was observed at 24h and 48h, reaching 
statistical significance in AA at 24h, with non-significant trends in other groups.  At 
48h, trends for induction were observed but, due to the small sample size, statistical 
significance was not reached (figure 5.41).  No significant differences were observed 
between groups.  Groups were combined to assess whether statistically significant 
induction at 24h and 48h was observed.  At 24h significant induction of all 
proinflammatory cytokines was observed (p<0.001 for all).  At 48h induction of IL-1β 
(p<0.05), IL-6 (p<0.001), CXCL8/IL-8 (p<0.01) and TNF-α (p<0.01) protein was 
observed in PBMCs stimulated with FLA (figure 5.42). 
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Figure 5.41.  Proinflammatory cytokine protein induction in PBMCs post stimulation with FLA at 24h 
(A, C, E and G) and 48h (B, D, F and H).  Squares denote NANA, circles denote ANA, downward 
triangles denote NAA, upward triangles denote AA; open shapes denote medium, black shapes 
denote FLA; * = p<0.05, ** = p<0.01, ns = non-significant.  IL-1β (A and B), IL-6 (C and D), CXCL8/IL-
8 (E and F), TNF-α (G and H).  In AA significant induction of all proinflammatory cytokines was 
observed at 24h, with non-significant increases observed in other groups.  At 48h trends for increased 
induction was observed, but these failed to reach statistical significance.  No differences were 
observed between groups. 
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Figure 5.42.  Proinflammatory cytokine protein induction at 24h (A, C, E and G) and 48h (B, D, F and 
H) in PBMCs from all groups combined stimulated with FLA.  IL-1β (A and B), IL-6 (C and D), 
CXCL8/IL-8 (E and F) and TNF-α (G and H).  Open squares denote medium (M); black squares 
denote FLA; * = p<0.05, ** = p<0.01, *** = p<0.001.  Significant induction of all proinflammatory 
cytokine protein was observed in all groups combined at 24h and 48h. 
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5.2.10 TLR 9 stimulation of PBMCs: type I and III IFN and proinflammatory 
cytokine protein induction 
 PBMCs were stimulated with the TLR 9 ligand CpG-C and induction of type I 
and III IFN and proinflammatory cytokine protein was assessed at 24h and 48h post 
stimulation.  Type I and III IFNs were not significantly induced following stimulation 
with CpG-C (appendix A, figure A10).  No statistically significant differences were 
observed between the 4 volunteer groups. 
 Proinflammatory cytokine induction from PBMCs stimulated with CpG-C was 
assessed at 24h and 48h.  In AA, at 24h, significant induction of IL-1β (p<0.05), IL-6 
(p<0.05), CXCL8/IL-8 (p<0.01) and TNF-α (p<0.05) protein was observed.  Non-
significant trends in induction were observed in other groups (figure 5.43 A, C, E and 
G).  No significant differences were observed between groups.  At 48h, induction of 
IL-1β protein was not observed, and weak non-significant trends in induction of IL-6, 
CXCL8/IL-8 and TNF-α protein were observed (figure 5.43 B, D, F and H).  No 
significant difference was observed between groups.  All samples were combined to 
assess whether significant induction of proinflammatory cytokine protein occurred at 
24h and 48h.  At 24h significant induction of all proinflammatory cytokines was 
observed in PBMCs stimulated with CpG-C (p<0.001, figure 5.44 A, C, E and G).  At 
48h only induction of CXCL8/IL-8 protein reached statistical significance (p<0.05, 
figure 5.44 F). 
 
 
225 
 
 
Figure 5.43.  Proinflammatory cytokine protein induction in PBMCs post stimulation with CpG-C at 
24h (A, C, E and G) and 48h (B, D, F and H).  Squares denote NANA, circles denote ANA, downward 
triangles denote NAA, upward triangles denote AA; open shapes denote medium, black shapes 
denote CpG-C; * = p<0.05, ** = p<0.01, ns = non-significant.  IL-1β (A and B), IL-6 (C and D), 
CXCL8/IL-8 (E and F), TNF-α (G and H).  At 24h, significant induction of proinflammatory cytokine 
protein was observed in AA, with non-significant trends observed in other groups.  At 48h, induction of 
IL-1β was not observed.  Only non-significant weak trends in the other cytokines were observed at 
48h.  No significant differences were observed between groups. 
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Figure 5.44.  Proinflammatory cytokine protein induction at 24h (A, C, E and G) and 48h (B, D, F and 
H) in PBMCs from all groups combined stimulated with CpG-C.  IL-1β (A and B), IL-6 (C and D), 
CXCL8/IL-8 (E and F) and TNF-α (G and H).  Open squares denote medium (M); black squares 
denote CpG-C; * = p<0.05, *** = p<0.001, ns = non-significant.  In all groups combined, significant 
induction of all cytokines was observed at 24h.  At 48h significant induction of CXCL8/IL-8 protein was 
observed.  Other proinflammatory cytokine protein induction was not observed. 
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5.2.11 Summary of type I and III IFN and proinflammatory cytokine induction in 
PBMCs stimulated with TLR1/2/4/5/6/9 ligands 
 
 Tables 5.8 to 5.14 summarise the induction of type I and III IFNs and 
proinflammatory cytokines in PBMCs stimulated with “bacterial” TLR ligands. 
 
Table 5.8 Summary of IFN and proinflammatory cytokine protein induction post PAM 
stimulation in PBMCs ns = non-significant increase observed, - = no induction 
 24h 48h 
 NANA ANA NAA AA NANA ANA NAA AA 
IFN-α2a - - - - - - - - 
IFN-β - - - - - - - - 
IFNλ1/IL-29 - - - - - - - - 
IL-1β ns ns ns ns ns ns ns - 
IL-6 ns ns ns - ns ns ns ns 
CXCL8/IL-8 ns ns ns ns ns ns ns - 
TNF-α - ns - ns ns ns ns - 
 
Table 5.9 Summary of IFN and proinflammatory cytokine protein induction post LTA 
stimulation in PBMCs ↑ = significant induction, ns = non-significant increase observed, - = no 
induction 
 24h 48h 
 NANA ANA NAA AA NANA ANA NAA AA 
IFN-α2a - - - - - - - - 
IFN-β - - - - - - - - 
IFNλ1/IL-29 - - - - - - - - 
IL-1β ns ↑ ns ↑ ns ns ns ns 
IL-6 ns ↑ ns ↑ ns ns ns ns 
CXCL8/IL-8 ns ↑ ns ↑ ns ns ns - 
TNF-α ns ns ns ↑ ns ns ns ns 
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Table 5.10 Summary of IFN and proinflammatory cytokine protein induction post PGN 
stimulation in PBMCs ↑ = significant induction, ns = non-significant increase observed, - = no 
induction 
 24h 48h 
 NANA ANA NAA AA NANA ANA NAA AA 
IFN-α2a - - - - - - - - 
IFN-β - ns - ns - - - - 
IFNλ1/IL-29 - - - - - - ns - 
IL-1β ns ns ns ↑ ns ns ns ns 
IL-6 ns ns ns ↑ ns ns ns ns 
CXCL8/IL-8 ns ns ns ↑ ns ns ns ns 
TNF-α ns ns ns ↑ ns ns ns ns 
 
Table 5.11 Summary of IFN and proinflammatory cytokine protein induction post FSL 
stimulation in PBMCs ns = non-significant increase observed, - = no induction 
 24h 48h 
 NANA ANA NAA AA NANA ANA NAA AA 
IFN-α2a - - - - - - - - 
IFN-β - ns - ns - - - - 
IFNλ1/IL-29 - - - - - - ns - 
IL-1β - ns - - - ns ns - 
IL-6 - ns - - ns ns ns - 
CXCL8/IL-8 - ns - ns ns ns ns - 
TNF-α - ns - ns ns ns ns - 
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Table 5.12 Summary of IFN and proinflammatory cytokine protein induction post LPS 
stimulation in PBMCs ↑ = significant induction, ns = non-significant increase observed, - = no 
induction 
 24h 48h 
 NANA ANA NAA AA NANA ANA NAA AA 
IFN-α2a - - - - - - - - 
IFN-β - - ns ns - - - - 
IFNλ1/IL-29 - - - - - - - - 
IL-1β ns ↑ ns ↑ ns ns ns ns 
IL-6 ns ↑ ns ↑ ns ns ns ns 
CXCL8/IL-8 ns ↑ ns ↑ ns ns ns ns 
TNF-α ns ↑ ns ↑ ns ns ns ns 
 
Table 5.13 Summary of IFN and proinflammatory cytokine protein induction post FLA 
stimulation in PBMCs ↑ = significant induction, ns = non-significant increase observed, - = no 
induction 
 24h 48h 
 NANA ANA NAA AA NANA ANA NAA AA 
IFN-α2a - - - - - - - - 
IFN-β - - - - - - - - 
IFNλ1/IL-29 - - - - - - - - 
IL-1β ns ns ns ↑ ns ns ns ns 
IL-6 ns ns ns ↑ ns ns ns ns 
CXCL8/IL-8 ns ns ns ↑ ns ns ns ns 
TNF-α ns ns ns ↑ ns ns ns ns 
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Table 5.14 Summary of IFN and proinflammatory cytokine protein induction post CpG 
stimulation in PBMCs ↑ = significant induction, ns = non-significant increase observed, - = no 
induction 
 24h 48h 
 NANA ANA NAA AA NANA ANA NAA AA 
IFN-α2a - - - - - - - - 
IFN-β - - - - - - - - 
IFNλ1/IL-29 - - - - - - - - 
IL-1β ns ns ns ↑ - ns ns - 
IL-6 ns ns ns ↑ - ns ns - 
CXCL8/IL-8 ns ns ns ↑ - ns ns - 
TNF-α ns ns ns ↑ - ns ns ns 
 
 
5.3 Discussion 
 
 In order to investigate IFN signalling in response to bacterial infection, 
responses of TLRs which recognise bacterial products were examined in HBECs 
and PBMCs.  These “bacterial” ligands to TLR1, 2, 4, 5, 6 and 9 were used to 
stimulate cells from asthmatics and non-asthmatics, atopics and non-atopics and 
responses of type I and III IFN and proinflammatory cytokines important in host 
defence against bacterial infections were assessed. 
 
5.3.1 TLR1, 2 and 6 stimulation 
 In HBECs no induction of type I IFN mRNA or protein was observed in any 
group.  For each of the ligands stimulating TLR1, 2 and 6 a trend for induction of 
type III IFN was observed (see tables 5.1 to 5.4), but no particular pattern in the 
different groups was observed, suggesting the asthmatic or atopic nature of the cells 
made little difference to the induction pattern.  This is the first study to suggest type 
III IFN induction in HBECs in response to these TLR ligands, though induction failed 
to reach statistical significance.  Proinflammatory cytokine mRNA and protein was 
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observed with Pam, LTA and FSL, reaching significance in certain groups (see 
tables 5.1 to 5.4).  No significant difference was observed between asthmatics or 
control groups.  Previous studies have only observed weak proinflammatory 
responses to TLR2 stimulation in airway epithelial cells 317. 
Non-significant induction of IFN-β protein was observed in PBMCs from AA 
and ANA at 24h following simulation with the TLR2/6 ligands peptidoglycan and 
lipoprotein.  Type I and III IFNs were not induced at any other time point or by 
TLR1/2 ligand Pam3CSK4 or the TLR2/6 ligand LTA.  Induction of proinflammatory 
cytokines was observed in PBMCs stimulated with LTA and PGN at 24h and 48h, 
and with Pam at 48h in NANA and NAA, and FSL at 24h in ANA and 48h in NANA 
and NAA (see tables 5.1 to 5.4).  No significant difference was observed between 
asthmatics or control groups.  Expression of TLR1, 2 and 6 on PBMCs has been 
identified previously as significantly reduced in asthmatics compared to non-
asthmatics 335.  Although TLR expression was not examined in this chapter, no 
difference in TLR function was identified between asthmatics and non-asthmatics.  
Previous studies have not reported TLR2 as an inducer of type I IFNs although in 
recognising viral TLR2 ligands (several DNA viruses, including vaccinia, 
cytomegalovirus and herpes simplex virus) and not bacterial TLR ligands, induction 
of type I IFN has been reported 259.  In contrast to this, TLR2 signalling has been 
identified as inhibitory to type I IFN induction by TLR9 336.  LTA has previously been 
reported not to be critical in TNF-α release from PBMCs in that no difference was 
observed in TNF-α induction from PBMCs incubated with LTA-rich or LTA-free wall 
fragments from Spn 337.  The increases in proinflammatory cytokines following 
stimulation with these TLR ligands and only weak data to suggest type III IFN 
induction in HBECs would suggest that TLR1, 2 and 6 signalling in HBECs and 
PBMCs is more important for the induction of proinflammatory cytokines than IFNs.  
Several other anti-bacterial cytokines could also be involved in host defence against 
bacteria, particularly IFN-γ.  This has a role in anti-bacterial immunity, though it 
appears to be microbe-specific 322.  Due to time and financial constraints of the 
project and the multiplex used not having IFN-γ as a cytokine to measure, the 
production of IFN-γ was not analysed.  IFN-γ responses to rhinovirus infection are 
deficient in atopic asthmatics 78.  As part of future work, induction of IFN-γ could be 
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analysed from cells stimulated with bacterial ligands to determine whether IFN-γ 
responses to bacterial infection are deficient in asthma.   
5.3.2 TLR4 stimulation 
 Induction of type I and III IFN mRNA and protein was not observed in HBECs 
stimulated with LPS.  Non-significant increases in proinflammatory cytokines was 
observed in all groups other than AA, which suggests confirmation of previous 
reports of cytokine induction from HBECs in response to LPS 338.  No significant type 
I or III IFN protein was induced from PBMCs stimulated with LPS.  A trend for 
induction of IFN-β was observed in asthmatics, but this was not significant.  This 
would suggest that PBMCs are not a major source of IFNs and the previously 
observed IFN deficiency in HBECs 60, 61 does not extend to PBMCs stimulated with 
LPS.  Other investigators have found airway epithelial cells unresponsive to LPS 339 
unless infected with RSV which leads to TLR4 upregulation 340.  Induction of 
proinflammatory cytokines in PBMCs was observed in all groups, reaching 
significance at 24h in ANA and AA.  No difference was observed between groups.  
Previous studies have found that LPS stimulated TNF-α induction from PBMCs is 
higher in mild-moderate than in severe asthmatics 341, which differs from other 
studies suggesting reduced TLR4 responses in asthma 330 and decreased induction 
of TNF-α and IL-1β from PBMCs stimulated with LPS in asthma 335.   
 To link the earlier investigation of Spn and IFN induction, pneumolysin, which 
is recognised by TLR4 and is a virulence factor for Spn, could be examined in a 
further study of HBECs and PBMCs in asthmatics. 
  
5.3.3 TLR5 stimulation 
 No significant induction of type I or III mRNA or protein was observed in 
HBECs stimulated with the TLR ligand flagellin.  A non-significant increase in type III 
mRNA was observed in NAA only, but sample size was small.  No induction of type I 
or III IFN protein was observed in PBMCs, suggesting TLR5 is not important in IFN 
induction in these cell types.  This differs from a previous study suggesting TLR5 
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stimulation of mouse bone marrow derived macrophages results in IFN-β induction 
268.   
A non-significant increase in CXCL8/IL-8 mRNA at 8h and IL-6 and CXCL8/IL-
8 protein at 24h was observed in HBECs, with no differences between groups.  
Increases in induction of proinflammatory cytokines was observed in PBMCs 
stimulated with flagellin, with significance obtained in AA.  No differences however 
were observed between groups.  This differs from the study which showed 
decreased ex-vivo induction of IL-1β, IL-10 and TNF-α from asthmatic PBMCs 
stimulated with flagellin 335.  The finding that TLR5 appears to lead to the induction of 
proinflammatory cytokines suggests the role of TLR5 lies more in anti-bacterial 
immunity than in IFN induction. 
 
5.3.4 TLR9 stimulation 
 The TLR9 ligand CpG-C did not induce type I or III IFN mRNA or protein in 
HBECs or PBMCs.  This would suggest TLR9 is not important in IFN induction, 
however studies have identified TLR9 as an important receptor mediating the 
induction of type I IFNs in mouse dendritic cells in response to bacterial infection 342.  
Recently, IFN-α induction in human PBMCs stimulated with TLR9 ligands has been 
observed 343 and TLR9 has been shown to be a strong inducer of IFN-β in mice in 
vivo 344, findings not supported by this study. 
 No increases in proinflammatory cytokine mRNA or protein were observed in 
HBECs.  Increases in proinflammatory cytokine protein were observed in PBMCs 
from all groups at 24h, with significance in AA, and a non-significant increase 
observed at 48h in NAA only.  This increase in proinflammatory cytokines and not 
type I and III IFNs suggests that, in PBMCs, TLR9 has more of a role in anti-bacterial 
immunity than in IFN induction.  No differences were observed between groups, 
suggesting the asthmatic or atopic status of the subjects’ cell type is of no 
importance. 
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5.4 Conclusions 
 This is the first report of type I and III IFN and proinflammatory cytokine 
responses to TLR1, 2, 6, 4, 5 and 9 stimulation in HBECs and PBMCs from AA, 
NAA, ANA and NANA and aimed to determine whether differences were observed 
between asthmatics and/or atopics.  Although induction of type I IFN was not 
observed in any cell type, non-significant induction of type III IFN was observed in 
HBECs, but not PBMCs.  Proinflammatory cytokines were induced, particularly in 
PBMCs, suggesting these TLRs have a role in anti-bacterial immunity and less of a 
role in IFN induction.  No differences were observed between AA, NAA, ANA or 
NANA.  The study hypothesis must therefore be rejected. 
 
5.5 Summary 
 This chapter investigated the type I and III IFN and proinflammatory cytokine 
responses to TLR1, 2, 6, 4, 5 and 9 stimulation in HBECs and PBMCs in AA, NAA, 
ANA and NANA.  HBECs responded to TLR1, 2, 6, 4 and 5 stimulation with largely 
non-significant increases in proinflammatory cytokines, but only limited data to 
support type III IFN induction.  PBMCs responded to TLR2, 6, 4, 5 and 9 stimulation 
with no induction of type I or III IFNs, but both significant and non-significant 
increases in proinflammatory cytokine protein.  No differences were observed 
between asthmatics or non-asthmatics, atopics or non-atopics. 
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Chapter 6: Discussion 
 
6.1 Key study findings 
6.1.1 RV16 induced type I and III IFN in BAL cells, whereas RV1B only induced 
type III IFN, but no deficiency was identified in asthmatics 
 The lack of deficiency identified in this study differs from that of another study 
where type I IFN induction in BAL cells was reduced in AA compared to NANA 208.  
The differences between the two studies may be a result of this study having a group 
of less severe asthmatics.  Whilst it would have been preferable to assess this earlier 
in the study, the nature of the project was such that data was only analysed at the 
end of the study period; an inherent flaw in the study design.  The observed lack of 
type III IFN deficiency as seen in another study at 48h post infection 61 may also 
have been due to only an 8h time point being used in the present study, due to the 
limited number of cells obtained at bronchoscopy.  The aim had been to perform 
both an 8h and 24h time point as these time points had revealed significant data in 
other work within the department and subsequent published work 208, though as 
there were a limited number of cells obtained, only an 8h time point was analysed.  It 
could be argued that a 24h time point would have revealed more pertinent results, in 
that the viral replication studies in HBECs demonstrated peak RV release at 24h with 
RV16 and 48h with RV1B. 
  
6.1.2 IFN induction in HBECs differed for major and minor group RVs, but no 
difference was observed between asthmatics and non-asthmatics 
 RV16 infection resulted in both type I and III IFN protein being induced at 48h, 
but RV1B infection only induced type I IFN protein.  The lack of IFN deficiency in 
HBECs identified in this study may not be surprising given that no deficiency was 
observed in BAL cells and the conclusion that asthmatics had a milder form of the 
disease.  It may be that the previously observed IFN deficiency 60, 61 is due to that 
being found in a subgroup of asthmatics and possibly related to disease severity.  It 
should be noted that absolute levels of IFN-β differed in this study compared to 
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original reports of defective RV-induced IFN (up to 500pg/mL compared to levels up 
to 1900pg/mL 60).  This is consistent with other studies that have shown lower levels 
of RV16-induced IFN-β protein than the original Wark et al. report.  A number of 
studies, published recently and long after this study was designed, have identified 
relationships between IFN deficiency and markers of severity.  Sykes et al. identified 
deficient type I IFN production from BAL cells and this was inversely proportional to 
airway hyperresponsiveness and skin prick test positivity 208.  Gill et al. identified 
deficient IFN-α from plasmacytoid dendritic cells in atopic asthmatics and that 
secretion was inversely correlated with serum IgE levels, suggesting the severity of 
atopy may be important 205.  Baraldo et al. identified deficient RV-induced IFN 
responses in asthmatic children irrespective of their atopic status and in atopic non-
asthmatic children, suggesting these deficiencies are not limited to asthma alone 209.  
These findings would certainly support the hypothesis that IFN deficiencies are 
identified in a subgroup of more severe asthmatics.    Due to problems of volunteer 
recruitment (over 20 suspected NAA volunteers were screened) and cells being lost 
to contamination, sample size was insufficient to determine whether a deficiency was 
observed in NAA.  Other investigators have also failed to report defective RV 
induced IFN production in asthma 203, 204.  Differences between the two RVs was 
also observed in that viral replication peaked at 24h with RV16 and 48h with RV1B, 
but no differences in viral replication were observed between asthmatics and non-
asthmatics.  The different responses between the strains of RV may be due to cells 
having differing levels RV receptor expression, different efficiencies of viral 
replication or different intracellular responses.  These differences have implications 
for the further investigation of RVs in asthma.  It would have been interesting to 
observe whether ICAM-1 and LDL-receptor expression differed between groups and 
whether a difference was related to asthma disease severity. 
 
6.1.3 RV16 and not RV1B infection induced type I and III IFN in PBMCs 
 RV1B induced type III IFNs in BAL cells, but not in PBMCs.  RV16 induced 
type I and III IFN in PBMCs, which is similar to that seen in BAL cells, but no 
differences were observed between asthmatics and controls.  The data presented in 
this study does not support RV infection of unsorted PBMCs as a useful clinical test 
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in asthma, which differs from previous studies 82, 206.  As in BAL cells, RV failed to 
induce proinflammatory cytokine production in PBMCs.  This is surprising.  High 
baseline levels of cytokines were observed in both BAL and PBMCs, suggesting the 
acquisition of BAL cells at bronchoscopy and the processing of PBMCs itself results 
in production of these cytokines.  The lack of induction differs from previous studies 
where proinflammatory cytokines have been shown to be deficient in adolescent 
asthmatics 81.  The differences observed between BAL cells and PBMCs may mean 
that further studies would have difficulties in extrapolating the findings of PBMCs as 
a surrogate to BAL cells in an attempt to search for a less invasive way to identify 
IFN deficiencies in asthma. 
 
6.1.4 TLR3 stimulation of HBECs resulted in induction of type I and III IFN, 
whereas TLR7/8 stimulation resulted in induction of type III IFN only 
 Induction of type I and III IFNs and proinflammatory cytokines was observed 
in HBECs stimulated with poly(IC).  No difference was observed between asthmatics 
and controls.  Induction differed in PBMCs with proinflammatory cytokines and not 
IFNs being induced suggesting that the expression/function of TLR3 may differ in 
different cell types.  Due to an insufficient number of cells being acquired at 
bronchoscopy the response to TLR stimulation in BAL cells was not investigated.  It 
would be of interest to observe whether similar findings to PBMCs were observed in 
BAL cells in order to further assess whether PBMCs are reliable cell surrogates for 
airway cells in the investigation of IFN production in asthmatics. 
 HBECs stimulated with the TLR7/8 ligand R848 produced type III and not type 
I IFN.  Significant induction of CXCL8/IL-8 and non-significant trends for induction of 
IL-1β and TNF-α were observed.  These findings support the expression of TLR7/8 
on HBECs, where previous reports have had conflicting data 317, 318.  No differences 
were observed between asthmatics and controls.  By contrast, significant induction 
of type I IFN was observed in PBMCs, again indicating that the expression/function 
of TLRs may differ in different cell types. 
 
  
238 
 
6.1.5 Spn failed to induce type I or III IFN mRNA or protein in BAL cells, HBECs 
or PBMCs 
 The in vitro model of pneumococcal infection of all cell types presented in this 
report failed to demonstrate the induction of type I and III IFN in response to Spn.  
Proinflammatory/anti-bacterial cytokines were not induced in BAL cells or HBECs, 
but induction was well demonstrated in PBMCs.  No differences were observed 
between asthmatics and controls.  The study failed to identify type I and III IFN 
induction in the innate immune response to Spn.  The lack of induction may be due 
to a number of factors.  The 8h time point chosen, to be in line with experiments 
performed with RV, may have been too early; the concentration of bacteria and/or 
the strain used may have been insufficient to elicit a response.  Other innate immune 
pathways may be involved, such as the anti-microbial peptides. 
This study also failed to find differences in proinflammatory/anti-bacterial 
cytokine induction in asthmatic subjects, in response to Spn infection of these cell 
types.  Thus a mechanistic explanation for increased susceptibility to invasive 
pneumococcal disease in asthma 104, 319 remains elusive.  This again may be 
because the asthmatics studied were too mild for deficiencies to be observed.  
Klemets et al. reported susceptibility to invasive pneumococcal disease to be much 
greater in more severe asthma (odds ratio ~12), than in milder asthma (odds ratio 
~3), supporting this hypothesis 104. 
 
6.1.6 HBEC responses to stimulation of TLRs which recognise bacterial 
products 
 Induction of type I IFN was not observed in HBECs from asthmatics or 
controls stimulated with TLR1/2/6/4/5/9 ligands.  In HBECs stimulated with TLR1/2/6 
ligands a trend for induction of type III IFN was observed, but no difference was 
observed between asthmatics and controls.  Although only a trend, this is the first 
report to make this observation.  Induction of anti-bacterial cytokines was observed, 
particularly with TLR1/2/6 ligands, which confirms previous reports that these TLRs 
are expressed on HBECs 317.  No deficiencies in induction of anti-bacterial cytokines 
were observed in asthmatics. 
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6.1.7 PBMC responses to stimulation of TLRs which recognise bacterial 
products 
 No robust induction of type I or III IFN was observed in PBMCs stimulated 
with TLR1/2/6/4/5/9 ligands.  Induction of anti-bacterial cytokines was observed, but 
no difference was observed between asthmatics and controls.  This would suggest 
that, in PBMCs, signalling of TLRs which recognise bacterial products results in the 
induction of anti-bacterial cytokines with subsequent anti-bacterial immunity and not 
in IFN induction. 
 
6.2 Future Work 
 
The most important question to answer from future work is whether IFN 
deficiency is related to asthma severity and whether differences between more 
severe atopic and/or non-atopic asthmatics and atopic non-asthmatics, or non-atopic 
healthy controls would be observed.  More recent studies, published after this study 
was designed and underway suggest this to be so 205, 208, 209.  As part of future work, 
volunteers with more severe asthma, and in particular those with a high exacerbation 
frequency, should be recruited to determine whether the deficiency is identified in 
different cell types and, in particular, in an adult population.  Due to the difficulties 
with recruitment, sample size for non-atopic asthmatics was small, so a larger 
sample size may provide more robust data.  Other work related to this study which 
could be performed includes:  
 To investigate a reliable surrogate to airway cells use of separated 
blood monocytes rather than unsorted PBMCs may identify a 
deficiency in asthma 
 To investigate whether IFN deficiency is acquired or present from birth, 
similar experiments could be performed in cells from asthmatic and 
non-asthmatic children 
 In order to investigate Spn further, the TLR4 ligand, pneumolysin, could 
be studied 
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 Although attempted in this study and abandoned due to time 
constraints, use of atypical bacteria such as Chlamydophila 
pneumoniae may be of more relevance to asthma exacerbations 
 Investigation of other proinflammatory/anti-bacterial cytokines such as 
IFN-γ may identify deficiencies in asthma 
 Investigation of other innate immune systems, such as anti-microbial 
peptides, may be of more relevance for the investigation of innate 
immunity against bacteria in asthma 
 
6.3 Conclusions 
 
 This is the first report of type I and III IFN and proinflammatory/anti-bacterial 
cytokine responses to stimulation with RV, Spn and TLR1-9 ligands in cells from 
adult asthmatics and non-asthmatics, atopics and non-atopics.  The hypothesised 
deficiencies in IFN production in asthmatic subjects was not observed in BAL cells, 
HBECs or PBMCs.  The most likely cause for this deficiency not being identified is 
the relatively mild nature of the disease in the asthmatics recruited.  Spn did not 
induce type I and III IFN production in any cell type.  A weak trend for induction of 
type III IFN was observed in HBECs stimulated with TLR1/2/6 ligands.   
Although the question of whether asthma or atopy is important for IFN 
deficiency in asthma has not yet been answered, the finding that atopic non-
asthmatics had no deficiency and that the group of asthmatics recruited had mild 
disease has advanced knowledge of the field.  It has also suggested that IFN 
pathways appear not to be involved in the response to bacterial infection and that 
deficiencies in production of anti-bacterial cytokines are not observed in any cell type 
in the asthmatics included in this study.  Thus a mechanism to explain increased 
susceptibility to invasive pneumococcal infection in asthma remains unknown.  This 
again may be because the asthmatic subjects were at the milder end of the asthma 
spectrum of disease and studies in more severe asthma are warranted.  
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Appendices 
 
Appendix A: Supplementary figures 
 
 
Figure A1.  Interferon protein production in HBECs post stimulation with LTA at 24h.  Squares denote 
NANA, circles denote ANA, downward triangles denote NAA, upward triangles denote AA; open 
shapes denote medium, black shapes denote LTA.  IFN-β (A), IFN-λ1/IL-29 (B). No IFN protein 
production was observed. 
 
 
Figure A2.  Interferon protein production in HBECs post stimulation with PGN at 24h.  Squares denote 
NANA, circles denote ANA, downward triangles denote NAA, upward triangles denote AA; open 
shapes denote medium, black shapes denote PGN.  IFN-β (A), IFN-λ1/IL-29 (B). No IFN-β protein 
production was observed.  A non-significant weak IFN-λ1/IL-29 protein production in NAA was 
observed with no production in other groups.  No differences were observed between groups. 
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Figure A3.  Interferon protein production in HBECs post stimulation with FSL at 24h.  Squares denote 
NANA, circles denote ANA, downward triangles denote NAA, upward triangles denote AA; open 
shapes denote medium, black shapes denote FSL.  IFN-β (A), IFN-λ1/IL-29 (B). No IFN protein 
production was observed. 
 
 
Figure A4.  Interferon protein production in HBECs post stimulation with LPS at 24h.  Squares denote 
NANA, circles denote ANA, downward triangles denote NAA, upward triangles denote AA; open 
shapes denote medium, black shapes denote LPS.  IFN-β (A), IFN-λ1/IL-29 (B). No significant IFN 
protein production above that of medium treated cells was observed. 
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Figure A5.  Interferon protein production in HBECs post stimulation with FLA at 24h.  Squares denote 
NANA, circles denote ANA, downward triangles denote NAA, upward triangles denote AA; open 
shapes denote medium, black shapes denote FLA.  IFN-β (A), IFN-λ1/IL-29 (B). No significant IFN 
protein production above that of medium treated cells was observed. 
 
Figure A6.  Interferon mRNA production in HBECs post stimulation with CpG-C at 8h (A, C and E) 
and 24h (B, D and F).  Squares denote NANA, circles denote ANA, downward triangles denote NAA, 
upward triangles denote AA; open shapes denote medium, black shapes denote CpG-C.  IFN-β (A 
and B), IFN-λ2,3/IL-28 (C and D), IFN-λ1/IL-29 (E and F).  No significant type I or III IFN mRNA 
induction was observed at 8 or 24h post stimulation with CpG-C. 
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Figure A7.  Interferon protein production in HBECs post stimulation with CpG-C at 24h.  Squares 
denote NANA, circles denote ANA, downward triangles denote NAA, upward triangles denote AA; 
open shapes denote medium, black shapes denote CpG-C.  IFN-β (A), IFN-λ1/IL-29 (B). No 
significant IFN protein production above that of medium treated cells was observed. 
 
 
Figure A8.  IL-6 and CXCL8/IL-8 mRNA production in HBECs post stimulation with CpG-C at 8h (A 
and C) and 24h (B and D).  Squares denote NANA, circles denote ANA, downward triangles denote 
NAA, upward triangles denote AA; open shapes denote medium, black shapes denote CpG-C.  IL-6 
(A and B), CXCL8/IL-8 (C and D).  Induction of IL-6 and CXCL8/IL-8 mRNA was not observed at 8 or 
24h 
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Figure A9.  Interferon protein production in PBMCs post stimulation with FLA at 24h (A, C and E) and 
48h (B, D and F).  Squares denote NANA, circles denote ANA, downward triangles denote NAA, 
upward triangles denote AA; open shapes denote medium, black shapes denote FLA.  IFN-α2a (A 
and B), IFN-β (C and D), IFN-λ1/IL-29 (E and F). No significant IFN-α2a production was observed.  
No IFN-β protein production was observed other than in a single AA participant’s sample at 24h. No 
IFN-λ1/IL-29 protein production was observed other than in a single AA participant’s sample at 48h.  
These findings were from different participants. 
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Figure A10.  Interferon protein production in PBMCs post stimulation with CpG-C at 24h (A, C and E) 
and 48h (B, D and F).  Squares denote NANA, circles denote ANA, downward triangles denote NAA, 
upward triangles denote AA; open shapes denote medium, black shapes denote CpG-C.  IFN-α2a (A 
and B), IFN-β (C and D), IFN-λ1/IL-29 (E and F). No significant IFN-α2a production was observed.  
No IFN-β protein production was observed other than in a single ANA participant’s sample at 24h. No 
significant IFN-λ1/IL-29 protein production was observed. 
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Appendix B:  Patient information sheet, consent, screening proforma and 
ethics approval letter 
 
Patient Information Sheet 
Asthmatic Participants 
(08/H0712/39, Version 5, 20/10/2009) 
You are invited to take part in a research study which aims to determine the important differences in 
the response of asthmatic subjects to a cold compared to normal healthy people. This will help us to 
understand why cold viruses trigger asthma and if this can be treated better. This study is being 
funded by the Medical Research Council. 
 
 
1. Name of the project: 
Role of Atopy in Deficient Interferon Production in Response to Rhinovirus and Streptococcus 
pneumoniae Infection 
 
2. The problem or question addressed by the research 
Asthma is a disease characterised by inflammation of the airways in the lung (bronchi).  People who 
suffer from it often have attacks when their breathing worsens and if very severe can even result in them 
being hospitalised.  One of the commonest causes for such attacks is the common cold.  Colds are 
caused by a number of different viruses and the commonest one is called the rhinovirus.  The rhinovirus 
usually only causes a mild cold in healthy individuals but in people with airway diseases such as asthma 
it causes more severe symptoms.  Asthmatics have been shown to have an association with the 
bacterium, Streptococcus pneumoniae.  We wish to understand the mechanisms whereby the rhinovirus 
and Streptococcus pneumoniae causes attacks of asthma and by doing this we may be able to develop 
new treatments in the future that can prevent or treat such attacks.  To do this we need to collect samples 
from blood and the airways of people who suffer from asthma and also a group of non-asthmatic people 
with which to make comparisons.  From the samples we collect we will isolate the cells that are involved 
in fighting virus and bacterial infection and study their responses to rhinovirus and Streptococcus 
pneumoniae that we have in our laboratory. You have been approached as you have a diagnosis of 
asthma and therefore may be suitable for the above study. 
 
3. Will you consider helping us? 
We need to perform a number of procedures that will allow us to obtain these cells for our research. 
 
4. The hoped-for benefits 
Respiratory virus infections (most commonly rhinoviruses) cause around 80% of asthma attacks in 
children and 60% in adults.  Despite being so common no specific therapy is available except steroids, 
which have potentially serious side effects.  Asthma is very common in the UK and is responsible for 
much time off work, GP consultations, hospital admissions and death.  Therefore finding an effective 
treatment for virus-induced asthma attacks has become a major priority.  A clear understanding of the 
mechanisms of such attacks, and the differences from the response of a normal subject undergoing 
the same infection; will lead to the identification of such targets.  There will be no immediate benefits 
of this study to you.  However, it is hoped the study will help us to understand asthma and respiratory 
infections better, and everyone may eventually benefit from improved treatments or vaccination. 
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5. What the request involves:  research practice 
The project involves attending the outpatients department three times. 
The first visit will last about 1.5 hours, and will involve visiting the hospital to have a brief medical 
examination, questions and investigations to determine your suitability as participant in the study. If 
suitable you will be asked to sign a consent form, have a chest X ray and lung function tests. If you 
have had any of these procedures in the last year they will not need to be repeated. 
The second visit will involve having an ECG, skin prick test for allergy, lung function, histamine 
challenge test and a blood test. These are described in more detail below as you may not have had 
these tests before. If you have had a histamine challenge test before it will not need to be repeated. 
Between visits you will be asked to do some simple lung measurements at home and will be given the 
equipment to do this at this visit. You should not have had a cold in the previous 6 weeks. 
ECG 
An ECG or electrocardiogram is a tracing of the electrical activity of the heart. It is painless, takes a 
few minutes and is measured by placing stickers on the chest wall. If you have had an ECG in the last 
year you will not need to have this repeated. 
The skin prick test 
We will test your skin to see if you are allergic to common allergens (e.g. cat, house dust and pollens), 
which involves tiny scratches on the forearm. A droplet of allergen substance is put onto the forearm 
and them a tiny scratch is made through it. Fifteen minutes later any substances that you are allergic 
to will have caused a small reaction in the skin. This is a small raised bump approx 1 -2 cm on the 
surface of the forearm which usually resolves over the next few hours. If you are not allergic we would 
expect you only to react to the control solution called histamine. The skin bump may be temporarily 
red and itchy and very rarely some people may have a more severe allergic reaction requiring 
antihistamines. If you have not had allergies before it is very unlikely that you will have a big reaction 
to skin prick testing. The vast majority of people who have this test do not have severe reactions and 
the procedure will be performed by a doctor who will be with you throughout. If you are taking 
antihistamines we will ask you to stop taking these for a short time (usually 3-5 days) before you have 
the skin prick test so that this medication does not interfere with the test results. 
Lung function testing 
We will also do a test to test the volumes of your lungs. This involves taking deep breaths in and 
breathing out through a tube attached to a machine. The machine measures how much and how fast 
you can breathe out and is usually performed three times and an average taken. Most people find this 
easy and it will not be uncomfortable. You will then use a salbutamol inhaler and go on to have the 
same measurements taken again to measure how much and how fast you can breathe out. This is to 
assess if using a salbutamol inhaler has any effect on your lung measurements. 
Histamine challenge 
Depending on the results of your lung function tests you may then go on to do the second part of the 
lung function test which is the histamine challenge. This measures how reactive your lungs are by 
asking you to breathe in a histamine solution and measuring your lung function to assess your 
response.  Histamine can cause chest tightness in people who are susceptible. People who have a 
positive reaction to the histamine challenge are usually already known to be asthmatic however it is 
possible that people who are not known to be asthmatic may experience a positive reaction. The test 
involves checking your lung function as above and then asking you to breathe via a nebuliser. This is 
a loose fitting mask which blows air and aerosolised droplets of saline (salty water) and allows you to 
breathe this in. Your lung function test is checked afterwards to check if it has affected you. The 
procedure is then repeated with solutions of different strengths of a substance called histamine. This 
is a test often used in clinical practice to make a diagnosis of asthma so it is common for asthmatic 
people to experience some chest tightness during the procedure.  In addition if you are on inhaled 
bronchodilator medication the study doctor may ask you to stop taking these up to 48 hours before 
the procedure. In the vast majority of people who have any chest tightness this is easily and quickly 
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reversed by using a salbutamol inhaler. Very rarely using the inhaler does not fully reverse the chest 
tightness and further medical attention may be required. Your lung function will be closely measured 
throughout the procedure and a doctor will be present throughout and will be able to ensure that in the 
rare case of problems they are dealt with promptly. The test will take place in a fully equipped 
outpatient department at St. Mary’s Hospital. 
Blood tests 
We will take a total of 90 ml of venous blood throughout the study period. This is approximately 18 
teaspoons.  It is possible that a small bruise may appear at the skin surface where the needle was 
inserted in order to take blood from vein. 
We have recently become aware of some research results which links certain genes to asthma.  One 
of the blood tests would be to perform DNA analysis to look for genes associated with asthma.  Your 
blood will be used to extract DNA which will be stored in a secure place for future research.  
 
Will this blood test affect my ability to get insurance? 
No. This blood test is not a “genetic test” as defined by insurance companies and your taking part in 
this project will have no effect on your eligibility for insurance. 
 
Will I get any feedback on the results of the blood tests? 
No. All genetic tests will be anonymous. We will not feed back any information as we will have no way 
of knowing which person donated which sample. 
 
The third visit 
If the above investigations indicate that you would be a good candidate to take part in the study then 
you will be invited back to have a further blood test and a bronchoscopy. 
The bronchoscopy procedure 
A bronchoscopy is a procedure that is commonly used to make a diagnosis of several different lung 
diseases. It is carried out with a bronchoscope, which is a narrow fibre-optic tube that is attached to a 
camera to look into the lungs. This allows us to see directly the airways of the lung and to take 
samples of airway fluids and cells of the lining of the airway for microscopic investigations 
You will have to attend the Endoscopy Suite at the hospital on an empty stomach. You must have no 
food or drink for 6 hours or more prior to the procedure, if the procedure is in the morning most people 
do not eat after midnight. The procedure is usually a half day procedure with you attending in the 
morning and going home in the early afternoon. A small needle will be inserted into the vein of one 
arm and will be used to give you a light sedative.  This will make you drowsy though you will remain 
conscious throughout the procedure.  In addition the sedative often has the effect that you do not 
remember the procedure afterwards.  This is not the same thing as a general anaesthetic.  The 
sedation can affect your judgement so it is advised that you will not be able to drive for the rest of the 
day.  We will also give you a local anaesthetic spray to your nose and the back of your throat that will 
minimise the discomfort when the bronchoscope passes into your lung. The bronchoscope passes 
into the lung via the mouth or nose. It is a flexible tube approx 0.75 cm in width, there is plenty of 
room to breathe around the scope and the team performing the test will be monitoring the oxygen in 
your blood via a small probe attached to one of your fingers. You will be able to ask any questions 
that you have prior to the procedure and you will be able to ask the doctor to stop at any point if you 
would like to, even after the test has started. 
When the bronchoscope enters your lung more local anaesthetic is sprayed into the lungs so that the 
airways themselves will be anaesthetised. The procedure is not painful but does cause you to cough 
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until the local anaesthetic starts to take effect.  Once the bronchoscope is in the lung we will pass a 
small brush down the bronchoscope and brush your airways to collect some of the cells that line your 
airways.  The lining of your airways is insensitive and so you will not feel the brush.  We will then 
insert some saline (salty water) through the bronchoscope, leave it for a few seconds in your lung and 
then suck it up again.  We will also remove a small tissue specimen by removing a small sample of 
the lining of your airways (biopsy).   In this way we will be able to collect the cells that are in your 
lungs and that we wish to study.  Again, this procedure may cause some cough but will not be painful. 
The bronchoscopy itself usually takes at the most 15 minutes but with preparation and administration 
of a light sedation, the whole procedure takes around an hour.  After the procedure you will need to 
remain in hospital for about 4 hours until the effect of the sedation has worn off completely.  Transport 
will be provided where needed, as you are not allowed to drive home.  You may alternatively like to 
arrange transport with a family member or friend if you prefer. 
Side-effects and risks of bronchoscopy 
There may be some discomfort during the bronchoscopy but importantly it will not be painful. Most 
commonly the discomfort is cough. Approximately half of people undergoing bronchoscopy will 
experience some cough especially when the bronchoscope passes across the vocal cords. This is 
minimised by application of local anaesthetic to the airways and vocal cords prior to passing the 
bronchoscope into the lungs and any cough usually settles down during the procedure. 
Bronchoscopy is a normally safe procedure that rarely gives rise to complications however there are 
some risks that you should be aware of. 
On occasions (up to 5% in asthmatics) it may cause some narrowing of your airways, similar to that 
experienced during a mild asthma attack. This is more likely if you have asthma but the risk is still 
small. You will have a nebuliser prior to the bronchoscope to minimise the occurrence of chest 
tightness as much as possible. If this were to occur the bronchoscopy would be stopped and you 
would be given a salbutamol nebuliser in the same way as during an asthma attack which would 
reverse the narrowing. It will be carried out by an experienced doctor who will be following 
internationally evaluated and approved guidelines for bronchoscopy. There are full facilities on site if 
you require any more than this. 
Another side-effect is that it can cause the level of oxygen in your blood to fall but we will be 
monitoring this continually by means of a probe attached to your finger so that if it does occur we will 
detect it immediately.  As we will be giving you oxygen throughout the procedure the risk of this 
happening is very small. 
Up to 10% of people may experience fever and flu-like symptoms within 24 hours after the 
investigation, but these are usually mild and transient.  Should you experience fever we would like 
you to contact us on the telephone numbers indicated.  If this does occur it usually resolves with 
paracetamol. 
A very rare (less than 0.1% chance) but more serious risk is a pneumothorax.  A pneumothorax is a 
condition in which air or gas collects in the space around the lungs. This can cause the lung(s) to 
collapse.  This condition is easily treated and may go away on its own. If it significantly interferes with 
breathing, a tube may need to be placed in the space around the lungs to remove the air. 
Should you feel discomfort of any kind at any time during the bronchoscopy and do not wish us to 
proceed then the procedure will be terminated. 
PLEASE NOTE IT IS IMPORTANT NOT TO DRIVE A MOTOR VEHICLE FOR THE REST OF THE 
DAY AFTER SEDATION. 
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6.  What if something goes wrong? 
Imperial College London holds insurance policies which apply to this study.  If you experience harm or 
injury as a result of taking part in this study, you will be eligible to claim compensation without having 
to prove that Imperial College is at fault.  This does not affect your legal rights to seek compensation. 
If you are harmed due to someone's negligence, then you may have grounds for a legal 
action.  Regardless of this, if you wish to complain, or have any concerns about any aspect of the way 
you have been treated during the course of this study then you should immediately inform the 
Investigators (Dr Jonathan Macintyre, j.macintyre@imperial.ac.uk, 020 7594 3763 or Prof Sebastian 
Johnston, s.johnston@imperial.ac.uk).  The normal National Health Service complaint complaints 
mechanisms are also available to you.  If you are still not satisfied with the response, you may contact 
the Imperial College Clinical Research Office. 
The above study has been reviewed by the ethics committee at St Mary’s Hospital. 
 
7. What about confidentiality? 
By signing this form you consent to the collection and use of your personal data for the study (Study 
Data).  This may include sensitive personal data about your age, gender, ethnic origin and health.  
Your consent to the use of your Study Data does not have a specific expiry date, but you may 
withdraw your consent at any time. 
The Study Data will be used by Imperial College and are protected by the use of a code, which is a 
number specific to you. Imperial College controls the code ‘key’, which is needed to connect coded 
Study Data back to you. A person appointed by Imperial College, regulatory authorities or other 
supervisory bodies may review any of your Study Data at Imperial College to ensure the proper 
running of the Study. 
Your Study Data will be used for research into the activity of Imperial College and may be used in 
research related to the development of pharmaceutical products, diagnostics or medical aids. Imperial 
College is responsible for its handling of your Study Data in accordance with applicable Data 
Protection law(s). 
The results of the Study may be published in medical literature, but you will not be identified. 
You have the right to request information about your Study Data and to be provided with a copy of 
them.  You also have the right to request that any inaccuracies in such data be corrected.  If you wish 
to make a request, then please contact Imperial College. 
We would normally inform your GP or hospital consultant that you are involved in this study.  If you do 
not wish us to inform them there is an option to do this on the consent form. 
 
8. What happens if I don't want to take part? 
Nothing.  You simply don't sign the consent form. This will not affect your medical care or your legal 
rights. 
 
9. Can I withdraw my permission? 
You may withdraw your permission to the use of your data and samples at any time without giving 
reasons for doing so, even after you have agreed to take part.  Your future medical care will not be 
affected if you do not want to enter the study or want to withdraw at any time during the study.  The 
investigator may also withdraw you from the study at any time if he/she considers this to be 
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appropriate.    If you withdraw your permission before your samples and data are used, we will not 
use the data and the samples will be destroyed. If you withdraw your consent after your samples have 
been analysed we will ensure that the remainder is destroyed. However, if analysis has already been 
performed we are not obliged to destroy results of this research. 
 
If you require any further information about this study, please contact the following: 
Dr Jonathan Macintyre or Professor Sebastian Johnston 
Department of Respiratory Medicine, 
Imperial College London, 
Norfolk Place, 
London 
W2 1PG 
Office phone no: 020 7594 3763 or 0759 025 0487 
Email: Respiratory.Research01@imperial.ac.uk 
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Participant Consent Form 
 
 
 
 
Study Number: 
Patient Identification Number for this trial: 
 
CONSENT FORM 
 
Title of Project:  Role of Atopy in Deficient Interferon Production in Response to 
Rhinovirus and Chlamydophila pneumoniae Infection 
 
Name of Investigators:  Dr Jonathan Macintyre & Prof Sebastian Johnston 
 
 Please initial box 
 
1. I confirm that I have read and understand the information sheet 
dated 20/10/2009 (version 5) for the above study.  I have had the 
opportunity to consider the information, ask questions and have had 
these answered satisfactorily. 
 
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving any reason and without my 
medical care or legal rights being affected. 
 
3. I consent to use the samples taken for research by Imperial College, 
London and I understand that full ethical approval will be sought for 
any future research project.   
 
4. I understand that I am consenting to attend St Mary’s Hospital on 
three further occasions. The study includes a medical history and 
examination, lung function tests with reversibility, blood tests, skin 
prick tests and challenge testing.  I understand that I am required to 
keep a peak flow chart between the second and third visit.  I 
understand that the third visit involves further blood tests and fibre 
optic bronchoscopy. 
 
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5. I consent to a blood sample being taken which will be used to obtain 
my DNA.  I understand that this is not a diagnostic test and that I will 
not receive any results 
 
6. I consent to the processing of my personal information for the 
purposes of this study only, and understand that my information will 
not be used for any other purposes by the Investigators.  I 
understand that my information will be treated as strictly confidential 
and handled in accordance with the provisions of the Data 
Protection Act 1998. 
 
7.   I understand that relevant sections of any of my medical notes and 
data collected during the study may be looked at by responsible 
individuals from Imperial College, from regulatory authorities or from 
the Imperial College Healthcare NHS Trust, where it is relevant to 
my taking part in this research.  I give permission for these 
individuals to have access to my records.                                                                                                                                             
 
8. I agree to my GP being informed of my participation in the study.  
9.   I agree to take part in the above study. 
 
 
 
_______________________ ________________ _______________               
Name of Patient Date Signature   
 
_________________________ ________________ ________________                  
Name of Witness Date Signature  
 
Investigator’s statement  
I have explained the nature, demands and foreseeable risks of the above research to the 
subject. 
 
_________________________ ________________ ___________________               
Investigator Date  Signature 
 
 
 
 
 
(08/H0712/39, Version 4, 20/10/2009) 
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Subject Screening Data 
 
Date  ………………………………………………………………………………………... 
 
Study no ………………………………………………………………………………………… 
 
Name  ………………………………………………………………………………………… 
 
Hospital No.  ………………………………………………………………………………………… 
 
Address ………………………………………………………………………………………… 
  ………………………………………………………………………………………… 
  ………………………………………………………………………………………… 
 
Tel no  ………………………………………………………………………………………… 
 
Email  ………………………………………………………………………………………… 
 
 
DOB (age) ………………………………………………………………………………………… 
 
 
Sex  ………………………………………………………………………………………… 
 
GP  ………………………………………………………………………………………… 
  ………………………………………………………………………………………… 
  ………………………………………………………………………………………… 
  ………………………………………………………………………………………… 
  ………………………………………………………………………………………… 
 
GP informed 
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Occupation ………………………………………………………………………………………… 
 
Notes  ………………………………………………………………………………………… 
  ………………………………………………………………………………………… 
  ………………………………………………………………………………………… 
  ………………………………………………………………………………………… 
  ………………………………………………………………………………………… 
  ………………………………………………………………………………………… 
  ………………………………………………………………………………………… 
  ………………………………………………………………………………………… 
  ………………………………………………………………………………………… 
  ………………………………………………………………………………………… 
  ………………………………………………………………………………………… 
  ………………………………………………………………………………………… 
  ………………………………………………………………………………………… 
  ………………………………………………………………………………………… 
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Subject  …………………………………………… Date…………………………… 
 
 Have you at any time in the last 12 months had whistling or wheezing in your chest? 
 
 Have you at any time in the last 12 months woken up in the morning with a feeling of 
tightness in the chest? 
 
 Have you at any time in the last 12 months had an attack of shortness of breath that came on 
during the day when you were not doing anything strenuous? 
 
 Have you at any time in the last 12 months had an attack of shortness of breath that came on 
when you had stopped exercising? 
 
 Have you at any time in the last 12 months been woken at night by an attack of shortness of 
breath? 
 
 If you were in a dusty place, near animals or near feathers would you get short of breath? 
 
 Have you ever been diagnosed with asthma? 
 
 Have you had an attack in the last 12 months? 
 
 Do you take any medication for asthma? 
 
Medication 
 
 
Drug allergies 
 
 
Other allergies 
 
 
Allergy history: hayfever  
eczema  
   urticaria 
   angioedema 
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Subject  ……………………………………      Date…………………………… 
 
FHx of asthma / allergic disease 
 
 
Animal / pet exposure 
 
 
Smoking status 
current 
   Lifelong non smoker 
Ex smoker  date stopped   pack years 
 
 
Alcohol intake 
 
 
 
Examination: 
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Subject  ……………………………………      Date…………………………… 
Asthmatics Only: 
 Asthma control ( Asthma control Questionnaire  {ACQ}) 
 On average, during the past week, how often were you woken by your asthma during 
the
 
night?         
  Never (0) 
  Hardly ever (1) 
  A few times (2) 
 Several times (3) 
 Many times (4) 
 A great many times (5) 
 Unable to sleep because of asthma (6) 
 On average, during the past week, how bad were your asthma symptoms when you 
woke up in the
 
morning?  
 No symptoms(0) 
 Very mild symptoms (1) 
 Mild symptoms (2) 
 Moderate symptoms (3) 
 Quite severe symptoms (4)  
  Severe symptoms (5) 
  Very severe symptoms (6) 
 In general, during the past week, how limited were you in your activities because of 
your
 
asthma?  
 Not limited at all (0) 
 Very slightly limited (1) 
 Slightly limited (2) 
 Moderately limited (3) 
 Very limited (4) 
 Extremely limited (5) 
 Totally limited (6) 
 In general, during the past week, how much shortness of breath did you experience 
because of your
 
asthma?  
 None (0) 
 A very little (1) 
 A little (2) 
 A moderate amount (3) 
 Quite a lot (4) 
 A great deal (5) 
 A very great deal (6) 
 In general, during the past week, how much of the time did you wheeze? 
 Not at all (0) 
 Hardly any of the time (1) 
 A little of the time (2) 
 A moderate amount of the time(3) 
 A lot of the time (4)  
 Most of the time (5)  
 All the time (6) 
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Subject  ……………………………………      Date…………………………… 
 
 On average, during the past week, how many puffs of short-acting bronchodilator 
(e.g., Ventolin) have you used each
 
day?  
 None (0) 
 1-2 puffs most days (1) 
 3-4 puffs most days (2) 
 5-8 puffs most days  (3) 
 9-12 puffs most days (4) 
 13-16 puffs most days (5) 
 More than 16 puffs most days (6) 
 
Questionnaire score: 
Section 1: score (out of 9) 
 
Precipitating factors 
 
Seasonal variation 
 
Frequency of inhaler use 
 
Age of onset 
 
Frequency of exacerbations 
 
Last exacerbation 
 
Hospital admissions 
 
ITU admissions 
 
Last course of oral steroids 
 
Additional Medical History 
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Subject  ……………………………………      Date…………………………… 
 
Spirometry   
 
Date: absolute % predicted Post salbutamol 
PEF (l/s)    
FEV1 (l)    
FVC (l)    
FEV1/FVC    
F50    
F25    
 
PEF diurnal variation (%) over 2 weeks 
Date: 
 
PC20 (histamine) 
Date: 
Histamine dose 1 min 3 min notes 
Saline    
0.03    
0.06    
0.12    
0.24    
0.48    
1    
2    
4    
8    
16    
Recovery   Inhaler given Y / N 
 
CXR 
Date: 
 
ECG 
Date: 
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Subject  …………………………………… Date…………………………… 
 
 
Skin Prick Tests – Results Sheet 
 
Investigator   ………………… 
 
Response (mm) 
diluent neg control  ……………… 
6 grass mix   ………………  
house dust mite (Der P)  ……………… 
cladosporium herbarum              ……………… 
alternaria alternata  ……………… 
aspergillus fumigatus          ……………… 
silver birch    ……………… 
3 trees                  ……………… 
nettle pollen   ……………… 
cat dander    ……………… 
dog hair    ……………… 
histamine pos control              ……………… 
 
1 response with wheal 3mm greater than the negative control indicates atopy. 
 
 
Atopic 
 
Non-atopic 
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Subject  ……………………………………      Date…………………………… 
 
TEST DATE RESULT 
   
FBC   
   
   
   
   
   
   
   
Biochemistry   
   
   
   
   
   
   
   
Coagulation screen   
   
   
IgE (total)   
   
 
 
(08/H0712/39, version 1, 26/03/08) 
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Ethics Approval Letter 
St Mary's REC 
Royal Free Hospital 
Research Ethics Committees 
Pond Street 
London 
NW3 2QG 
Telephone: 0207 794 0635 
10 June 2008 
 
Professor Sebastian Johnston 
Professor of Respiratory Medicine 
National Heart and Lung lnstitute 
Department of Respiratory Medicine 
lmperial College London 
Norfolk Place 
London 
W2 1PG 
 
 
Dear Professor Johnston 
 
Full title of study:  Role of Atopy in Deficient lnterferon Production in 
Response to Rhinovirus and Chlamydophila pneumoniae 
lnfection 
 
REG reference number:  08/H0712/39 
 
Thank you for your letter, responding to the Committee's request for further information on 
the above research and submitting revised documentation, subject to the conditions 
specified below. 
 
The further information was considered at the meeting of the Sub-Committee of the REC 
held on 16 May 2008. Your further information was reviewed on behalf of the REC by the 
Chairman, Barrie Newton and Aidan Moss. 
 
Confirmation of ethical opinion 
 
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the 
above research on the basis described in the application form, protocol and supporting 
documentation as revised. 
 
Ethical review of research sites 
 
The favourable opinion applies to the research sites listed on the attached form. 
 
Conditions of the favourable opinion 
 
The favourable opinion is subject to the following conditions being met prior to the start of 
the study. 
 
Management permission or approval must be obtained from each host organisation prior to 
the start of the study at the site concerned. 
 
Management permission at NHS sites ("R&D approval") should be obtained from the 
relevant care organisation(s) in accordance with NHS research governance arrangements. 
Guidance on applying for NHS permission is available in the lntegrated Research 
Application System or at http://www.rdforum.nhs.uk. 
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Approved documents 
 
The final list of documents reviewed and approved by the Committee is as follows: 
 
Document Version Date 
Application   27 March 2008 
lnvestigator CV   
Protocol  1 26 March 2008 
Covering Letter   09 May 2008 
Letter from Sponsor   18 March 2008 
Peer Review   02 January 2007 
Compensation Arrangements   27 March 2008 
Questionnaire: Clinical Questionnaire 1 10 March 2008 
Advertisement  1, Volunteers needed 26 March 2008 
GP/Consultant Information Sheets 1 04 March 2008 
Participant lnformation Sheet  2 09 May 2008 
Participant Information Sheet  2 09 May 2008 
Participant Consent Form   2 09 May 2008 
Response to Request for Further lnformation   
Bronchoscopy protocol 1 10 March 2008 
Protocol Skin Prick Testing to Common Allergens 1 26 March 2008 
 
Chart for diurnal peak flow record & use of medication 1 11 March 2008 
 
Cover letter for information pack 1 13 March 2008 
 
Subject Screening Data: General Details 1 26 March 2008 
 
 
Statement of compliance 
 
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees (July 2001) and complies fully with the Standard Operating 
Procedures for Research Ethics Committees in the UK. 
 
After ethical review 
 
Now that you have completed the application process please visit the National Research 
Ethics Website > After Review 
 
You are invited to give your view of the service that you have received from the National 
Research Ethics Service and the application procedure.  lf you wish to make your views 
known please use the feedback form available on the website. 
 
The attached document "After ethical review - guidance for researchers" gives detailed 
guidance on reporting requirements for studies with a favourable opinion, including: 
 
 Notifying substantial amendments 
 Progress and safety reports 
 Notifying the end of the study 
 
The NRES website also provides guidance on these topics, which is updated in the light of 
changes in reporting requirements or procedures. 
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We would also like to inform you that we consult regularly with stakeholders to improve our 
service. lf you would like to join our Reference Group please email 
referencegroup@nres.npsa.nhs.uk. 
 
 
 
 
With the Committee's best wishes for the success of this project 
 
Yours sincerely 
 
 
Barrie Newton 
Chairman 
 
Email: adriana.fanigliulo@royalfree.nhs.uk 
 
Enclosures:   "After ethical review - guidance for researchers" 
Site approval form 
 
Copy to:   Gary Roper, lmperial College London 
Selvy Raju, R&D office for lmperial College Healthcare NHS Trust 
 
08/H0712/39   Please quote this number on all correspondence 
